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SUMMARY 
Malaria is the most important parasitic infection in humans, causing an estimated one 
million deaths annually. Most cases occur in young children in sub-Saharan Africa, 
supporting the vicious circle of disease and poverty.  
 
Current control strategies have so far failed to reduce the disease in most parts of 
sub-Saharan Africa. Insecticide-treated mosquito nets (ITN) are effective in 
preventing malaria episodes and efficacious drugs (such as artemisinin-based 
combination therapies or ACTs) exist to cure malaria. However, a major problem is 
the delivery of quality health services, including life-saving drugs, to the ones in need. 
A variety of inter-linked factors influences patients’ access to prompt and effective 
treatment. While growing resistance against commonly used antimalarials such as 
chloroquine or sulphadoxine-pyrimethamine (SP) is being addressed with the 
introduction of ACTs, obstacles to effective malaria treatment have been identified at 
the levels of the households (the demand side), the health system (the supply side), 
and in health policy.  
 
The present thesis aimed at contributing to a better understanding of factors 
influencing access to malaria treatment in a positive or a negative way. The insights 
gained should inform the development of targeted interventions to improve access to 
malaria treatment and help to develop a general access framework.  
 
The research was carried out as part of the ACCESS Programme, which aims to 
understand and improve access to effective malaria treatment in the districts of 
Kilombero and Ulanga, in south-eastern Tanzania. The ACCESS strategy is based 
on a set of integrated interventions, including (1) social marketing for improved care 
seeking at community level, (2) strengthening the quality of case-management in 
health facilities, and (3) strengthening the commercial drug retail sector. The 
interventions are accompanied by a comprehensive set of monitoring and evaluation 
activities.  
 
Quantitative, semi-quantitative and qualitative methods were used for data collection 
in the area of the local Demographic Surveillance System (DSS) and the nearby 
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semi-urban centre of Ifakara. Between 2004 and 2006, community-based surveys 
were conducted to investigate treatment-seeking behaviour and estimate community-
effectiveness of malaria treatment. A shop census and mystery shoppers (simulated 
clients) were used to monitor drug availability and the performance of shopkeepers in 
the retail sector. The DSS served as sampling frame for the community-based 
studies and provided demographic indicators, including morbidity and mortality data. 
 
The investigation of treatment-seeking and illness perception revealed a better 
overlap of local and biomedical illness concepts than reported in earlier studies from 
the same area. This is likely to reflect the intensive social marketing and health 
education campaigns carried out during the past decade. Modern medicine was 
clearly preferred by most patients and 87.5% (95% CI 78.2-93.8) of the fever cases in 
children and 80.7% (68.1-90.0) in adults were treated with one of the recommended 
antimalarials (at the time SP, amodiaquine or quinine). However, an estimation of 
community-effectiveness revealed that only 22.5% (13.9-33.2) of the children and 
10.5% (4.0-21.5) of the adults received prompt and appropriate antimalarial treatment, 
despite high health facility usage rates. Quality of case-management was not 
satisfactory and the exemption mechanism for under-fives was not functional. 
Consequently, the commercial drug retail sector played an important complementary 
role in the provision of malaria treatment. In order to increase treatment effectiveness 
and maintain the high efficacy of the recently introduced ACT, both treatment sources 
should be strengthened and their quality should be improved. 
 
The seasonal movement of families to distant farming sites did not increase the risk 
of family members contracting malaria. In the fields, 97.9% (95.2-100) of all people 
were protected with mosquito nets but since few households stocked antimalarials at 
home, treatment had to be sought from distant health facilities or drug stores. Of the 
episodes that happened in the fields, 88.2% (72.6-96.7) were finally treated with an 
antimalarial, indicating that households made a considerable effort to obtain malaria 
treatment. It appeared that during the farming season, difficulties to mobilize 
resources coupled with the long distance to treatment sources led to delays in 
treatment-seeking. In this context, a comprehensive approach should be considered 
to improve access to treatment while at the same time assuring rational use of 
medicines and protecting fragile livelihoods.  
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Investigations in the retail sector found that antimalarial availability had decreased by 
almost 50% in commercial shops following the policy change from chloroquine to SP 
as first-line treatment in 2001. This decline was noted mainly in general shops, which 
were not tolerated any more to sell SP (while they could generally sell chloroquine 
prior to the policy-change). In 2004, five out of 25 studied villages with a total 
population of 13,506 (18%) had neither a health facility, nor a shop as source of 
malaria treatment. While there was no immediately apparent impact on overall 
antimalarial use, the decline may have disproportionately affected the poorest and 
most remote groups in the community. In the light of the policy change to ACT these 
issues need to be addressed urgently if the benefits of these efficacious drugs are to 
be extended to the whole population.  
 
The assessment of shop keepers knowledge and behaviour revealed that drug store 
keepers had better knowledge of malaria and its treatment than their peers in general 
shops. In drug stores, mystery shoppers were more likely to receive an appropriate 
treatment (OR=9.6, 95% CI 1.5-60.5), even though at a higher price. As a distribution 
channel for ACTs, complementary to health facilities, upgraded drug stores may be 
the most realistic option. However, shopkeepers in drug stores need to be trained on 
the provision of correct malaria treatment. At the same time, the role of general shops 
as first contact points for malaria patients needs to be re-considered. Taking the 
importance of shops into account, interventions to increase the availability of ACTs in 
the retail sector are urgently required within the existing legal framework. 
 
The insights gained in the ACCESS studies helped to design a generic access 
framework embedded into the context of livelihood insecurity. This framework links 
social science and public health research with broader approaches to poverty 
alleviation. Apart from offering an analytical frame for further scientific research, it 
suggests access policies and interventions that reach beyond health services.  
 
In conclusion, the findings of this thesis underline the need for a comprehensive 
approach to analyze and improve access to treatment. In this setting, health systems 
factors appear to be major obstacles to treatment, while local disease perceptions did 
not appear to have a big influence on treatment access. There is an urgent need to 
improve quality of care at all levels and new avenues have to be explored to achieve 
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equitable coverage with essential health interventions. Health policies need to be 
formulated and implemented in a way that they effectively improve the quality of 
services for all population groups. Considering the close link of disease and poverty, 
any health intervention is unlikely to succeed without taking the demand side into 
consideration. A comprehensive approach should therefore not only include 
measures that enable patients to access providers of good quality care, but also 
contribute to the strengthening of household economies. In order to achieve a decline 
in malaria morbidity and mortality in Africa, a concerted effort of all stakeholders is 
required to translate efficacious tools into effective, equitable and sustainable 
interventions. 
Zusammenfassung XIV 
ZUSAMMENFASSUNG 
Malaria ist die bedeutendste parasitäre Erkrankung des Menschen, mit 
schätzungsweise einer Million Todesfällen pro Jahr. Die meisten dieser Fälle werden 
in jungen Kindern in Afrika südlich der Sahara verzeichnet, was zu dem Teufelskreis 
aus Krankheit und Armut beiträgt.  
 
Die bisher angewandten Strategien zur Kontrolle der Malaria haben in den meisten 
Gebieten Afrikas südlich der Sahara noch nicht zu einer Reduktion der Malariafälle 
geführt. Zwar bieten mit Insektizid behandelte Mückennetze (ITN) einen wirksamen 
Schutz gegen eine Übertragung und die Krankheit kann mit neuen Medikamenten 
erfolgreich behandelt werden (z.B. mit Kombinationspräparaten auf der Basis von 
Artemisinin). Eine grosse Herausforderung ist aber weiterhin die Frage, auf welche 
Weise Patienten am besten mit Gesundheitsdienstleistungen (wie z. B. 
lebensrettenden Medikamenten) erreicht werden können. Verschiedene in 
gegenseitiger Beziehung stehende Faktoren beeinflussen ob Patienten rechtzeitig 
Zugang zu wirksamer Behandlung erhalten. Aufgrund zunehmender Resistenzen 
werden gegenwärtig gebräuchliche Malariamedikamente, wie z. B. Chloroquin oder 
Sulphadoxin-Pyrimethamin (SP), durch Artemsinin-Kombinationspräparate (ACT) 
ersetzt. Weitere Hindernisse sind jedoch auf der Ebene der Haushalte (Nachfrage-
Seite), der Gesundheitssysteme (Angebots-Seite) und in der Gesundheitspolitik zu 
finden.  
 
Das Ziel der vorliegenden Dissertation ist es, zum Verständnis der Faktoren 
beizutragen, welche den Zugang zur Malariabehandlung positiv oder negativ 
beeinflussen. Die dadurch gewonnen Einsichten sollten einerseits in die Entwicklung 
zielgerichteter Interventionen einfliessen, welche den Zugang zur Malariabehandlung 
verbessern, und andererseits zur Entwicklung eines umfassenderen Zugangs-
Modells beitragen.  
 
Die Forschungsarbeiten wurden im Rahmen des ACCESS Programms durchgeführt, 
welches zum Ziel hat, den Zugang zur Malariabehandlung in den Distrikten 
Kilombero und Ulanga im südöstlichen Tansania sowohl besser zu verstehen als 
auch zu verbessern. Die Strategie von ACCESS beruht auf einer Kombination 
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verschiedener Interventionen, einschliesslich (1) soziales Marketing für 
angemessenere Behandlung auf Gemeindeebene, (2) Qualitätsverbesserung der 
Behandlung in Gesundheitszentren und (3) Stärkung der Medikamentenbranche im 
Einzelhandel. Die Interventionen werden dabei von umfassenden Kontroll- und 
Evaluationsaktivitäten begleitet.  
 
Daten für die vorliegenden Studien wurden mittels quantitativer, semi-quantitativer 
und qualitativer Methoden im Gebiet des lokalen demographischen 
Überwachungssystems (DÜS) und im angrenzenden semi-urbanen Ifakara erhoben. 
Zwischen 2004 und 2006 wurde mittels Befragungen auf der Ebene der Haushalte 
das Verhalten der Bevölkerung im Fall einer Fieberepisode untersucht, was eine 
Schätzung der Effektivität der Malariabehandlung ermöglichte. Durch eine Erhebung 
von Einkaufsläden und mittels Testkäufer wurde die Verfügbarkeit von 
Malariamedikamenten sowie die Leistung der Verkäufer im Einzelhandel überwacht. 
Das DÜS diente dabei zur Stichprobenplanung für Studien auf Gemeindeebene und 
lieferte demographische Daten, einschliesslich Daten zur Morbidität und Sterblichkeit.  
 
Aufgrund der Studien zum Behandlungsverhalten bei Malariafällen konnte festgestellt 
werden, dass das lokale konzeptuelle Verständnis der Malaria dem biomedizinischen 
Konzept näher kommt als aus früheren Studien in der gleichen Gegend hervorgeht. 
Dies spiegelt höchst wahrscheinlich die intensiven Sozialmarketing und 
Gesundheitserziehungs-Kampagnen der letzten Jahrzehnte wider. Moderne 
medizinische Behandlung wurde von den meisten Patienten deutlich bevorzugt. 
87.5% (95% CI 78.2-93.8) der Fieberfälle in Kindern und 80.7% (68.1-90.0) der Fälle 
in Erwachsenen wurden mit einem der empfohlenen Malariamedikamente (damals 
SP, Amodiaquine oder Chinin) behandelt. Eine Schätzung des Wirkungsgrades der 
Behandlung auf Gemeindeebene ergab jedoch, dass nur 22.5% (13.9-33.2) der 
Kinder und 10.5% (4.0-21.5) der Erwachsenen rechtzeitig mit einem geeigneten und 
richtig dosierten Malariamedikament behandelt wurden und dies obwohl zahlreiche 
Patienten ein Gesundheitszentrum aufgesucht hatten. Die Qualität der 
Malariabehandlung war nicht zufrieden stellend und die Mechanismen zur 
Kostenbefreiung für Kinder funktionierten nicht. Folglich spielte der kommerzielle 
Medikamenten-Einzelhandel eine wichtige Rolle in der Versorgung mit 
Malariamedikamenten. Um die Effektivität der Malariabehandlung zu erhöhen und die 
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hohe Wirksamkeit der eben eingeführten ACTs zu erhalten sollten beide 
Behandlungsquellen bestärkt und deren Qualität verbessert werden.  
 
Saisonale Verschiebungen von Haushaltungen auf weit entfernte Anbauflächen 
erhöhten deren Risiko einer Malariaerkrankung nicht. Auf den Feldern waren 97.9% 
(95.2-100) der Haushaltsmitglieder durch Mückennetze geschützt. Da jedoch nur 
wenige Haushaltungen Malariamedikamente mit auf die Felder nahmen, mussten 
Patienten zur Behandlung zu weit entfernten Krankenstationen oder 
Medikamentenläden reisen. 88.2% (72.6-96.7) der Malariaerkrankungen auf den 
Feldern wurden letztendlich mit einem Malariamedikament behandelt, was darauf 
schliessen lässt, dass Haushaltungen einen grossen Aufwand betreiben um eine 
Behandlung zu bekommen. Es schien als ob Schwierigkeiten Ressourcen zu 
mobilisieren in Kombination mit langen Distanzen zur nächsten Behandlungsquelle 
während der Anbauzeit zu Verzögerungen in der Behandlung führten. In dieser 
Situation sollte daher ein umfassender Interventionsansatz in Erwägung gezogen 
werden, welcher den Zugang zur Behandlung verbessert, gleichzeitig aber den 
rationalen Gebrauch von Medikamenten sicherstellt und ebenso die fragilen 
Lebensgrundlagen der Menschen sichert.  
 
Untersuchungen im Einzelhandel ergaben dass die Verfügbarkeit von 
Malariamedikamenten um fast 50% gesunken war, nachdem in 2001 Chloroquin 
durch SP als Erstbehandlung der Malaria ersetzt wurde. Diese Abnahme war 
überwiegend in normalen Läden zu verzeichnen, welchen es fortan nicht mehr 
gestattet war, SP zu verkaufen (im Gegensatz zu Chloroquin vor dem Kurswechsel). 
2004 befand sich in 5 der 25 Studiendörfer mit einer Bevölkerung von 13'506 (18% 
der Gesamtbevölkerung) weder eine Krankenstation, noch ein Laden als 
Behandlungsort. Zwar konnte keine unmittelbare Wirkung auf den Gebrauch von 
Malariamedikamenten festgestellt werden, die Abnahme könnte jedoch die ärmsten 
und entlegensten Bevölkerungsgruppen am meisten getroffen haben. Im Zuge des 
derzeitigen Wechsels auf ACTs sollten diese Punkte dringend angegangen werden 
um den Nutzen dieser wirksamen Medikamente auf die ganze Bevölkerung 
auszudehnen.  
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Eine Beurteilung des Wissensstandes und Verhaltens von Verkäufern in Läden 
ergab, dass das Personal in Medikamentenläden besser über Malaria und 
Malariabehandlung bescheid wussten, als das Personal in normalen Läden. In 
Medikamentenläden erhielten Testkäufer eher ein geeignetes Malariamittel (OR=9.6), 
allerdings zu einem höheren Preis. Verbesserte Medikamentenläden wären wohl die 
realistischste Option für den Vertrieb von ACTs ausserhalb von Gesundheitszentren. 
Gleichzeitig sollte jedoch die Rolle, welche der normale Einzelhandel als erster 
Kontaktpunkt für Malariapatienten spielt, neu überdacht werden. Angesichts der 
Wichtigkeit des Einzelhandels, einschliesslich der Medikamentenläden, sind 
Interventionen dringend nötig, welche auf den gegebenen rechtlichen Grundlagen die 
Verfügbarkeit von ACTs im kommerziellen Sektor verbessern. 
 
Die Einsichten, welche in diesen ACCESS-Studien gewonnen wurden, halfen mit, ein 
generisches Zugangs-Modell zu entwerfen, welches in den Rahmen unsicherer 
Lebensgrundlagen eingebettet ist. Unter den untersuchten Gegebenheiten waren 
Faktoren im Gesundheitssystem wichtige Hindernisse auf dem Weg zur Behandlung, 
lokale Auffassungen von Krankheit hingegen weniger. Die Qualität der 
Malariabehandlung muss darum dringend verbessert werden und neue Lösungen 
sind nötig um eine faire Abdeckung mit Gesundheitsdienstleistungen zu erreichen. 
Gesundheitspolitische Richtlinien müssen auf eine Art und Weise formuliert und 
implementiert werden, dass sie die Qualität der Behandlung für alle 
Bevölkerungsgruppen wirksam verbessern. Angesichts des engen Zusammenspiels 
von Krankheit und Armut können Gesundheitsinterventionen nur wirksam sein, wenn 
auch die Seite der Nachfrage berücksichtigt wird. Ein umfassender Ansatz sollte 
daher nicht nur dazu beitragen, dass Patienten gute Behandlungsorte erreichen, 
sondern sollte ebenfalls zur Stärkung der Haushalts-Ökonomien beitragen. Um eine 
Abnahe der Malariaerkrankungen und Todesfälle in Afrika zu erreichen braucht es 
eine gemeinsame Anstrengung aller Beteiligten, so dass wirksame Instrumente in 
effektive, faire und nachhaltige Interventionen umgesetzt werden können. 
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MUHTASARI 
Malaria ni ugonjwa muhimu wa vimelea unaomshambulia binadamu, unasababisha 
takribani vifo milioni moja kila mwaka. Mashambulizi mengi yanawapata watoto 
wadogo katika jangwa la Sahara, hali inayosababisha mzunguko mzima wa 
magonjwa na umasikini. 
 
Mikakati ya kupambana na malaria kwa sasa inaonekana kushindwa kukabili 
ugonjwa huu katika sehemu nyingi za kusini mwa jangwa la sahara. Vyandarua 
vilivotiwa dawa vinafanya kazi ya kuzuia malaria pamoja na dawa zenye ubora (kama 
dawa mseto - ALu) zipo kwa ajili ya tiba ya malaria. Lakini kubwa limekuwa ni utoaji 
wa huduma bora za afya, pamoja na dawa za kuokoa maisha kwa wanaohitaji. 
Muungiliano wa sababu mbalimbali unasababisha mgonjwa kupata tiba sahihi ya 
malaria mapema. Wakati dawa za kutibu malaria kama chloroquine na SP 
zimethibika kushindwa kutibu malaria na badala yake dawa mseto (ALu) kuchukua 
nafasi, vikwazo katika kupata tiba sahihi ya malaria vimeelezwa kuwepo katika ngazi 
ya kaya (kwa wahitaji), na sekta ya afya (watoaji), na pia katika sera za afya. 
 
Lengo la utafiti huu ni kuchangia katika uelewa bora wa sababu nzuri na mbaya 
zinazosababisha jamii kupata tiba ya malaria. Matokeo ya utafiti huu yatatoa mwanga 
kwa mikakati mbalimbali ya kimaendeleo kuimarisha upatikanaji wa tiba sahihi ya 
malaria na pia kutengeneza dira ya mradi wa ACCESS 
 
Utafiti huu ulifanyika kama sehemu ya Mradi wa ACCESS, wenye lengo la kuongeza 
uelewa na kuimarisha upatikanaji wa tiba sahihi ya malaria katika wilaya za 
kilombero na ulanga, kusini-mashariki mwa Tanzania. Mikakati ya mradi wa ACCESS 
imelenga katika sehemu mbalimbali zikiwemo 1) Kuhamasisha jamii kuboresha 
huduma katika ngazi ya jamii 2) kuimarisha ubora wa huduma za afya katika vituo 
vya afya and 3) kuimarisha maduka yanatoa huduma za dawa. Mikakati hii 
imeambatana na shughuli mbalimbali za tathimini na ufuatiliaji. 
 
Njia mbalimbali za  kiutafiti zilitumika kukusanya maelezo ndani ya eneo linalotumika 
kukusanya takwimu za afya na pia katika tarafa ya Ifakara. Kati ya mwaka 2004 na 
2006, utafiti katika jamii ulifanyika kuchunguza tabia za utafutaji matibabu na 
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makadirio ya uelewa wa tiba ya malaria. Sensa ya maduka na watafiti walitumika 
kufanya tathimini ya upatikanaji wa madawa na uwezo wa wauza maduka katika 
uuzaji dawa. Utafiti huu ulifanyika ndani ya eneo linalotumika kukusanya takwimu za 
afya ambapo maelezo binafsi ya wahojiwa yalikusanywa pamoja na maelezo ya 
magonjwa na vifo. 
 
Utafiti huu wa utafutaji matibabu na uelewa wa magonjwa ulionyesha muungiliano 
mzuri wa maneno ya kisayansi na kijamii katika kuelezea ugonjwa zaidi ya 
ilivyoripotiwa kabla katika tafiti mbalimbali ndani ya eneo hilo. Hii inaweza kutokana 
na uhamasishaji jamii na kampeni za afya zilizofanyika hapo zamani. Dawa za kisasa 
ziliongoza kutumiwa na wagonjwa wengi na asilimia themanini na nane ya matatizo 
ya homa kwa watoto na asilimia themanini na moja ya watu wazima walitibiwa kwa 
dawa ya malaria iliyopendekezwa (kwa wakati huo SP, amodiaquine au quinine). 
Lakini makadirio ya utumikaji katika jamii yalionyesha kwamba ni asilimia ishirini na 
mbili nukta tano tu ya watoto and asilimia kumi nukta tano ya watu wazima walipata 
tiba sahihi ya malaria mapema, ukiachilia mbali matumizi makubwa ya huduma 
katika vituo vya afya. Ubora wa huduma za afya haukuwa wa kutosheleza na watoto 
chini ya miaka mitano ambao wanatakiwa kupata matibabu bure, hali haikuwa hivyo. 
Kwa hakika maduka yanayouza dawa, yalionekana kuwa mbadala kwa utoaji 
huduma kwa tiba ya malaria. Kwa ajili ya kuongeza mafanikio na kuimarisha ubora 
wa dawa mpya iliyopendekezwa, dawa mseto, vyanzo vyote vya utoaji huduma 
vinatakiwa vidumishwe na ubora wake uongezwe. 
 
Uhamaji wa vipindi wa familia kwa ajili ya shughuli za kilimo mashambani 
haukuongeza uwezekano wa kushambuliwa na malaria kwa familia hizo. Katika 
mashamba asilimia tisini na saba nukta tisa ya watu wote walitumia vyandarua kwa 
ajili ya kinga lakini kwa sababu ni kaya chache tu zilizohifadhi dawa za malaria, 
matibabu yalitafutwa vituo vya afya vilivyokuwa mbali au katika maduka ya madawa. 
Kati ya matatizo yaliyojitokeza kipindi cha shamba, asilimia themanini na nane nukta 
mbili yalitibiwa kwa dawa za malaria, hii inaonyesha kwamba kaya zitumia jitihada za 
kutosha kutafuta tiba ya malaria. Ilitokea kwamba, kipindi cha shamba, matatizo 
katika kutafuta mali pamoja na umbali kufikia vituo vya tiba, vilisababisha 
ucheleweshaji wa utafutaji matibabu. Katika hili basi, njia sahihi inatakiwa ili 
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kuongeza upatikanaji wa huduma na wakati huo huo kuwezesha utumiaji mzuri wa 
madawa kusaidia wananchi wanaohama kwa ajili ya shughuli mbalimbali 
 
Utafiti katika maduka ulionyesha kwamba upatikanaji wa dawa za malaria 
umepungua kwa asilimia hamsini  katika maduka kutokana na mabadiliko ya sera ya 
afya kutoka chloroquine kwenda SP, kama dawa ya malaria iliyopendekezwa kwa 
tiba ya malaria mwaka 2001. upungufu huu ulionekana sana katika maduka ya 
kawaida, ambayo hayakuruhusiwa tena kuuza SP (kinyume na ilivyokuwa kwa 
chloroquine kabla ya mabadiliko ya sera). Mwaka 2004, vijiji vitano kati ya ishirini na 
tano vilivyofanyiwa utafiti na vilivyokuwa na jumla ya wakazi 13,506 (asilimia kumi na 
nane) hawakuwa na aidha kituo cha afya au duka lolote kama chanzo cha tiba ya 
malaria. Wakati kulikuwa hamna madhara ya papo kwa papo katika matumizi ya 
dawa za malaria, upungufu huu umeathiri wasiokukuwa na uwezo na wale wanaoishi 
maeneo ya mbali zaidi na huduma katika jamii. Katika mabadiliko ya sera mpya ya 
dawa mseto, mambo haya yanatakiwa kuangaliwa kwa kina kama faida ya hizi dawa 
bora zitapanuliwa kuifikia jamii yote. 
 
Tathmini ya uwezo na uelewa wa wauza maduka ulionyesha kwamba wauza maduka 
ya dawa wana uelewa mzuri wa malaria na tiba zake kuliko wauzaji wa maduka ya 
kawaida. Katika maduka ya dawa, watafiti waliweza kupata tiba sahihi, ingawa kwa 
bei kubwa zaidi. Kwa ajili ya usambazaji wa dawa mseto, na mbadala wa vituo vya 
afya, maduka ya dawa muhimu yanaweza kuwa suluhisho sahihi. Lakini, wauzaji wa 
maduka ya dawa wanatakiwa kupata mafunzo ya jinsi ya kutoa dawa sahihi za 
malaria. Na pia, umuhimu wa maduka ya kawaida kama kimbilio ya kwanza 
yanatakiwa kufikiriwa tena. Ukichukulia umuhimu wa maduka, mikakati inatakiwa 
kuongeza upatikanaji wa dawa mseto za malaria kwenye maduka haya. 
 
Matokeo ya tafiti hizi yaliyofanyika ndani ya mradi wa ACCESS yamesaidia kujenga 
mtazamo mpya ndani ya mradi, na kuibua mtazamo wa kuangalia jamii kwa jinsi 
inavyojishughulisha kutafuta tiba. Mtazamo huu unaunganisha utafiti wa sayansi ya 
jamii na afya ya jamii kuangalia janga zima la kuondoa umasikini. Pia unatoa 
mwangaza kwa tafiti nyingine za kisayansi, na unapendekeza uwepo wa sera na 
mikakati inayovuka mipaka na kuangalia zaidi ya huduma za afya tu. 
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Kwa kuhitimisha, matokeo ya utafiti huu yanalenga kuwepo kwa muingiliano wa 
kimitazano katika kuchambua na kuongeza upatikanaji wa matibabu. Katika hili, 
sekta ya afya imeonekana kuwa kikwazo katika matibabu, wakati mitazamo ya 
magonjwa katika jamii haikuwa na madhara katika utafutaji matibabu.  Kuna 
umuhimu wa haraka wa kuongeza ubora wa huduma za afya katika ngazi zote na 
uchunguzi kuendelea ili kuwe na usawa katika uwepo wa mikakati muhimu ya afya. 
Sera za afya zinatakiwa kuundwa na kufanyiwa kazi kwa njia ambayo itawezesha 
kuboresha huduma za afya kwa wanajamii mbalimbali. Ukichukulia muingiliano wa 
karibu kati ya magonjwa na umasikini, mikakati yoyote ya kiafya haitafanikiwa kwa 
urahisi kama haitachukua mategemeo ya wanjamii na kuyafanyia kazi. Mitazamo na 
mikakati mbalimbali inatakiwa sio tu kusaidia wagonjwa kupata huduma bora za afya 
bali pia kudumisha uchumi wa kaya. Ili kuweza kufikia lengo la kupunguza magonjwa 
na vifo vinavyosababishwa na malaria barani Africa, wadau wote wanatakiwa 
kuunganisha nguvu na kubadilisha nyenzo kuwa zenye usawa, imara na kuwa na 
mikakati ya kudumu. 
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1 INTRODUCTION 
1.1 Malaria 
Malaria is a parasitic infection caused by protozoa of the genus Plasmodium. 
Plasmodia are transmitted from humans to humans by several species of blood-
feeding female Anopheles mosquitoes. The four human-pathogenic Plasmodia 
species P. falciparum, P. vivax, P. malariae and P. ovale differ in pathogenesis and 
global distribution. P. falciparum causes most of the severe and fatal cases of 
malaria. It is the predominant species throughout sub-Saharan Africa. Since P. vivax 
can develop in mosquitoes at a lower temperature than P. falciparum, its 
geographical distribution is wider. P. vivax and P. ovale can form resting stages in 
the liver (hypnozoites) which may cause clinical relapses many months after the first 
attack. In humans, malaria parasites are found in the liver and in the blood where 
they invade, grow and replicate in erythrocytes (schizogony). Once sexual forms 
(gametocytes) of the parasite have developed and circulate in the bloodstream, they 
may be taken up by a female Anopheles, and the parasite’s sexual reproduction can 
take place in the gut of the mosquito. After extensive replication in the outer wall of 
the mosquito-gut (sporogony), the parasites can pass via the salivary glands into the 
next human host, usually 10-14 days after the initial blood-meal (Figure 1.1) (Warrell 
& Gilles 2002; Greenwood et al. 2005).  
 
 
Figure 1.1: Lifecycle of the malaria parasite in humans and mosquitoes 
Source: Greenwood et al. 2005 
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1.2 Clinical features of malaria 
The clinical features of uncomplicated malaria are well known. In semi-immune 
populations, malaria infections often results in asymptomatic parasitaemia. Clinical 
attacks manifest themselves as febrile paroxysms with accompanying symptoms 
such as headache, cough, body pains, chills, vomiting and diarrhoea (Warrell & 
Gilles 2002). Then, there is a continuum from mild to severe disease. Severe malaria 
is a complex multi-system disorder, characterized by one or more of the following 
clinical features: severe anaemia, prostration, impaired consciousness, respiratory 
distress (acidotic breathing), multiple convulsions, circulatory collapse, pulmonary 
oedema, abnormal bleeding, jaundice, and haemoglobinuria (WHO 2000b; 
Mackintosh et al. 2004). Impaired consciousness and respiratory distress were found 
to be the most dangerous clinical features (Marsh et al. 1995; Schellenberg et al. 
1999). 
 
Cerebral malaria and severe anaemia are the most common syndromes of severe 
malaria in semi-immune children and they are responsible for long-term 
developmental impairments and most of the deaths in children (Carter et al. 2005). 
Cerebral malaria is a heterogeneous syndrome with a high case-fatality rate, in which 
the sequestration of parasites in peripheral blood vessels plays a certain role. Apart 
from the direct fatal outcome, cerebral malaria can result in brain damage in surviving 
children and lead to behavioural disorders and impaired growth and development 
(Breman 2001; Greenwood et al. 2005). Severe anaemia results from the destruction 
of red blood cells, either directly by the malaria parasite or indirectly by immune 
mechanisms. It may have multiple aggravating causes and goes often unnoticed as it 
is not easily recognised by caretakers. Severe anaemia in children may lead to long-
term neurological, cognitive, and developmental impairments (Breman 2001; 
Schellenberg et al. 2003b). A special risk group are pregnant women who are more 
likely to develop severe malaria than non-pregnant adults, especially during the 
second and third trimesters. During pregnancy, severe malaria endangers the life of 
both the pregnant woman and her foetus. Placental malaria is common and 
associated with low birth-weight and subsequent increased infant and child mortality 
(Marchant 2004). Maternal anaemia may result in impaired development of the foetus 
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and anaemic neonates. Cases of congenital malaria, however, are rare (WHO 
2000b; Breman 2001; Schellenberg et al. 2003b).   
 
1.3 Global malaria situation 
Malaria is the most important parasitic infection in humans. Most estimates of 
malaria-related mortality suggest that about 1 million deaths a year are directly due to 
malaria (Snow et al. 2005). However, it is difficult to obtain an accurate measurement 
of how many people die from this disease (de Savigny & Binka 2004). National health 
statistics of most developing countries are found to be an unreliable source of 
information and estimates are often based on different and sometimes contradictory 
sources. Furthermore, indirect effects of the disease on other infections, such as HIV 
(ter Kuile et al. 2004), or on nutrition and more broadly on poverty, may contribute to 
an even higher death toll. This impact is reflected in estimates of up to 3 million 
malaria-related deaths a year worldwide (Breman et al. 2004). Almost all of these 
deaths occur in children and are caused by P. falciparum (Phillips 2001). 
 
The enormous impact of malaria on morbidity and mortality poses a challenge for 
achieving the Millennium Development Goals (MDG) (United Nations 2005). These 
goals for the development of the most deprived regions in the world were adopted by 
the United Nations General Assembly in September 2000 and range from halving 
extreme poverty to halting the spread of major diseases and providing universal 
education by the year 2015 (United Nations General Assembly 2000). Three out of 
the eight MDGs are directly linked to the successful reduction of the disease burden 
caused by malaria: to reduce the mortality rate among children under five by two 
thirds (MDG 4); to reduce the maternal mortality ratio by three quarters (MDG 5); to 
halt and begin to reverse the incidence of HIV/AIDS, malaria and other major 
diseases (MDG 6). In order to achieve the targets set by the health MDGs, several 
publications have recently called for a bigger effort in controlling disease in 
developing countries, as well as for the re-evaluation of currently applied strategies 
(Molyneux & Nantulya 2004; Travis et al. 2004; United Nations 2005; Evans et al. 
2005; Bryce et al. 2006).  
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Historically, the distribution of endemic malaria ranged from temperate to tropical 
regions. In the temperate regions of the world, the elimination of malaria has been 
successful. In the 1930s to 1950s, countries such as the United States, Italy, Greece 
and Spain have become free of autochthonous malaria, as a result of socioeconomic 
development (i.e. improved housing) and intensive antimalarial interventions. The 
measures applied comprised environmental management such as draining of 
swamplands to eliminate Anopheles breeding sites, and the use of insecticides, 
including indoor house spraying using dichlorodiphenyltrichloroethane (DDT). 
Climatic conditions with cold winters facilitated these measures as they shorten 
mosquito life and prolong the time period required for the parasite to complete its life-
cycle within the cold-blooded mosquito (Warrell & Gilles 2002).  
 
Today, endemic malaria is spread throughout the tropical and sub-tropical regions of 
Africa, Asia and Latin-America (Figure 1.2). The tropical areas of the world have a 
combination of rainfall, temperature and humidity that maximizes survival of the 
Anopheles mosquito and speeds-up completion of the parasite life-cycle (Craig et al. 
1999).   
 
Recent progress has been made in controlling malaria in parts of Asia and Africa 
(Barat 2006; Barnes 2007). However, a literature review documents a dramatic 
increase in the global population at risk over the last century, mainly due to 
demographic changes in Africa and Asia. It estimates that by 2010, 3.4 billion people 
will live at risk of malaria, compared to 0.9 billion in 1900 and about 3 billion in 2002 
(Hay et al. 2004). In recent years, not only the absolute number, but also the 
percentage of the global population at risk of malaria has increased again (Figure 
1.3). Recent trends of urbanization in developing countries will also affect the change 
of the epidemiological pattern of malaria (Donnelly et al. 2005). 
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Figure 1.2: Geographical distribution of malaria  
Source: World Health Organization 2005 (http://www.who.int/globalatlas) 
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Figure 1.3: Global population at risk of malaria 
Data source: Hay et al. 2004 
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The brunt of the malaria burden is born by the population of sub-Saharan Africa, 
where P. falciparum is the predominant species and the mosquito vectors are the 
most efficient. 60% of the global estimate of 0.5 billion clinical malaria episodes and 
70-90% of the 1 to 3 million malaria deaths a year occur in Africa, mostly south of the 
Sahara (Breman et al. 2004; Snow et al. 2005; WHO & UNICEF 2005).  
 
In areas of stable P. falciparum transmission, such as in large parts of sub-Saharan 
Africa, very young children and pregnant women are the groups at highest risk. Most 
malaria deaths in these areas occur in children under 5 years of age, who have not 
yet acquired partial immunity against infection. Pregnant women, whose immunity to 
malaria is temporarily impaired, are particularly at risk as their infections are often 
asymptomatic and may be overlooked because peripheral blood films may be 
negative (Snow et al. 1999; WHO 2000a).  
 
Estimates suggest that out of the 0.5 billion clinical attacks that occur every year, 2-3 
million are severe cases (Figure 1.4). The final outcome of an infection with P. 
falciparum parasites depends on a variety of factors, such as virulence of the 
parasite, genetic and immunological factors and the nutritional status of the human 
host. Malaria and other infectious diseases such as HIV/AIDS may adversely affect 
each other. Furthermore, sociological factors, including treatment seeking behaviour 
are also likely to play an important role (Greenwood et al. 1991; Greenwood et al. 
2005).  
 
 
 
Figure 1.4: Possible outcomes of infection with Plasmodium in children 
Numbers indicate estimated annual number of cases (in millions) of African children 
likely to fall into each category. Data source: Greenwood et al. 2005 
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1.4 Malaria and poverty 
The burden of malaria in endemic countries extends beyond the direct health impact. 
Malaria imposes economic costs on households and states. Repeated malaria 
attacks contribute to prolonged absence from school and work. Consequences are 
poorer school performances and the loss of workdays and income. Furthermore, 
evidence suggests that repeated disease episodes may impair intellectual 
development (Fernando et al. 2003). In addition to income loss, household 
economies can be overburdened by expenditures for the prevention and treatment of 
illness episodes, sometimes leading to cases of catastrophic household expenditures 
(Xu et al. 2003). Malaria increases government spending on vector control, health 
services, subsidies for treatments, research, and training. It has further been 
suggested that malaria has a major impact on local economies through changes in 
household behaviour, demography, schooling or migration. Additionally, on a 
macroeconomic level, malaria may impede tourism, trade and foreign investments 
(Sachs & Malaney 2002).  
 
A mutual link between malaria and poverty is now widely accepted. While malaria 
can promote poverty, poverty also increases vulnerability to malaria. On a macro-
level, malaria is most widespread in countries in development. Malaria endemic 
countries are poorer and have slower economic growth than non-malarious countries. 
A comparison of malarious and non-malarious countries found a more than five times 
lower average gross domestic product (GDP) in countries with intensive malaria 
transmission (US$ 1,526 vs. US$ 8,268). Further, countries with intensive 
transmission had a 1.3% lower annual economic growth rate between 1965 and 1990 
than other countries (Gallup & Sachs 2001; Sachs & Malaney 2002). In addition to 
the differences between countries and regions, there are inequities within countries. 
People of all socio-economic groups in malaria-endemic countries fall ill from malaria. 
Yet, the children of the poorest people often bear the heaviest disease burden. They 
are more exposed to additional risk factors, less resistant to diseases, less likely to 
use preventive measures and less likely to get appropriate care when ill. They often 
live in areas under-served by health facilities (Victora et al. 2003; Worrall et al. 2005; 
Njau et al. 2006).  
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1.5 Burden of malaria in Tanzania 
Tanzania has an estimated population of about 38 million people with an annual 
population growth rate of 2.2% in 2005 (WHO 2006c). The risk of malaria 
transmission along with the length of the transmission season varies over time and 
space, mainly due to climatic variations across the country. Of the total population, 
87% live in regions suitable for stable perennial or seasonal malaria transmission (4 
or more months per year) and therefore at risk of endemic malaria. 4% live in areas 
with highly seasonal or unstable transmission and 9% face no transmission in 
average years (Figure 1.5). This data was derived from a model of seasonality of 
transmission based on climatic suitability using MARA LITe software (Mapping 
Malaria Risk in Africa/Atlas du Risque de la Malaria en Afrique [MARA/ARMA] 
collaboration, South African Medical research Council) (MARA/ARMA 2004).  
 
 
Figure 1.5: Duration of the malaria transmission season in Tanzania 
Source: MARA/ARMA collaboration (http://www.mara.org.za) 
 
Transmission intensity in Tanzania is characterized by high entomological inoculation 
rates (EIR), a measure for the number of infectious bites per person per year. EIR 
and multiplicity of infection were shown to be associated with increased malaria 
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morbidity. A tenfold increase in the EIR corresponded to a 1.6-fold (95% confidence 
interval [CI] = 1.4-2.0) increase in malaria incidence (Smith et al. 1998). A review of 
EIR values across Africa found that Tanzanian EIR estimates were among the 
highest with a mean of 367 infectious bites per person per year (ib/p/y, range 94-667). 
The overall mean of EIR for Africa was 146 ib/p/y (range 0-884) (Hay et al. 2000).  
 
Reliable estimates of the morbidity and mortality burden of malaria in Tanzania are 
compromised by a lack of reliable data sources. In most developing countries, health 
management information systems (HMIS) are weak and data collection incomplete 
(de Savigny & Binka 2004). This is partly the reason for contradictory data from 
health statistics, facility-based and community-based studies, or demographic 
surveillance systems (DSS).  
 
District-level statistics from health facilities reported 11.2 million outpatient (OPD) 
attendances, 2.1 million admissions and 18,000 deaths due to malaria in 2004 
(MOHSW 2006a). Yet in reality, many malaria episodes are managed outside the 
formal health sector and many deaths occur at home, thus escaping official records 
(Breman 2001). In the Ifakara DSS, which has a good network of health facilities and 
a highly frequented district hospital nearby, still about 30% of all deaths occur outside 
a health facility (Ifakara DSS 2002). Facility-based data are therefore most likely to 
provide an underestimation of the real disease burden. More reliable data should be 
expected from DSS or cross-sectional community-surveys. On the other hand it 
should be noted that misdiagnosis of malaria in health facilities is common and that 
not all cases of febrile illness (often used as proxy indicator for malaria in community 
surveys) are really cases of malaria (Reyburn et al. 2004; Amexo et al. 2004).  
 
During the 2004 Demographic and Health Survey (DHS) 24% of under-fives were 
reported to have had a fever (as proxy indicator for malaria) in the two weeks 
preceding the survey (National Bureau of Statistics 2005). A household survey 
carried out by the National Malaria Control Programme (NMCP) found 32% of under-
fives with a recent fever in 2005 (MOHSW 2006b), representing a decline compared 
to 35% in 1999 (United Republic of Tanzania 2005). Data from the Ifakara DSS 
suggests a malaria-related mortality in under-fives of 3.7 per 1,000 person-years in 
2003 (Ifakara DSS, unpublished, cited in United Republic of Tanzania 2005). Overall, 
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32% of total mortality is attributed to malaria (41% in under-fives) (USAID - CDC 
2005). In absolute numbers, there are 100,000–125,000 deaths per year from 
malaria, up to 80,000 of which are in children under the age of five years. Most of the 
under five deaths occur during the rainy seasons between November and December 
(short rains), and between March and June (long rains), a seasonality that is most 
likely due to malaria. It is estimated that a Tanzanian child under five years has on 
average 0.7 episodes of malaria per year (USAID - CDC 2005).  
 
This high number of clinical attacks, including many cases of severe disease, 
presents a challenge to the Tanzanian health system. Data from district-level health 
statistics for 2004 suggest that malaria, acute respiratory infections, pneumonia and 
diarrhoeal diseases were the major causes for outpatient attendance in health 
facilities. Malaria accounted for 39% of all outpatient attendances in under-fives and 
for 48% in the age-group of five years and above. In inpatients under five years, 34% 
of the primary diagnoses were uncomplicated malaria and 11% severe malaria. In 
the age group over five, malaria accounted for 42% and severe anaemia for 10%. In 
peripheral health facilities (i.e. excluding referral hospitals), 48% of deaths in under-
fives and 26% of deaths in patients over five years were attributed to malaria 
(MOHSW 2006a).  
 
It is estimated that US$ 121 million are spent annually on the prevention and control 
of malaria in Tanzania, amounting to 3.5% of the GDP. One-third of public health 
facilities’ expenditures are devoted to malaria (USAID - CDC 2005). An economic 
analysis on data from 1998 concluded that 71% of total malaria expenditures came 
from private sources (e.g. households) (Jowett & Miller 2005). However, this is likely 
to have changed recently, considering the latest influx of money from malaria control 
initiatives and funding agencies such as the US President’s Malaria Initiative (PMI) or 
the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM). 
 
1.6 Malaria control 
In order to develop successful malaria control measures, a sound understanding of 
the local epidemiology, as well as of the socio-cultural and political context is 
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fundamental. Strategies for controlling malaria have changed over the past decades, 
differing from one setting to the other, depending to a large extent on priority-setting 
at global and national level, on the costs and effectiveness of available control tools, 
and on the local feasibility of their implementation. In 1956, the World Health 
Organization (WHO) launched the Malaria Eradication Campaign with the aim to 
completely stop malaria transmission in malarious countries. As a result, large parts 
of southern Europe, the USA, Latin America, the Middle East and parts of Asia were 
freed from malaria. This was achieved through the widespread and meticulously 
organized application of the insecticide DDT and through environmental 
management. In tropical regions, this approach was less successful and the global 
eradication strategy was abandoned after 1969 (Nájera 2001; Warrell & Gilles 2002).  
 
Since 1992, the focus has been on malaria control (rather than eradication) with the 
aim to reduce morbidity and mortality to an extent that the disease is no longer a 
major public health problem (Nájera 2001). This approach is at the heart of a 
renewed effort to fight malaria, which started at the turn of the 21st century. At the 
African Summit on Roll Back Malaria, held in April 2000 in Abuja (Nigeria), African 
Heads of State agreed on a concerted effort to reduce the burden of malaria on the 
continent. They endorsed the ambitious goal of halving the number of malaria deaths 
by the year 2010 (Yamey 2000). They agreed to ensure, that by 2005: 
• at least 60% of those suffering from malaria have prompt access to affordable 
and appropriate treatment within 24 hours of the onset of symptoms,  
• at least 60% of those at risk of malaria, particularly children under five years of 
age and pregnant women, are protected by insecticide-treated mosquito nets 
(ITNs) and other interventions, and  
• at least 60% of all pregnant women who are at risk of malaria have access to 
chemoprophylaxis or intermittent preventive treatment (IPT). 
 
In 2005, these goals were changed from 60% to 80% to be reached by 2010, 
although most of the countries had not even managed to meet the 2005 targets 
(Yamey 2004; RBM Partnership 2005). 
 
To achieve this, the WHO and the Roll Back Malaria (RBM) Partnership promote a 
control strategy for Africa that emphasises the importance of using the most effective 
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existing tools and resources to the fullest extent (WHO & UNICEF 2005; RBM 
Partnership 2005). The strategic components and the tools, which should be chosen 
in consideration of the local setting, have been identified as: 
• Effective malaria prevention through vector control 
o ITNs, preferably long-lasting insecticidal nets (LLIN) 
o Indoor residual spraying (IRS) with DDT or other recommended 
insecticides 
• Intermittent preventive treatment (IPT) 
o IPT during pregnancy (IPTp) with sulphadoxine-pyrimethamine (SP) 
o IPT in infants (IPTi) as soon as safety and effectiveness is proven 
• Prompt and effective treatment 
o Artemisinin-based combination therapies (ACTs) 
• Reduction of the impact of emergencies and epidemics 
o Early warning and rapid response systems 
 
These updated guidelines now consider the re-emerging use of IRS (WHO 2006b), 
the proven efficacy of ACT (WHO 2001a) along with the potential benefits of IPTi 
(Schellenberg et al. 2005) and the well-known effectiveness of ITNs (Lengeler 2004). 
Importantly, the current strategy addresses the fact that most existing health systems 
do not have a sufficient capacity (human resources, management, infrastructure) to 
implement the increased interventions package. Hence, it stresses the need for 
strengthening health systems, building local capacity and ensuring sustained 
financing (RBM Partnership 2005).  
 
The WHO recommendations have been adopted by most African countries and 
adapted to the local context. The NMCP of Tanzania formulated its four strategic 
approaches to malaria control in the 2002-2007 Medium Term Strategic Plan (Figure 
1.6) (MOH 2002).  
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Figure 1.6: Tanzanian malaria control strategy  
 
Combining different control approaches, together with a strong management, have 
led to some important initial successes. Recent progress in malaria control was 
reported from South Africa, namely KwaZulu-Natal (Barnes et al. 2004), Eritrea 
(Nyarango et al. 2006), Bioko (Kleinschmidt et al. 2006), Madagascar (Romi et al. 
2002), southern Mozambique (Sharp et al. 2007), and Zambia (Singer 2005). These 
efforts all benefited from the renewed attention that has been devoted to malaria in 
recent years. It led to new initiatives and a ten-fold increase in financing for malaria 
control activities between 1998 and 2006 (Feachem & Sabot 2007).  
 
With effective control tools and up-to-date implementation guidelines at hand, the 
challenge remains to deliver the interventions to those who are affected, particularly 
the most vulnerable young children and pregnant women living in underserved areas. 
Increased attention is therefore being devoted to the question of how to build health 
systems, delivery mechanisms and a political environment which improve people’s 
access to malaria prevention and treatment (Barnes 2007).  
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2 ACCESS TO MALARIA TREATMENT 
2.1 Access to health in the global discussion 
With growing prosperity, and technical and scientific advances, the availability of 
means to improve health has constantly increased. At the same time, the gap 
between rich and poor – between, as well as within countries and regions - has 
become wider. While for all major diseases (including malaria, HIV/AIDS and 
tuberculosis) effective treatments or preventive measures exist, large parts of the 
world’s population are unable to gain access to these means (Victora et al. 2003). In 
a vicious circle, the poorest suffer from the greatest burden of disease while at the 
same time they often lack access to effective health care (Goddard & Smith 2001; 
Victora et al. 2003; WHO 2005b). According to WHO estimates, 1.7 billion people, i.e. 
30% of the world’s population (1999), have inadequate or no access to essential 
medicines. To a similar extent, they may lack access to diagnostics, preventive 
measures or general health infrastructure. 80% of these people live in low-income 
countries (WHO 2004c).  
 
In recent years, access to health care has become an important topic in international 
health. The discussion arose partly as a consequence of growing drug resistance, an 
issue which is not only relevant for antimalarial medicines but also for other anti-
infectious agents. Antimalarial drug resistance emerged in the 1960s and has 
steadily progressed and spread over the last decades. The main foci for resistance 
have been found in South-East Asia and South America, leading to more and more 
complex first-line drug regimens. Africa has seen the emergence of drug resistance 
against the widely used chloroquine since the 1980s, starting in East Africa and 
spreading rapidly over the whole continent. Nowadays, chloroquine is virtually 
useless as a first-line treatment and SP is following in its footsteps in much of sub-
Saharan Africa. A resulting increase in malaria-specific mortality may therefore loom 
if alternative treatments are not rapidly implemented (Trape et al. 1998; White et al. 
1999; White 2004). The increasing need for new efficacious treatment and prevention 
has driven the creation of international initiatives such as Medicines for Malaria 
Venture (MMV) (MMV 2007a), the Drugs for Neglected Diseases initiative (DNDi) 
(DNDi 2003), or the Global Alliance for Vaccines and Immunization (GAVI) (GAVI 
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Alliance 2007). The declared aim of these organizations is to develop and introduce 
new and efficacious drugs and vaccines for diseases of the developing world – a 
market which is largely beyond the economic interests of pharmaceutical companies. 
Similarly, the “Grand Challenges in Global Health” initiative also focuses on new 
technologies for better tools in order to achieve advances in prevention and 
treatment of diseases of the poor (GCGH 2006).   
 
The development of efficacious drugs, especially for so-called neglected diseases, or 
diseases of the poor, is of paramount importance. However, it is essential to consider 
that in the most deprived regions of the world, developing a new intervention (drug, 
vaccine, etc.) and delivering it to country-level will not necessarily translate into 
effectiveness at community-level (Amin et al. 2004). The same can be observed in 
marginalised population-groups within otherwise well-off countries (Goddard & Smith 
2001).  
 
One central question is whether countries (i.e. their health budget) and patients can 
afford the medicines they require. This aspect of access is addressed by the 
campaigns of leading international non-governmental organizations, such as Oxfam 
(Oxfam 2007) and Médecins Sans Frontières (MSF 2007). They advocate access to 
essential drugs as a human right and criticize commercial pricing and patenting for 
drugs. Some of these advocacy campaigns are rooted in the HIV/AIDS activist 
movement and many are inspired by it (GAP 2007). Criticism of patents and prices 
also comes from the Commission on Intellectual Property, Innovation and Public 
Health which argues that international agreements, such as the Trade-Related 
Aspects of Intellectual Property Rights (TRIPS) agreement impede poor countries 
from creating competitive medicine markets, resulting in unaffordable drug prices (t 
Hoen 2006). Unaffordable drug prices are often seen as the only major reason why 
people in developing countries do not receive effective treatment for curable 
diseases. This argument is especially popular among activist movements in 
industrialized countries. Sometimes, even health agencies assume that, once drug 
prices are lowered, access will be guaranteed. For example, in a recent newsletter on 
ACTs, the WHO lists, "how access to ACTs is being ensured". The list includes 
quality assurance, a call for tenders of ACTs, negotiating prices and financing of 
ACTs (WHO 2006a). Similarly, authors affiliated with the World Bank put a major 
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focus on macroeconomic aspects of drug purchasing and delivery mechanisms in 
order to improve access (Attridge & Preker 2005). 
 
While efficacious drugs at affordable prices are essential for access to effective 
health care, they alone do not adequately reflect the complexity of the issue. Access 
to health is a multifaceted problem and factors limiting access are numerous, 
complex and often interrelated. Diverse solutions to overcome the problem of access 
have been proposed based on various different definitions of access, some of which 
will be further discussed in the following chapters (Penchansky & Thomas 1981; 
Waters 2000; Aye et al. 2002; Adamson et al. 2003).  
 
The central prerequisite for patients to have access to health care is that they are 
reached by efficacious interventions. The question is therefore, how (and which) 
health systems can best respond to the health needs and deliver essential 
interventions to all parts of the society, explicitly including the poorest and most 
vulnerable (Travis et al. 2004; Singh 2006). Using the example of child health, Bryce 
et al. showed that the coverage with existing key interventions is critically low in most 
of the 60 countries that account for 94% of child deaths (Bryce et al. 2006). In most 
developing countries, weak or hardly functional health systems are preventing 
effective interventions from reaching the people in need (Travis et al. 2004). Vertical 
programmes such as campaigns for immunization or distribution of ITNs are likely to 
provide only short-term solutions which need to be complemented by improved 
routine delivery in order to be sustainable (Grabowsky et al. 2007; Lengeler & de 
Savigny 2007). However, little is known about which strategies are most suitable for 
scaling-up health interventions in resource-poor settings, and more research on this 
issue is urgently needed (Victora et al. 2003). 
 
Several organisations have acknowledged the importance of an adequate supply, 
delivery and deployment to translate efficacy of new drugs or vaccines into health 
impact. As a result, some actors, such as MMV or GAVI have widened the scope of 
their activities and do not only work on the development of new tools, but also 
consider issues linked to their deployment (GAVI Alliance 2007; MMV 2007a). 
Similarly, the Global Health Program of the Bill and Melinda Gates Foundation is 
committed to not only encourage the development of lifesaving medical advances but 
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also help ensure they reach the people who are disproportionately affected (BMGF 
2007). At the Ministerial Summit on Health Research organised in Mexico in 2004, 
Ministers of Health identified failing health systems as a central obstacle to achieving 
the MDGs by 2015 (Anonymous 2004). At the same time, the host country Mexico 
was an encouraging example of how improvements in the health system can lead to 
community-wide health impact (Sepulveda et al. 2006). The UN task force on the 
MDGs also acknowledged that the basis for any successful disease-control 
intervention would be functioning health systems. The specific health-related targets 
of the MDGs and the Abuja declaration can not be reached simply by the use of new 
and innovative control tools. Most importantly, existing interventions have to be 
implemented more effectively i.e. access needs to be optimized. Without increased 
investment in improving the performance of health systems in developing countries, 
neither malaria nor HIV/AIDS or tuberculosis can be effectively controlled (Ruxin et al. 
2005).  
 
Following the arguments of Penchansky and Thomas (1981) which are further 
discussed in the following chapter, access can be seen as the fit between the health 
providers (i.e. the health care system) and the patients. Hence what is needed is not 
only an optimal supply, but also a demand for the type of health-care which is offered 
by professional providers. Focusing only on the provider side may result in 
inequitable access if the demand side is not taken into account. While poorer people 
are more exposed to disease risks, they are also less likely to seek care from 
available appropriate providers, as shown in a study in Tanzania (Armstrong 
Schellenberg et al. 2003).  
 
Demand-side barriers may hence be important factors deterring people from 
obtaining appropriate treatment (Ensor & Cooper 2004). One example is the 
differences between traditional and biomedical illness concepts. Febrile convulsions 
may be a sign of severe malaria and should, from a biomedical point-of-view, be 
treated promptly with an efficacious antimalarial drug and potentially an 
anticonvulsant. However, in parts of Tanzania, these symptoms are known as an 
illness called degedege which is often attributed to supernatural causes and 
preferably treated with traditional medicine (Makemba et al. 1996; Hausmann Muela 
2000). Similar examples exist for other diseases, illustrating the importance of the 
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perspective of those affected. In a development-context this was taken up by the UK 
Department for International Development (DFID) in its Sustainable Livelihoods 
Framework (DFID 2001). This framework puts people at the centre of development. It 
considers their ability to mobilize resources within a given vulnerability context, 
influenced by their institutional and socio-cultural environment, in order to achieve 
sustainable livelihoods. In a similar way, this may be used for care-seeking models, 
as outlined in one of the following chapters. A recent paper by Ruger (2007) argues 
in a similar way, stressing the importance of individuals' ability to work towards health 
goals they value and the degree of support they receive from the society. 
 
All these approaches cover fundamental, sometimes very specific aspects of access. 
Considering the complexity of the issue and taking into account the evident link of 
poverty, development, and health, a comprehensive analysis of access is essential in 
order to elucidate obstacles to effective health care. The following section reviews the 
evidence of obstacles to treatment for the concrete case of malaria. In chapter 10, we 
then propose an comprehensive access model which is based on several different 
analytical approaches and embedded in the context of rural livelihood insecurity. 
 
2.2 Access to malaria treatment 
Previous research has identified several factors affecting access to appropriate 
malaria treatment and care beyond the point where drugs are available at the level of 
local providers. This section focuses specifically on malaria treatment and reviews 
studies on treatment-seeking behaviour, health services and health policy, rather 
than the development and production of efficacious medicines (Figure 2.1).  
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Figure 2.1: All stages of drug development and deployment need to be 
considered in order to ensure equitable access by patients 
 
An unpublished literature review (Lengeler et al. 2002) identified a variety of barriers 
to prompt and effective malaria treatment, many of them inter-linked and 
interdependent. These barriers interfere with a successful treatment seeking process 
on several levels.  
 
On the demand-side, i.e. at the level of the household, factors influencing access 
relate to the household's ability to initiate and successfully complete an appropriate 
treatment-seeking process. This includes the ability to mobilise and make use of 
available resources as described in more detail in chapter 10.  
 
Local illness experience and concepts influence the recognition of a malaria episode 
and the initiation of treatment seeking. In Tanzania, there are different concepts of 
malaria in the population depending on the signs and symptoms of the disease. A 
clear distinction is often made between uncomplicated and severe forms of malaria. 
While uncomplicated cases with fever as main symptom are usually known as 
malaria (or malaria) and often associated with mosquitoes, there are different 
taxonomies for symptoms of severe malaria. As already briefly described in the 
previous section, degedege for example stands for febrile convulsions and is often 
linked with supernatural causes. Uncomplicated malaria is usually treated with 
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antimalarials or antipyretics, whereas the understanding of the causation of 
degedege leads to a more complex process of treatment seeking, often involving 
traditional medicine or healers at some stage (Makemba et al. 1996; Winch et al. 
1996; Hausmann Muela 2000; Minja 2001; Mayombana 2004). However, this pattern 
appears to have changed in recent years, especially in areas where extensive health 
education campaigns were implemented (de Savigny et al. 2004b).  
 
The socio-economic situation of a household determines its ability to pay for 
treatment of malaria episodes. Households have to cover direct costs, such as for 
diagnostics, drugs, or user fees but also indirect costs for the loss of working time, 
the travel to a care provider, or for alternative child care (Goodman et al. 2000). In 
the study area cash availability is low and seasonal, with shortages shortly after the 
beginning of the farming season when most cash was used to buy seeds and 
fertilizer, employ workers on the fields, etc. Availability of cash may influence the 
choice of treatment provider, as shown by Hausmann et al. (2000). The authors 
found evidence that people may be willing but not able to pay for biomedical health 
care, even when they can afford costly traditional medicine. They suggest that the 
ability to pay for traditional treatment can differ from the ability to pay for hospital 
attendance since many healers offer alternatives to cash payments (i.e. 
compensation in kind or in work, payment on a credit basis). Even more importantly, 
the activation of social networks for financial help is easier in the case of traditional 
healing, especially for poorer people. Overall, little is known about the willingness and 
ability-to-pay for malaria episodes. But there is substantial experience from the user 
fee literature that even modest amounts (a few USD) are enough to prevent at least 
the poorest households from accessing health care services (Armstrong 
Schellenberg et al. 2003; Manzi et al. 2005; Njau et al. 2006). 
 
Household circumstances, such as the presence of a key decision-maker at the time 
of a medical emergency, are of importance for access to malaria treatment. Often it is 
the husband or an older woman who are in a position to allocate cash or other 
resources in the case of such an event. In absence of such a person a delay in care-
seeking may happen. Molyneux et al. (2002) described how mothers received 
financial assistance or advice for 71% of the treatment-actions taken outside the 
home in Kenya. Reported disputes over perceived causes and appropriate therapy of 
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convulsions highlighted the importance of age, gender and relationship to the 
household head in treatment decision-making.  
 
Another crucial element is the timing of a disease episode, both during the year and 
during the day. Disease episodes occurring during the farming season may bear a 
higher risk of not being addressed adequately compared to episodes taking place 
during other times of the year. This is in part related to the increased work burden at 
that time, but also to the lack of cash before the new harvest. Similarly, episodes 
taking place during the night or the week-end when health facilities are closed may 
lead to a delay in care-seeking (Lengeler et al. 2002). 
 
On the supply side, access is determined by the degree to which the services and 
interventions reach those in need. While this comprises the availability of 
infrastructure as well as the supply of preventive and diagnostic tools and medicines, 
it also depends on how well the services offered by different providers fit the 
(perceived) needs of the patients.  
 
Geographic access to health facilities is comparatively good in Tanzania, with 75% of 
the population living within 5 km of a health centre or dispensary. However, this 
proportion is lower in rural areas (68%) compared to urban centres (98%) and there 
are clear inequities in access (United Republic of Tanzania 2005). In Rufiji district, 
where the average travel time to the nearest facility was 20 minutes, the poorest 
households had 3 times longer travel times than the least poor (J. Armstrong 
Schellenberg and R. Nathan, personal communication). 
 
A variety of different providers may be potential sources for antimalarial treatment. 
On the one hand, research in the study area revealed that most patients were using 
both the traditional and the formal health sector, often in parallel, depending on the 
perceived cause of their illness, the course of treatment and available financial 
means (Hausmann Muela et al. 2002). The services provided by traditional healers, 
which have been described elsewhere (Gessler 1995), will not be dealt with in detail 
in this thesis. On the other hand, there are several levels of providers in the formal 
sector, offering a range of different types of care. Health facilities may be run by the 
government, a non-governmental organization (NGO) or mission, or by a private 
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practitioner. NGO facilities in Tanzania were found to be more expensive than 
facilities run by the government, catering therefore rather to the better-off (Njau et al. 
2006). Government health facilities should be more affordable and exemption 
systems should enable them to target also vulnerable population groups, such as 
young children and pregnant women. The private retail sector plays an important role 
in providing malaria treatment (Brugha et al. 1999; McCombie 2002; TDR/WHO 
2006). In many settings over 50% of all fever episodes are treated primarily through 
retailers with minimal or no medical qualifications (Deming et al. 1989; 
Nydomugyenyi et al. 1998; Molyneux et al. 1999; Hamel et al. 2001). Depending on 
the country and the setting within a country (e.g. urban vs. rural), there may be 
several types of commercial retailers, such as pharmacies, drug stores, general 
shops, or mobile drug vendors (Molyneux et al. 1999; Marsh et al. 1999; Goodman et 
al. 2004; Granado 2007). In Tanzania, pharmacies and drug stores may sell 
antimalarial medicines, but general shops are not legally allowed to do so. Mobile 
drug vendors are virtually non-existent. Given the importance of the retail sector there 
are concerns over the lack of knowledge of correct treatment regimens by shop 
keepers, as well as a lack of quality control of drugs, leading to sub-standard drugs 
being found on the retail market (Braun 2005).  
 
Quality of care is also a concern in the formal health sector (HERA 2006) and both 
technical and perceived quality of care need to be taken into consideration. Problems 
with technical quality relate to the appropriateness of a diagnosis or the prescribed 
treatment, but also to inter-personal care including proper advice. Studies on quality 
of services of health facilities in Tanzania found many shortcomings in the diagnoses 
and treatments provided (Eriksen et al. 2007). In another study, 30% of confirmed 
malaria cases were not prescribed any antimalarial drug (Font et al. 2001). While 
problems with supplies are frequent (Dillip et al. 2007), a further concern is 
inefficiencies in service delivery, such as irrational use of drugs, polypharmacy, and 
excessive use of injectables (Le Grand et al. 1999). 
 
Perceived quality as assessed by patients does not necessarily correspond with the 
technical quality of care. Poor inter-personal skills of health workers, such as rude 
behaviour, long waiting times and concerns about a lack of diagnostics and drugs are 
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common reasons for a lack of trust in health services (Gilson et al. 1994; Gilson et al. 
2005).  
 
While there is general agreement about the problem, it seems less obvious which 
interventions can lead to improved health worker performance and better quality of 
care (Rowe et al. 2005; Gilson et al. 2005). In an effort to cope with the widespread 
lack of diagnostic tools, such as working microscopes, the Integrated Management of 
Childhood Illness (IMCI) strategy was developed (WHO 1997). The strategy is built 
on locally adaptable algorithms for the diagnosis and treatment of childhood illnesses 
based on clinical signs and symptoms. Its implementation was shown to result in a 
cost-effective improvement of quality of care (Bryce et al. 2005a). On the other hand, 
quality in the health sector is intrinsically linked to the adequate staffing of facilities 
and the motivation of health workers. Both are to some extent structural problems 
which need to be addressed not only at the level of health facilities but by the 
implementation of adequate policies.  
 
On a policy level, decisions on the structure, staffing and financing of the health 
system are made and priorities for health interventions are defined. Interventions on 
the entire health system have been shown to result in improved health indicators (de 
Savigny et al. 2004a; Sepulveda et al. 2006). Health legislation on payment 
mechanisms or the selection and deployment of essential drugs can greatly 
determine equitable access to health care. Cost-sharing, user-fees, community 
health funds or other social protection schemes, as well as exemption mechanisms 
may enhance or obstruct access to prompt and appropriate treatment and care, 
depending on the local setting and complementary initiatives (Hutton 2004). Currently, 
the most controversial debate is on how and through which channels ACTs should be 
delivered to malaria patients. Limiting ACTs to the formal sector may result in less 
misuse of the drugs, while wider availability in drug stores might increase coverage. 
In addition, solutions have to be found to make the very expensive artemisinin-drugs 
affordable and accessible even to the poorest (Charlwood 2004; Pagnoni et al. 2005; 
D'Alessandro et al. 2005; Mutabingwa 2005). 
 
The following chapter puts selected barriers to access in the context of an 
intervention programme aimed at improving access to malaria treatment. The 
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research for this thesis was carried out within the ACCESS Programme, in a rural 
Tanzanian setting. The research results are then presented in chapters 6-10 with a 
focus on the demand side (chapters 6 and 7), the supply side (chapters 8 and 9) and 
a general access framework which draws upon the evidence gathered so far in the 
frame of the ACCESS Programme.  
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3.1 Abstract 
3.1.1 Background 
Prompt access to effective treatment is central in the fight against malaria. However, 
a variety of interlinked factors at household and health system level influence access 
to timely and appropriate treatment and care. Furthermore, access may be influenced 
by global and national health policies. As a consequence, many malaria episodes in 
highly endemic countries are not treated appropriately.  
 
3.1.2 Project 
The ACCESS Programme aims at understanding and improving access to prompt 
and effective malaria treatment and care in a rural Tanzanian setting. The 
programme’s strategy is based on a set of integrated interventions, including social 
marketing for improved care seeking at community level as well as strengthening of 
quality of care at health facilities. This is complemented by a project that aims to 
improve the performance of drug stores. The interventions are accompanied by a 
comprehensive set of monitoring and evaluation activities measuring the 
programme’s performance and (health) impact. Baseline data demonstrated 
heterogeneity in the availability of malaria treatment, unavailability of medicines and 
treatment providers in certain areas as well as quality problems with regard to drugs 
and services. 
 
3.1.3 Conclusions 
The ACCESS Programme is a combination of multiple complementary interventions 
with a strong evaluation component. With this approach, ACCESS aims to contribute 
to the development of a more comprehensive access framework and to inform and 
support public health professionals and policy-makers in the delivery of improved 
health services.  
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3.2 Background 
The impact of malaria on health and local economies in sub-Saharan Africa is 
staggering. Between one and three million people die each year, mostly young 
children under five years of age. Deaths and illness contribute to a vicious circle of ill-
health and poverty (Sachs & Malaney 2002; WHO & UNICEF 2005). In recent years, 
the fight against malaria has gained an increased level of attention from governments 
of affected African states as well as from international donor agencies. African heads 
of state agreed in the Abuja Declaration on a concerted effort to reduce the burden of 
malaria on the continent and endorsed the ambitious goal of the Roll Back Malaria 
Partnership of halving the number of malaria deaths by the year 2010 (Yamey 2000). 
Among the malaria control strategies promoted internationally and adopted by most 
endemic African countries, prompt access to effective treatment especially for young 
children and pregnant women features prominently (WHO & UNICEF 2005).  
 
The need for prompt and effective treatment to prevent progression to severe 
disease and death essentially raises two important issues: first, the choice of a safe 
and efficacious drug and second, questions of how to optimize equitable access to 
rationally prescribed treatment.  
 
In order to address the first point, artemisinin-based combination therapies (ACT) 
have been advocated as treatment of choice in Africa (White et al. 1999) in an effort 
to improve on drug efficacy following the increasing failure rate of a number of other 
drugs. Tanzania adopted this policy in 2004 and implemented it at the end of 2006 
(MOHSW 2006c). However, the choice of an efficacious drug does not necessarily 
directly result in improved effectiveness, and issues related to safety, use in 
pregnancy, and cost are also still being discussed. Yet, it would go beyond the scope 
of this paper to thoroughly debate all issues related to a specific drug. 
 
With regard to the second point, it is widely acknowledged that access to quality 
treatment is insufficient in many settings. The poorest people often have least access 
to effective treatment (Victora et al. 2003) and the underlying causes of this situation 
are increasingly debated. On a macro-level, the discussion on access to treatment 
often focuses around the development of new drugs (t Hoen 2006) and global 
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affordability issues, including pricing and patenting of drugs. International initiatives, 
such as Medicines for Malaria Venture (MMV) (MMV 2007b), are increasingly 
financing and speeding up the development and introduction of new efficacious 
antimalarials. At a local community level however, the situation is a lot more complex 
and availability and affordability of drugs are only few among a number of factors 
influencing prompt and effective treatment (McCombie 2002; Committee on the 
Economics of Antimalarial Drugs 2004). In many developing countries, weak health 
systems as well as lack of equipment and qualified staff lead to incorrect diagnosis 
and treatment (Font et al. 2001; Nsimba et al. 2002). Physical access may be 
impeded by long distances to the nearest point of care, inadequate logistics or 
inability to pay for secondary costs such as transport (Noor et al. 2003). Further, 
malaria is a common and socially well accepted illness in endemic countries and its 
potential severity is often underestimated. Insufficient knowledge of the appropriate 
treatment or an understanding of the illness that differs from the bio-medical 
explanation can lead to the use of alternative treatment sources and non-adherence 
to recommended regimens (Makemba et al. 1996; Tarimo et al. 2000). 
 
Several initiatives have attempted to address access questions on a local level, either 
by strengthening home-based management (WHO 2005a), by improving the 
involvement of commercial drug providers (Marsh et al. 2004) or through a general 
improvement of health system performance. Information and education of caretakers 
and care providers has been useful in improving malaria case management and 
compliance at home and in drug selling shops (Kidane & Morrow 2000; Marsh et al. 
2004; Afenyadu et al. 2005). Several models for improving case-management in 
health facilities have been tested and combined approaches were most likely to have 
a (sustainable) impact (Rowe et al. 2005). In any case, considering the complexity of 
the issues involved it seems obvious that there is no such thing as a single “magic 
bullet” approach to solve the problem. What is needed is a comprehensive concept 
addressing several of the access dimensions, ranging from availability and 
affordability to accessibility, acceptability and quality of care. This paper presents a 
programme that was developed to understand and improve comprehensively access 
to appropriate malaria treatment in a highly malaria-endemic rural area of south-
eastern Tanzania. 
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The aim of the ACCESS Programme is to investigate factors influencing access to 
malaria treatment in rural Tanzania in order to develop a set of interventions 
addressing the main obstacles to access. These interventions are then thoroughly 
evaluated. The focus is on children below five years of age and pregnant women, 
who are the most vulnerable groups in this holo-endemic setting in terms of the 
detrimental consequences of malaria (WHO & UNICEF 2003; Breman et al. 2004). 
This paper presents a general overview of the ACCESS Programme, while future 
reports will provide detailed study results of the major evaluation and monitoring 
components. 
 
3.3 Project description  
3.3.1 Study area 
The programme’s intervention area comprises the two districts of Kilombero and 
Ulanga in the south-east of Tanzania (Figure 3.1). The Kilombero River separates the 
two districts and forms the vast Kilombero Valley floodplain. Large parts of this valley 
are flooded during the rainy season which usually lasts from November to May. The 
valley is delimited by the Udzungwa Mountains in the north and the Mahenge 
Mountains in the south. Parts of Ulanga’s southern and south-eastern areas, as well 
as Kilombero’s extreme east are part of the Selous Game Reserve. The Kilombero 
district is connected to the Tanzania-Zambia highway through a mostly unpaved but 
well maintained road. For vehicles the only connection to the Ulanga district is made 
by a motorized ferry over the Kilombero River.  
 
In 2002, there were 517,000 people living in the 109 villages of the two districts. 
Ifakara, the administrative capital of Kilombero, is the major settlement in the valley 
with a population of approximately 46,000. Ulanga’s capital Mahenge is smaller with 
7,300 inhabitants (United Republic of Tanzania 2003a). In the early 1970s, the 
national social engineering project to build communal villages (“vijiji vya ujamaa”) 
brought the valley’s scattered inhabitants to more organised village centres along the 
edges of the valley (Minja 2001). Most people there rely on subsistence farming for 
their livelihoods. Labour intensive rice farming on distant fields in the floodplain forces 
many families to move to their farming sites (shamba in Kiswahili) during the 
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cultivation period. In the fields people stay in improvised “shamba huts” for up to six 
or more months. Rice, maize and cassava are the main cash crops. The main 
agricultural exports from both districts are rice, timber, charcoal and some fish. Since 
the 1980s, an increasing number of nomadic Maasai and Sukuma pastoralists had 
moved to the valley with large cattle herds until a government directive ordered them 
in April 2006 to move to other parts of the country or to reduce their herds in order to 
preserve the Kilombero wetland ecosystem (Tanner et al. 1991; Liganga 2006). 
 
 
Figure 3.1: Map of Kilombero and Ulanga districts with DSS area 
 
The climatic and ecological conditions in the floodplain are favourable for mosquito 
breeding. Malaria transmission in the valley is high and perennial. Recent work has 
confirmed entomological inoculation rates (EIR) of 350 infective bites per person per 
year, despite high mosquito net usage rates of 75% (G. Killeen, personal 
communication). At the level of health services, malaria is the most frequent 
diagnosis in outpatients in rural health facilities.  
 
A number of malaria control interventions have been tested and/or implemented in 
the area by the Ifakara Health Research and Development Centre (IHRDC 2007) in 
collaboration with the Swiss Tropical Institute (STI 2007). The most extensive 
operation was the large-scale introduction of insecticide-treated nets (ITN) in the 
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frame of the KINET project (Armstrong Schellenberg et al. 1999). Today, promotion 
of ITN use through social marketing is ongoing in the frame of the national ITN 
programme.  
 
Monitoring and evaluation (M&E) of the ACCESS Programme is carried out in the 
area of the local Demographic Surveillance System (DSS) (Armstrong Schellenberg 
et al. 2002). The DSS serves as a comprehensive epidemiological framework for 
studies on the project’s impact. In the absence of a vital registration, DSS field 
workers routinely record births, deaths, migrations and socio-economic indicators for 
every household in a defined geographical area of 2400 km2 (Figure 3.1). Each 
household is visited every four months. The area comprises 12 villages in Ulanga 
and 13 in Kilombero. In mid 2004, the total DSS population was 74,200 (Ulanga: 
31,800; Kilombero: 42,400) in 17,050 households. The DSS does not include Ifakara 
town where ACCESS M&E activities are also implemented.  
 
3.3.2 Main interventions 
ACCESS interventions apply two main approaches: 
 
1. Creating demand for appropriate malaria diagnosis and treatment in the 
community through a social marketing approach. 
 
2. Strengthening the supply of quality malaria case-management at health 
facilities and drug shops through training, quality management, improved 
supportive supervision and new diagnostics. 
 
The main areas of intervention are described below and summarized in Figure 3.2 
(status at the end of 2006). Activities may change in the future as experience is 
gathered and analyzed by the programme’s M&E activities.  
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Area 2: Health facilities
Area 3: Drug shops
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Figure 3.2: Timeline with main interventions and M&E activities. 
 
3.3.3 Intervention area 1:  Behaviour change campaigns for prompt 
and appropriate health care seeking  
Sensitization of community leaders 
As a first preparatory step in implementing community activities, local community 
leaders (political and religious leaders, leaders of social groups, non-governmental 
organizations and other key opinion leaders) were informed about ACCESS 
objectives and activities to gain their support and collaboration. The meetings also 
provided space for participants to share their views and concerns on programme-
related issues.  
 
Social marketing 
A social marketing approach was chosen to increase knowledge and awareness of 
malaria and to promote prompt and appropriate treatment seeking from reliable 
sources. The design of the behaviour change communication campaign was based 
on experiences from projects such as KINET (Kilombero Net Project) (Armstrong 
Schellenberg et al. 1999; Minja et al. 2001), TEHIP (Tanzania Essential Health 
Interventions Project) (de Savigny et al. 2004a) and IMPACT-Tz (Interdisciplinary 
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Monitoring Project for Antimalarial Combination Therapy in Tanzania), as well as the 
national social marketing for ITNs and the results from exploratory focus-group 
discussions. In the first year, implementation was done in the DSS area and Ifakara 
only, followed by a step-wise scaling-up to the other villages of Kilombero and Ulanga. 
 
The main target audience of the campaign are mothers and caretakers of children 
under five years of age and pregnant women. However, other household members 
and the general population are secondary audiences in order to achieve 
homogeneity of understanding in the population. 
 
Messages stress the importance of prompt recognition of malaria symptoms and 
immediate correct treatment with the recommended first-line drug (sulphadoxine-
pyrimethamine [SP] until end 2006). Health facilities and licensed drug stores 
(pharmacies, part II drug stores [duka la dawa baridi] and Accredited Drug 
Dispensing Outlets [ADDO; duka la dawa muhimu]) are promoted as sources of 
proper treatment and advice. Prevention methods, such as the use of ITNs and 
Intermittent Preventive Treatment in pregnancy (IPTp) are also advocated. Finally, 
one set of messages highlights high fever with convulsions (locally known as 
“degedege”) as a sign of severe malaria that can and should be treated at health 
facilities (rather than by traditional healers) (Makemba et al. 1996; Minja et al. 2001). 
ACCESS messages are in line with malaria-related messages on key family practices 
of the community-based Integrated Management of Childhood Illness (IMCI) (WHO 
2004b). 
 
Communication channels and materials to disseminate behaviour change messages 
were developed to reach a poor rural population in an efficient and cost-effective way. 
Road shows are the main vehicle for the campaign. The platform of a truck is used as 
a mobile stage for a health promotion team (Figure 3.3). The shows are divided in 
four parts:  
1. Dancing competition to attract a large audience  
2. Comedies and role plays portraying appropriate treatment seeking and 
consequences of delaying treatment  
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3. Public lecture on malaria transmission, signs and symptoms, dangers of 
malaria for young children and pregnant women, and prevention and correct 
treatment 
4. Cinema show featuring stories on prompt and effective malaria treatment 
 
Question-and-answer sessions at the end of each part allow interaction with the 
audience and distribution of promotion-materials (e.g. stickers, leaflets, T-shirts).  
 
  
Figure 3.3: ACCESS road show with 
social marketing truck 
 
Figure 3.4: ACCESS billboard 
promoting prompt and correct 
treatment 
 
Permanent billboards were erected in major villages along the main road and posters 
affixed in public places (Figure 3.4). All materials carry campaign-related messages 
and the ACCESS logo (Figure 3.5). Materials were locally designed and pre-tested in 
the community.  
 
Remote villages which are inaccessible with the truck are reached by a small 4WD 
vehicle branded with behaviour change slogans. It transports a mobile video unit and 
rooftop speakers to air behaviour change radio spots.   
 
Special campaigns in Mother and Child Health (MCH) clinics 
Special campaigns were implemented in MCH clinics. They were targeted especially 
at pregnant women and mothers of young children who may not attend road shows if 
they overlap with the women’s duties in the household. During special sessions, 
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ACCESS health promoters and MCH clinic staff informed mothers on malaria, its 
prevention and its proper treatment. The benefits of malaria prevention using ITNs 
and IPTp were particularly emphasized. 
 
 Figure 3.5: ACCESS Programme logo 
 
Improved access for households spending the cultivation period away from home: 
The shamba component 
The main farming season, when many families stay in their field-huts, overlaps with 
the high malaria transmission season. Furthermore it represents a period of high 
vulnerability as it coincides with peak food insecurity, labour stress and difficult 
access to health services, family support and child care time. A study was 
undertaken within the programme to investigate the specific risks posed by staying in 
the fields. Results from this study may lead to the design of a “shamba intervention” if 
specific measures are deemed necessary.  
 
3.3.4 Intervention area 2: Improved quality of care in health facilities 
Trustworthy health care services of good quality are a core element for the delivery of 
effective diagnosis and treatment for malaria. As a result of the social marketing, the 
demand for quality services is expected to increase. In order to meet this demand, 
the health facility staff must be in the position and willing to deliver a good quality of 
care. The programme aims to improve quality of care with a focus on the following 
areas: 
• Correct diagnosis through the proper use of the IMCI algorithm or with 
improved laboratory diagnosis 
• Rational prescription of antimalarials, antipyretics and other drugs 
• Appropriate advice on prescribed treatment and malaria prevention 
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Key activities of this component include initial refresher training for health facility staff 
on malaria treatment, followed by the strengthening of routine supportive supervision 
and the implementation of a quality management scheme in all health facilities. 
Training was based on IMCI algorithms for diagnosis and treatment which have 
proven (cost-)effective in improving quality and efficiency of child health care in rural 
Tanzania (Bryce et al. 2005a). A protocol for the refresher training was developed in 
close collaboration with the Council Health Management Teams (CHMT) of 
Kilombero and Ulanga. The training was targeted at clinical staff, lab technicians, and 
medical aids of public and private health facilities. It was carried out by the CHMT, 
appointed trainers and ACCESS staff with financial resources from the district and 
ACCESS.  
 
The follow-up with routine supportive supervision will not focus on malaria only. It is 
planned to implement a comprehensive package of activities aiming at improving 
performance management for improvement of quality of services delivery: The 
Quality Improvement and Recognition Initiative (QIRI) was originally developed by 
USAID and adapted and implemented in Tanzania by the Ministry of Health (MOH) to 
improve the quality of reproductive and child health services within the 2001-2005 
USAID-Tanzania programme support (MOH 2004). Between 2003 and 2006, the 
United Nations Population Fund (UNFPA) Tanzania through the European 
Union/UNFPA Sexual and Reproductive Health programme supported the MOH for 
further QIRI expansion in Tanzania (MOH 2003).  
 
QIRI offers an integrated approach for the evaluation of quality of care combined with 
a strategy to establish the root causes of performance gaps and to develop 
implementable strategies to address them. A central element of this component is 
capacity building for joint supportive supervision and quality management, conducted 
by the regional and district health management teams together with community 
representatives. It is the aim of the programme to integrate quality management into 
the health supervision activities in the decentralized health system. Acknowledging 
the importance of patient-provider relationships and trust in health care (Gilson 2003; 
Gilson et al. 2005), QIRI is designed to pay particular attention to the patients’ 
perception of the health services.  
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In most malaria endemic areas, diagnosis of malaria relies mainly on clinical signs 
and symptoms, especially in low level health facilities. In Tanzania, only hospitals and 
health centres are expected to have the possibility of performing microscopy for 
malaria diagnosis (MOH 2002), while dispensaries rely on a syndromic IMCI 
approach (WHO 1997). In the programme area, the malaria-attributable fraction 
estimated using the method of Smith et al. (Smith et al. 1994) showed that only 40% 
of all fever episodes were likely to be due to malaria (S. P. Kachur and S. Abdulla, 
personal communication). Absence of lab diagnosis may result in misdiagnoses and 
irrational drug-prescription (Font et al. 2001; Reyburn et al. 2004). 
 
A promising alternative to microscopy are rapid diagnostic tests (RDT) based on the 
detection of Plasmodium antigens. However, there is little experience with RDTs in 
sub-Saharan Africa although they are widely used in Asia and Latin America (Bell et 
al. 2006). ACCESS plans to introduce RDTs in three dispensaries, so far lacking 
diagnostic tools for malaria. To compare the feasibility and value of RDTs versus 
conventional diagnostics, high quality microscopy will be assured in two health 
centres. The efficacy, effectiveness and cost-effectiveness of this intervention will be 
evaluated. 
 
3.3.5 Intervention area 3: Improved malaria case management in drug 
selling shops 
Self-treatment at home is often the first and quickest response to a malaria episode 
(McCombie 1996; Hamel et al. 2001; WHO 2005a). In many settings, the private drug 
retail sector plays an important role in providing drugs for home-based management 
of fever or malaria. On the other hand, drug shops often leave patients with sub-
standard malaria drugs and poor prescribing practices (Marsh et al. 1999), leading to 
ineffective treatment and increasing drug resistance. Experience in Kenya showed 
that training private drug retailers can considerably improve the services they offer 
(Marsh et al. 2004). However, Tanzanian drug regulations do not allow general shops 
to sell the first-line antimalarial drugs (SP; or ACT since end 2006), even though the 
national malaria control strategy mentions explicitly the availability of antimalarials on 
household-level (MOH 2000; Hetzel et al. 2006; MOHSW 2006c).  
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As a result of this ambiguous policy, the initial plan to train general shop keepers had 
to be withdrawn and other avenues explored. As an alternative, the programme 
supports the introduction of Accredited Drug Dispensing Outlets (ADDO; duka la 
dawa muhimu in Kiswahili) in the two districts. The ADDO project is being 
implemented by the Tanzania Food and Drugs Authority (TFDA) and Management 
Sciences for Health (MSH). It aims to improve access to affordable, quality medicines 
and pharmaceutical services in drug retail outlets in rural and peri-urban areas where 
there are few or no registered pharmacies (Mbwasi 2005; MSH 2006). The main 
components of the ADDO project are activities to change the behaviour of shop 
owners and dispensing staff through the provision of education, incentives and 
regulatory coercion. It also entails efforts to positively affect client demand and 
expectation of quality products and services. 
 
ADDOs are allowed to dispense a limited range of prescription-only medicines that 
are found on the national essential drugs list. Ideally at least one ACT should be 
available through this channel, most logically the one recommended as first-line 
treatment in the country (currently artemether/lumefantrine [ALu], brand name 
Coartem®). For the districts of Kilombero and Ulanga, ACCESS could successfully 
negotiate the introduction of highly subsidized ALu in ADDOs. The ACCESS social 
marketing campaign promotes ADDOs as source of quality malaria treatment.  
 
3.3.6 Monitoring and evaluation 
The M&E activities of ACCESS are based on three key components: (1) A semi-
quantitative analysis aiming at a better understanding of factors influencing access to 
malaria treatment in order to develop an improved access framework, (2) process 
monitoring in order to understand how interventions operate, and (3) a thorough 
evaluation of the programme’s impact on treatment seeking, quality of case-
management and most importantly on the health of the population. An overview of 
the different evaluation activities in relation to key work areas is given in Table 3.1. 
 
Overall and health impact evaluation is based on a plausibility assessment of the 
programme’s impact within a before-after design, i.e. a historical control group 
(Habicht et al. 1999; Victora et al. 2004). In an attempt to control for possible 
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confounders, all other malaria control activities in both districts as well as other 
relevant parameters such as temperature and rainfall are closely monitored. 
Longitudinal data will also be compared to trends observed in Demographic and 
Health Surveys (DHS). A basic assumption is that the malaria transmission and other 
relevant epidemiological parameters remain largely unchanged during the period of 
observation with the exception of the factors that are monitored in the frame of the 
programme. 
 
3.3.6.1 Health impact assessment through the DSS   
The health impact assessment will be based on data collected through the DSS. The 
main outcome indicators are: overall and malaria-specific mortality, reported fever 
incidence rates in children and adults, as well as reported degedege (convulsion) 
rates in children. Furthermore, the DSS will be used as a sampling frame for 
representative community-based epidemiological studies.  
 
Cause-specific mortality is calculated on the basis of “verbal autopsies”. Since 2002, 
specially-trained DSS supervisors elicit information on causes of deaths by 
interviewing bereaved relatives about the circumstances of the death, the signs and 
symptoms observed during the illness leading to the death, and the action taken. 
This information is coded to give likely causes of death in broad categories. 
 
The socio-economic status (SES) of households is assessed once a year on the 
basis of a list of household assets. This allows the results of DSS data and other 
community-based studies to be stratified by wealth quintiles, which is essential in 
order to consider equity dimensions in the analysis. The aim of the ACCESS 
Programme is to contribute to an equitable reduction of (malaria-related) mortality. 
 
3.3.6.2 Exploratory focus-group discussions 
Initial exploratory focus-group discussions (FGD) with parents and caretakers of 
young children informed the programme on knowledge, attitudes and practices 
related to malaria treatment. A total of 88 people participated in the ten FGDs, four of 
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which were done with men, six with women. Main issues that came up during FGDs 
are listed in the results section. 
 
3.3.6.3 Community-based surveys on treatment-seeking for fever 
Repeated cross-sectional community surveys are the programme’s main tool to 
assess changes in care-seeking behaviour for fever episodes. Explanatory Model 
Interview Catalogues (EMIC) are used to simultaneously collect cultural 
epidemiological qualitative and quantitative data on patterns of distress, perceived 
causes and help seeking (Weiss 2001). A baseline survey was carried out in 2004 in 
the DSS villages and Ifakara town. Interviews were done with 80 caretakers of 
children and with 68 adults who experienced a fever episode in the preceding two 
weeks. Only people who had recovered from their illness the day of the interview 
were included while others were advised to consult a health professional. The same 
methodology will be applied in follow-up surveys every two years. It is expected that 
over the course of the programme, the number of appropriately treated fever 
episodes will increase with more people shifting to qualified care providers.  
 
The EMIC was also used in a longitudinal study exploring treatment seeking during 
the cultivation period, when many people live in their shamba huts. About 100 
household owning a temporary home in the fields were randomly sampled from DSS 
villages and followed up during one farming season. Each household was visited 
once a month by a team of field workers who recorded each family member’s stay in 
the field, the occurrence of fever episodes and other indicators. In case of a fever 
episode in the preceding two weeks, an EMIC interview was conducted.  
 
A household survey in a larger sample of 3’654 persons carried out in 2006 by a 
partner project (IMPACT-Tz) in the study area was used to assess uptake of social 
marketing messages by the population.  
 
3.3.6.4 Case-control study on degedege  
A case-control study on degedege (convulsions) was nested in the DSS data 
collection. The study compares treatment seeking patterns and self-observed signs 
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and symptoms for fatal (“cases”) and non-fatal (“controls”) degedege episodes in 
children. Degedege has commonly been treated by traditional healers rather than 
with modern medicine (Makemba et al. 1996). However, this may have changed over 
time. EMIC questionnaires and extended verbal autopsies (VA) were used as data 
collection tools for non-fatal and fatal cases respectively. Non-fatal degedege cases 
were reported routinely by DSS field-workers. A random sample was then followed 
up every two weeks for an EMIC interview. This study is expected to provide 
information on observed “danger signs” and factors related to treatment seeking and 
leading to death or recovery. It will add an important aspect to the existing knowledge 
on management of fatal malaria including cases of convulsions as described by de 
Savigny et al. (2004b). 
 
3.3.6.5 Quality of care at health facilities 
Initial assessment of quality of care is based on yearly surveys in a sample of public 
and private/mission health facilities. Tools were adapted from the multi-country 
evaluation of IMCI (Bryce et al. 2005b). Activities include patient-provider 
observations, as well as staff and patient exit interviews. Furthermore, laboratory 
equipment is checked for functionality and drug stocks are recorded. With the 
implementation of the QIRI tools for supportive supervision in 2007 (as outlined 
above), evaluation of quality of care will be done largely through QIRI which will 
assess quality of care twice annually in all health facilities. Results will then feed 
directly into activities aimed at improving quality of care. It is expected that the 
programme’s interventions will lead to improved malaria case-management and more 
rational prescription of antimalarial drugs. 
 
3.3.6.6 Health facility attendance and availability of antimalarials 
Health facility attendance data and frequency of specific diagnoses are routinely 
recorded by health facility staff for the health management information system 
(HMIS). This information is collected bi-monthly from all private and public health 
facilities in Ifakara (one public, one private) and the DSS area (10 public, five private) 
by ACCESS staff. Together with the DSS fever incidence data which provides a 
community estimate, this information will allow to calculate the proportion of fever 
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cases diagnosed as malaria and treated at health facilities. This proportion is 
expected to rise over the course of the project. In the frame of this activity, availability 
of antimalarial drugs is monitored in all health facilities in the DSS.  
 
3.3.6.7 Quality of antimalarial drugs 
In 2005, a study was designed to get an overview of the quality of antimalarials 
available in the programme’s study area. For this purpose, all antimalarial selling 
points in the 25 DSS villages as well as in Ifakara were visited, including general 
shops, drug stores, pharmacies and health facilities. Samples of SP, amodiaquine 
and quinine products were purchased and the amount of active ingredient quantified 
according to the United States Pharmacopoeia (USP 24) using previously set up 
high-performance liquid chromatography (HPLC) methods (Anonymous 2000; Braun 
2005). In accordance with USP standards, products with less than 90% and more 
than 110% of the labelled amount of active ingredient were counted as failures. 
 
3.3.6.8 Quality of services at shops selling drugs 
Based on the methodology developed by Goodman et al. (2004) for monitoring 
antimalarial drug availability, the DSS villages and Ifakara are searched annually for 
drug-selling shops and the shopkeepers are interviewed. A structured questionnaire 
is used to record current drug stock and shopkeeper’s knowledge of malaria 
treatment. Simultaneously, the shop’s locations are recorded with hand-held GPS 
devices. This approach allows monitoring the shopkeepers’ knowledge of malaria 
treatment, the services and drugs offered, as well as the coverage of shops stocking 
drugs as a proxy for availability and accessibility.  
  
In a second approach, “mystery shoppers” (simulated clients) buy drugs in local 
commercial outlets. For this purpose, local villagers are hired and instructed to go to 
a nearby shop and ask for treatment for fever/malaria on the basis of standard case 
scenarios. 
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3.3.6.9 Costing of implementation activities 
A financial analysis of the intervention costs will be performed after the interventions 
have been running for at least two years. A cost-effectiveness analysis will combine 
measures of effectiveness (see under health impact assessment) and financial costs. 
For this purpose, a clear distinction is maintained at the level of IHRDC 
administration between the cost related to interventions and the cost related to 
research, monitoring and evaluation.  
 
3.3.6.10 Assessing the impact of the introduction of Artemether-Lumefantrine  
Tools developed by the ACCESS Programme will be used to monitor prospectively 
the health impact of the switch in first-line treatment for malaria from SP to 
Artemether-Lumefantrine. This assessment will be done in the frame of a related but 
separate project, called “Artemether-Lumefantrine in vulnerable patients - exploring 
health impact” (ALIVE). It will include monitoring changes in child mortality trends as 
well as annual community-based cross-sectional studies and an in-depth compliance 
study in 500 children. 
 
3.4 Progress and results to date 
3.4.1 Community leaders’ sensitization and social marketing 
Community activities started with the sensitization of community leaders followed by 
road shows in the 25 villages of the DSS area and in Ifakara town in 2004. The 2005 
round covered an additional 56 non-DSS villages in both districts (59%) and by the 
end of 2006, a total of 114 (79%) villages were reached with both activities (Figure 
3.6). On average 40 community leaders per village (90% of the invited) attended the 
sensitization meetings (total of over 5,000 in three years) and shared their views and 
concerns, such as: 
 
“We have seen different health care providers prescribing malaria treatment to 
patients differently. Some prescribe quinine alone, or SP alone and sometimes 
quinine and later on SP. We get confused! Which is the appropriate treatment for 
malaria?” (Participant, Idete village) 
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“Children, wives and sometimes relatives of the drug shop owners sell in some of the 
drug shops. We know these people; they have no formal training, only instructions. It 
is dangerous.” (Participant, Igima village). 
 
 
Figure 3.6: Map of the study area showing intervention areas 2004 – 2006. 
 
Road shows were generally very well attended. Turn-up varied considerably 
depending on the size of the village, ranging from few hundred to a few thousand 
people during big shows such as in Ifakara. In a cross-sectional survey done in 2006 
in the DSS area, 39% (95% CI 37.2 to 40.4) of the people mentioned that they had 
attended an ACCESS road show. Men were 2.2 (95% CI 1.9 to 2.5) times more likely 
to have attended such a show than women (P<0.001) and younger people were 
more often exposed than older (Figure 3.7). Further, many people had been in 
contact with or seen promotion materials such as t-shirts and caps (48%), a vehicle 
displaying ACCESS slogans (46%), or billboards (35%). Community leaders’ 
sensitization meetings reached 16% of the interviewed.  
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Figure 3.7: Coverage of social marketing campaign in 25 DSS villages: 
proportion of the population that has attended an ACCESS road show by age 
group 
 
3.4.2 MCH campaigns 
So far, 18 special sessions for pregnant women have been carried out in MCH clinics 
in the DSS area, one in Ifakara and 28 in non-DSS villages of both districts. In the 
DSS alone, about 4,700 mothers attended the sessions, representing approximately 
28% of all women in reproductive age.  
 
3.4.3 Health facility intervention 
Between November 2004 and April 2005, several refresher training sessions were 
organised in collaboration with the CHMTs of Kilombero and Ulanga. In Ulanga, 100 
(89% of total) clinicians, nurses, medical aids and technicians from rural dispensaries 
and health centres attended the trainings. In Kilombero, 39 (93% of total) clinicians 
were trained. The tools for supportive supervision and quality management are 
currently being developed. 
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3.4.4 Accredited Drug Dispensing Outlets 
The ADDO programme was targeted at the 32 existing drug stores in Ulanga and 93 
in Kilombero District (Mbwasi et al. 2005; Risha et al. 2005). After a preparatory 
phase of training shop owners and dispensers, setting up or renovating shop 
infrastructure and a licensing procedure, ADDOs were launched in Ulanga in May 
2006 and in Kilombero in July 2006. By end 2006, there were 114 ADDOs 
operational in Kilombero district and 44 in Ulanga (R. Mbwasi, personal 
communication). 
 
3.4.5 Monitoring & evaluation 
2004 baseline population of the DSS area was 74,200 people, with a crude death 
rate of 11.6/1,000 people-years observed (PYO). The probability of dying before 
reaching the age of one year is 63.9/1,000 PYO and before the age of five 
109.5/1,000 PYO. The risk of a fever episode (”homa kali”) in the two weeks 
preceding the interview was estimated at 144/1,000 people between May and August 
and 119/1,000 between September and December. The risk of a degedege episode 
in the previous two weeks was 12/1,000 people between September and December. 
Mosquito net coverage during the main cultivation period (and peak malaria 
transmission season) was high in the field huts, with 93-100% of households having 
a net in their huts and an average of over 97% of people in the huts sleeping under a 
net (treated or not) the night preceding the interview (Fankhauser 2006). 
 
There were seven health facilities in the 13 Kilombero DSS villages and seven in the 
12 Ulanga DSS villages in 2004 (one facility per 5,300 people). By 2006, one private 
dispensary had closed down in Kilombero and a new public dispensary had been 
opened in Ulanga. The St. Francis Designated District Hospital in Ifakara serves as 
main referral hospital for all villages in the DSS. On average per month, each of 
these facilities recorded 240 out-patient visits due to malaria, over 60% of which were 
children under five. Malaria accounted for 52% of all out-patient visits of children 
under five and for 37% of all patients over the age of five (Figure 3.8). In addition to 
health facilities, there were 30 shops in Kilombero DSS, 13 in Ulanga DSS and 14 in 
Ifakara offering antimalarial drugs (Hetzel et al. 2006).  
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Figure 3.8: Average monthly out-patients attendance at 16 health facilities in 
the DSS and Ifakara in 2004 (ARI=Acute Respiratory Infections) 
 
Focus-group discussions revealed mainly the following malaria-related concerns: 
• SP had a bad reputation in Tanzania following media coverage on severe 
side-effects (Stevens-Johnson syndrome) at the time of its introduction as first-
line treatment in 2001(Nsimba 2006). Some people feared SP although they or 
their children had never experienced severe side-effects, which are known to 
be rare (Gimnig et al. 2006). People were confused about different SP brand 
names. 
• Modern medical treatment was preferred over traditional medicine and 
children were treated more quickly than adults. Drug shops were often more 
conveniently reachable and adults would often buy paracetamol from a shop 
as first treatment for a fever episode. 
• A majority of the people failed to resort to sources of treatment that they 
otherwise would prefer - such as a hospital. Factors such as cost, absence of 
trusted medical professionals, unavailability of diagnostic instruments, long 
waiting time, and distance were mentioned as important obstacles. 
These findings, together with national treatment guidelines and information from 
other projects and surveys were used as basis for developing the behaviour change 
campaign. 
 
Quality tests of antimalarials (SP, amodiaquine and quinine) purchased from health 
facilities and shops in 2005 confirmed the existence of sub-standard drugs in the 
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study area. In total 25% of the collected tablet samples did not meet the USP 
specifications for the amount of active ingredient and were mostly under-dosed. 12% 
of them contained only minimal amounts of active ingredient. Overall, 24% of the 
collected SP tablets and 40% of the quinine sulphate tablets were sub-standard. All 
amodiaquine tablets and quinine injections contained the labelled amount of active 
ingredient. Sub-standard drugs were found mainly at general and drug shop level 
and mostly originated from Tanzania and India (Braun 2005).  
 
3.5 Discussion and conclusions 
In order to develop and validate a generic framework on issues related to access to 
treatment (Obrist et al. 2007), the ACCESS Programme took malaria as an empirical 
case study. Of course, access issues are also pressing with regard to most other 
high-burden or neglected diseases in developing countries. By focusing on malaria 
we chose a poverty-related disease that affects large parts of sub-Saharan Africa in 
terms of both, disease and economic development, at a time when funding for its 
control is more readily available than ever before (Nafo Traore 2005).  
 
The Kilombero Valley is an area for which the malaria situation has been particularly 
well described thanks to numerous research activities (Smith et al. 1993; Smith et al. 
1998; Drakeley et al. 2003; Schellenberg et al. 2003a). The preventive use of 
insecticide-treated mosquito nets has been advocated through the large social-
marketing of the KINET project between 1997 and 1999. It resulted in high levels of 
ITN ownership and use (Armstrong Schellenberg et al. 1999; Armstrong 
Schellenberg et al. 2001). However, access to prompt and appropriate treatment is 
still poor. A baseline study in the frame of this programme found that only 14% of 
young children received an effective antimalarial in the correct dose on the day of 
illness onset (Hetzel et al. 2007b). The aim is, therefore, to expand the successful 
approach chosen for ITNs to the crucial issue of access to treatment. The main target 
groups of the interventions are those most at risk in holo-endemic areas such as the 
Kilombero Valley: young children and pregnant women (WHO & UNICEF 2003; 
Breman et al. 2004; WHO 2004a).  
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Interventions to improve the complex issue of access to malaria treatment are more 
likely to be successful if several working approaches are combined. Social marketing 
applies concepts and techniques used in commercial marketing to prompt behaviour 
change that benefits the target group (Andreasen 1995). In recent years, it has 
become increasingly popular in health promotion where it has been proven effective 
e.g. in promoting the use of ITNs and reducing child mortality (Armstrong 
Schellenberg et al. 2001). However, care has to be taken that men and women profit 
equally from the approach – a challenge that has to be tackled by the programme. In 
the frame of ACCESS, the marketed “product” is the knowledge and awareness of 
malaria and the concept of treating a malaria episode appropriately. The “price” to be 
paid by the community is the adoption of the desired care-seeking and preventive 
behaviour. However, inducement of behaviour change alone is not sufficient; health 
services which are acceptable and of good quality must be available. Hence, the 
behaviour change campaign is also a way of empowering the community to demand 
for good quality health care.  Activities to improve quality of health services become 
central components of the programme.  
 
The major providers of malaria treatment services remain health workers. Their 
practices are influenced by a variety of factors and environments (Rowe et al. 2005). 
The Integrated Management of Childhood Illness (IMCI) strategy adopted by 
Tanzania is an effective step to improve health worker performance leading to a 
reduction in child mortality (Armstrong Schellenberg et al. 2004) and out-of-pocket 
expenditures by patients (Manzi et al. 2005). However, health systems often fail to 
implement effective guidelines in a sustainable way (Haines et al. 2004). The 
challenge therefore remains to assure adherence to IMCI guidelines and to address 
factors not directly related to case-management (e.g. motivation or job satisfaction). 
Multi-faceted approaches including supervision and strengthening of district-level 
health management are more likely to improve performance (Rowe et al. 2005). The 
ACCESS Programme therefore combines training and information with the 
implementation of a quality-improvement process including strengthening the 
supportive supervision capacity of the district health management team.  
 
As an alternative to formal health services, antimalarials can be obtained from the 
commercial sector. Drug shops and general stores are the most important alternative 
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treatment sources for malaria in the study area (Goodman et al. 2004; Goodman 
2004). In an attempt to ensure quality of services, antimalarial drugs sales have 
recently been banned in general shops. With no alternative sources replacing 
general shops this policy resulted in a decreased availability of antimalarials in the 
study area (Hetzel et al. 2006). An alternative approach which has worked well in 
Kenya would be training of drug vendors (Marsh et al. 2004). However, current 
Tanzanian legislation does not allow the selling of antimalarials in general shops. 
Consequently, any national strategy has to focus on improving the performance of 
drug stores and their dissemination to underserved areas through the ADDO project.  
 
For the impact evaluation of ACCESS, a plausibility design had to be adopted 
(Habicht et al. 1999). Identifying a comparable place as control area would not have 
been possible and randomization of different areas for intervention would not be 
feasible within the frame of this programme. Supporting evidence for causally linking 
an observed impact with the programme’s interventions will be obtained through the 
collection of multiple indicators on intervention delivery, coverage and potential 
confounders. While the limits of such a design in establishing a causal link are 
obvious and well known, it needs to be recognized that any large-scale 
implementation goes through an iterative process of measuring progress and impact 
while continuously adapting and improving the process. Consequently, the 
interpretation of results has to take into account contextual changes and external 
influences. Data from other DSS sites and DHS in Tanzania will be of particular 
importance in interpreting mortality data and putting them into perspective.  
 
Baseline data demonstrated heterogeneity in the availability of treatment sources, 
unavailability of medicines and providers and serious quality problems with regard to 
drugs and services. This supports the basic assumption that there are several inter-
linked factors influencing access to effective malaria treatment.  
 
The comparative advantage of the ACCESS Programme is its combination of 
multiple interventions on different levels of the health system, including a strong 
evaluation and research component. With this approach, the programme also aims to 
contribute to the wider debate on access to appropriate health care in developing 
countries. Based on Penchansky and Thomas’ (1981) understanding of “access” as 
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the degree of “fit” between the health system and its users, the ACCESS Programme 
aims at developing a more comprehensive access framework (Obrist et al. 2007). 
This can then inform and support public health professionals and policy-makers in the 
delivery of improved health services, ideally leading to better health and well-being.  
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Table 3.1: ACCESS Programme components and corresponding indicators for evaluation (refer to main text for details) 
Indicator Sources of verification/study methods Sample Timing 
Intervention area 1: Behaviour change campaign 
(Expected results: Improved health care seeking behaviour for all fever/malaria episodes) 
Cross-sectional community surveys (fever 
and degedege) with EMIC tool 
Random sample of 
households 
Repeated (baseline, 
mid-term, end) 
Proportion of episodes treated according to national guidelines 
within 24h 
Treatment-shift to qualified providers DSS (morbidity) and health facility 
attendance 
DSS area, all health 
facilities 
Continuous 
Equitable access to appropriate treatment DSS SES data DSS area, all health 
facilities 
Continuous 
Intervention area 2: Quality of care in health facilities 
(Expected results: Improved quality of care in health facilities, especially malaria case-management, incl. diagnosis, prescription, treatment, advice, compliance) 
Quality of care surveys in health facilities 
 
Sample of health 
facilities 
Repeated (baseline, 
mid-term, end) 
Proportion of episodes receiving correct prescription and 
appropriate advice 
Patient’s satisfaction with services QIRI All health facilities Continuous 
Intervention area 3: Malaria case-management in shops 
(Expected results: Improved quality of malaria case-management in drug selling shop, such as retailing practices, prescriptions, advice) 
Proportion of episodes receiving correct prescription and 
appropriate advice 
Mystery shoppers All drug stores and 
random sample of 
general shops 
Annually 
Shop-keepers’ knowledge of malaria symptoms, correct 
treatment and advice 
 
Availability of first- and second-line antimalarial drugs 
Cross-sectional surveys in shops stocking 
drugs 
All retailers stocking 
drugs 
Annually 
 
 Table 3.1 (continued) 
Indicator Sources of verification/study methods Sample Timing 
Shamba component 
(Expected results: Coverage of appropriate malaria treatment and care services extended to underserved areas, incl. shamba households) 
Proportion of households within 5km range of qualified provider DSS GPS data All households, health 
facilities and shops 
stocking drugs 
Repeated 
Proportion of episodes in underserved areas / poor households 
/shamba houses receiving correct treatment 
Cross-sectional community surveys (fever 
and degedege), DSS SES data 
Random sample of 
households 
Repeated (baseline, 
mid-term, end) 
Health impact  
(Expected results: Reduction of malaria related morbidity and mortality, especially in children under five and pregnant women) 
Proportion of malaria-related deaths DSS mortality data: overall and cause-
specific. 
All households Continuous 
Number of fever episodes. DSS fever incidence All households Continuous 
Additional studies 
Understanding and perception of malaria, its treatment and 
prevention 
Focus-group discussions 10 groups of caretakers 
of children under five 
years in Ifakara and 
DSS  
Once prior to 
interventions 
Risk factors for fatal outcome of degedege Case-control study Cases: degedege-
related child deaths in 
DSS 
Controls: recovered 
degedege cases 
Once 
Vulnerability and coping strategies of households during the 
farming season; movement patterns and health seeking 
Cohort study with shamba households Random sample of 
households with field 
(shamba) house 
Once 
Antimalarial drug quality  Cross-sectional survey All drug stocking 
retailers and health 
facilities 
Once 
EMIC = Explanatory Model Interview Catalogue. DSS  = Demographic Surveillance System. SES = Socio-economic Status. QIRI = Quality 
Improvement and Recognition Initiative. GPS = Geographic Positioning System.  
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Goodluck John and Sixbert Msagwa during field work 
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4 AIMS AND OBJECTIVES 
4.1 Aims and objectives 
The overall aim of the studies presented here was to contribute to a better 
understanding of the factors influencing access to malaria treatment in a rural 
Tanzanian setting. The insights gained should inform ACCESS Programme 
interventions and help to develop an improved general access framework.  
 
The general and specific objectives of the studies were as follows: 
 
1. To investigate treatment-seeking behaviour for malaria related illness 
episodes 
1.1. To investigate patterns of distress and perceived causes related to malaria 
1.2. To quantify treatment-seeking options 
1.3. To investigate factors related to prompt and effective case-management 
 
2. To enable a better understanding of the disease burden, access to health 
services, and responses to malaria related illness episodes of farming 
families during the cultivation period 
2.1. To quantify risks of fever episodes during the farming season 
2.2. To investigate movement patterns of farming families 
2.3. To investigate preventive measures taken while in the fields 
2.4. To understand treatment-seeking actions taken while in the fields 
 
3. To assess the availability of antimalarials in the private retail sector 
following the change of first-line treatment from chloroquine to SP 
3.1. To quantify the number of shops offering antimalarial treatment 
3.2. To assess the availability of different antimalarial products on the private 
market 
3.3. To map spatial coverage of shops selling antimalarials 
3.4. To investigate changes of private-sector availability of antimalarials following 
the policy change from chloroquine to SP in 2001 
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4. To assess the knowledge and behaviour of private drug retailers in terms of 
case-management of febrile illness episodes 
4.1. To validate data obtained on antimalarial availability through mystery 
shoppers (simulated clients) 
4.2. To assess shop keepers’ understanding of malaria symptoms  
4.3. To assess treatment and advice offered in different types of shops selling 
drugs 
 
As reflected in these objectives, this thesis focused on demand-side aspects of 
access and on the performance of the commercial retail sector on the supply-side. An 
assessment of the quality of care in health facilities was not part of this thesis since. 
 
All studies were designed to contribute to the overall goal of the ACCESS 
Programme, which is to contribute to the reduction of overall and child mortality 
through improving access to prompt and effective malaria treatment in two rural 
districts in Tanzania.  
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5 STUDY AREA 
All studies were carried out in the two districts of Kilombero and Ulanga, Morogoro 
Region, southern central Tanzania (Figure 5.1).  
 
Ulanga
District
Kilombero
District
Ifakara
MahengeTanzania
 
Figure 5.1: Location of Kilombero and Ulanga Districts in Tanzania 
 
The Udzungwa Mountains in Kilombero and the Mahenge limestone plateau in 
Ulanga define the Kilombero valley which has been described as the largest 
seasonal freshwater lowland floodplain in East Africa (Wetlands International & 
Ramsar 2007). Basic demographic indicators for the area are summarised in Table 
5.1. 
 
Table 5.1: Basic demographic indicators of the study districts 
Indicator  Kilombero Ulanga Total 
Population (2002)1 322,779 194,209 516,988 
Percentage female1 49.6 50.7 50.0 
Percentage <5 years1 14.8 16.3 15.4 
Average household size1 4.4 5.3 4.7 
Population growth rate 1988-20021,2   2.6 
1Source: 2002 Population and Housing Census 
2Morogoro Region 
 
In 1996, prior to the implementation of a large-scale ITN intervention trial (Kilombero 
Insecticide-Treated Net Project [KINET] project), a DSS was established in the two 
districts (Armstrong Schellenberg et al. 1999; Armstrong Schellenberg et al. 2002). 
The DSS covers 12 villages in Ulanga District and 13 in Kilombero District in an area 
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of approximately 2400 km2. In mid-2004, the population of the DSS was 31,800 in 
Ulanga and 42,400 in Kilombero.  
 
Just outside the DSS area, Ifakara town is the Kilombero District headquarter and 
major trading centre in the valley. According to the national census in 2002, the 
town’s population was 45,680 (United Republic of Tanzania 2003a). Ifakara has a 
long tradition of development cooperation and health research (Tanner et al. 1994). 
From here, the Ifakara Health Research and Development Centre (IHRDC) 
implemented several research and intervention projects on malaria, such as the 
successful social marketing for ITNs through the KINET project (Armstrong 
Schellenberg et al. 2001; Abdulla et al. 2001), the first trial of the SPf66 malaria 
vaccine in Africa (Alonso et al. 1994), studies on antimalarial drug resistance 
development (Mshinda et al. 1996; Mugittu et al. 2005; Mugittu et al. 2006), and the 
efficacy and safety of IPTi with SP (Schellenberg et al. 2001).  
 
The studies presented here were carried out in the DSS villages and, partly, in the 
town of Ifakara. Additional and more detailed information on the study area can be 
found in the ACCESS Programme description in chapter 3. 
 
5.1 Malaria situation in the study area 
In the Kilombero valley, P. falciparum-malaria is highly endemic and perennial with 
seasonal transmission patterns. Principal vectors are Anopheles gambiae sensu lato 
and Anopheles funestus. Historical EIR estimates reached over 300 ib/p/y for rural 
areas, including 2979 ib/p/y in one particular house (Smith et al. 1993). Recent 
studies confirmed a decline of EIR from a mean of 1481 to 244 following large-scale 
social marketing of ITNs (G. Killeen, personal communication). At the level of 
outpatient health services, malaria is the most frequent problem to which 40% (over 
five years of age) to 50% (under five years of age) of all visits are attributed (Hetzel et 
al. 2007c). The malaria-related mortality in under-fives in the area was 3.7 per 1,000 
person-years in 2003 and total under-five mortality was 32.7 per 1,000 person-years 
in the same year (Ifakara DSS, unpublished and United Republic of Tanzania 2005). 
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5.2 Malaria control and other health interventions in the study 
area 
Within the DSS area, there are a number of government and private (mostly 
missionary) dispensaries and health centres offering malaria treatment and care 
(Table 5.2). The St. Francis Designated District Hospital (SFDDH) in Ifakara is the 
largest hospital and primary referral point in the two districts, with approximately 400 
beds. Apart from health facilities, malaria treatment can be obtained from a range of 
private retailers, including drug stores and general shops.  
 
Table 5.2: Health facilities in the DSS area and Ifakara town 
Location Level Category 
Kilombero District, DSS villages 
Idete Dispensary Govt. 
Lukolongo Health centre Govt. 
Mbingu Dispensary Mission 
Mbingu Dispensary Govt. 
Mchombe Dispensary Mission 
Mngeta Dispensary (closed end 2004) Private 
Namwawala Dispensary Govt. 
Ulanga District, DSS villages 
Idunda Dispensary (open since 2005) Govt. 
Igota Dispensary Mission 
Iragua Dispensary Govt. 
Iragua Dispensary Mission 
Kichangani Dispensary Govt. 
Kivukoni Dispensary Govt. 
Lupiro Health centre Govt. 
Milola Dispensary Govt. 
Ifakara, Kilombero District 
Ifakara (SFDDH) Designated district hospital Govt. / mission 
Ifakara Dispensary Private 
 
Malaria control in the two districts follows the strategy of the National Malaria Control 
Programme (NMCP) (MOH 2002). However, due to IHRDC’s research activities in 
the area, some control strategies may have been pursued with more emphasis than 
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in other districts. While the trials carried out in a clinical setting in few health facilities 
may not have had a large community-effect, ITN activities had a verifiable impact.  
 
The KINET project introduced large scale social marketing for ITNs and treatment 
kits in the DSS villages in 1997 following formative research on people’s perceptions 
of causes of child death, mosquito nets, net treatment, and malaria (Minja et al. 2001). 
In mid-1999, all villages in the two districts had been reached. Within three years, ITN 
coverage rose from 10% to over 50% and a 27% increase in child survival was 
associated with ITN use (Armstrong Schellenberg et al. 2001). Considerable 
beneficial effects on morbidity in children (Abdulla et al. 2001), anaemia in pregnant 
women (Marchant et al. 2002) and cost-effectiveness of social marketing were also 
demonstrated (Marchant et al. 2002; Hanson et al. 2003). A discount voucher for 
pregnant women was tested within KINET and later served as the model for the 
Tanzanian National Voucher Scheme (Mushi et al. 2003). From 2000 on, a national 
ITN strategy was implemented with countrywide social marketing through Population 
Services International (PSI) (Magesa et al. 2005). In Kilombero and Ulanga, 
marketing of the KINET-ITNs branded Zuia Mbu was abandoned in favour of the PSI-
marketed ITNs and treatment kits in 2004. KINET had already demonstrated how 
continuous exposure to social marketing increased the use of ITNs. This is today 
reflected in an ITN coverage of over 75% following 10 years of continuous social 
marketing activities (Killeen et al. 2007).  
 
With regard to malaria case-management, the introduction of IMCI in health facilities 
was an important step towards improved quality of child care. Kilombero and Ulanga 
Districts began IMCI implementation in 2002 after having been non-IMCI control 
districts for the evaluation of IMCI in Tanzania from 1997 to 2002 (Tanzania IMCI 
Multi-Country Evaluation Health Facility Survey Study Group 2004). In this evaluation, 
IMCI was associated with better observed quality of care at no additional costs for 
caretakers or the districts (Armstrong Schellenberg et al. 2004; Tanzania IMCI Multi-
Country Evaluation Health Facility Survey Study Group 2004; Bryce et al. 2005a).  
 
Children below the age of five years and pregnant women are generally exempted 
from expenditures at government facilities. This includes (at least in theory) free 
consultation and medicines. However, unofficial (“under the table”) fees may be 
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charged occasionally or stock-outs of drugs may force people to pay for medicines 
elsewhere. For the remaining patients, different payment schemes exist in the two 
districts. Kilombero District government health facilities are running on a cost-sharing 
scheme, which has been described as significantly more expensive to users, than 
non-cost-sharing schemes (Manzi et al. 2005). No user fees are charged in Ulanga 
district and a Community Health Fund (CHF) constitutes a form of risk-protection for 
members of the fund. However, anecdotal evidence found that membership is not 
very popular due to the relatively large advance-payments. Different health financing 
schemes have a clear impact on out-of-pocket expenditures by patients and may 
positively or negatively influence access to health services, especially by the poorest. 
According to Manzi et al. (2005) the now prevailing payment scheme in government 
facilities in Ulanga (no user fees and IMCI implemented) seems to be more economic 
than the one in Kilombero.  
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6 METHODOLOGY 
The studies described hereunder are part of the baseline assessment within a 
before-after design for the evaluation of the ACCESS Programme. Quantitative, 
semi-quantitative and qualitative methods were used for data collection in order to 
gain an in-depth understanding of behavioural and other factors related to treatment 
access.  
 
Data collection for the several studies was done during a three-year field stay 
between 2004 and 2006, as outlined in Figure 6.1. Different sampling strategies, data 
collection tools and procedures were developed to investigate treatment seeking 
behaviour under varying circumstances (to achieve objectives 1-3) as well as 
availability and quality of case-management and advice in the retail sector (to 
achieve objectives 4-5). All data collection tools were developed in English and 
translated into Kiswahili for use in the field.  
 
Community survey (2.3.1.1)
Shamba survey (2.3.1.2)
Shop survey (2.3.2, 2.3.3)
Health impact (2.3.4)
2004 2005 2006
Jan-Apr May-Aug Sep-Dec Jan-Apr Sep-DecMay-Aug Sep-Dec Jan-Apr May-Aug
 
Figure 6.1: Timeline of studies 
 
6.1 Treatment-seeking surveys 
Treatment-seeking behaviour for recent episodes of fever was investigated using 
Explanatory Model Interview Catalogues (EMIC) (Weiss 2001). EMIC are semi-
structured questionnaires which allow the collection of qualitative and quantitative 
cultural epidemiological data on patterns of distress, perceived causes and help 
seeking. The development of the EMIC was based on qualitative research on 
people’s understanding of malaria and prevailing and preferred treatment seeking 
options. Qualitative research included focus-group discussions carried out in the 
frame of the ACCESS Programme and previous more in-depth studies on malaria in 
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the Kilombero valley or other parts of Tanzania (Hausmann Muela 2000; Minja 2001; 
Mayombana 2004). The EMIC were administered to a caretaker (if the patient was 
younger than 12 years) or to the patient. A “fever episode” was defined as any febrile 
illness perceived as such by the patient or caretaker. Patients with an illness episode 
who had not recovered prior to the interviewer’s visit were not included in the studies 
but were advised to seek care from a reliable source.  
 
The same EMIC was used in three different studies described hereunder. In each of 
these, a different form was used for patients under the age of five years and patients 
above five years. The original EMIC forms used in the field were in Swahili. An 
English version of the EMIC for children can be found in Appendix 1.  
 
6.1.1 Cross-sectional community survey on treatment-seeking for a 
recent fever episode 
This survey was done between May and August 2004 in the DSS villages and Ifakara. 
It included children and adults with a reported fever episode in the preceding two 
weeks. A random sample of households was drawn from the DSS database, relative 
to the size of each village. For Ifakara, no household database was available. We 
therefore used the local administrative structure and collected data on households 
through village, hamlet and ten-cell leaders (Figure 6.2) to perform a two-stage 
random sampling (ten-cell, household). Results of this survey are reported in chapter 
7. 
 
??????
?
??
?
?????? ?
?
?
?
Village (kijiji)
Hamlet 
(kitongoji)
Ten-cells
 
Figure 6.2: Administrative structure used for random sampling 
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6.1.2 “Shamba survey” on treatment-seeking for recent fever during 
the farming season 
A longitudinal study of a cohort of farming households was conducted between mid-
January and August 2005. A two-stage stratified sampling was performed to select 
households from four randomly sampled DSS villages in each of the two districts. 
Households were followed-up during their stay in the fields (shamba) and visited 
monthly over the study period. At each visit, a structured questionnaire was used to 
record each household member’s whereabouts, activities, use of mosquito nets and 
recent fever episodes. In case a fever episode was reported, an EMIC interview was 
done with the patient or the caretaker. Families’ main houses in the villages and their 
shamba locations were recorded with GPS units for distance-calculations. Results of 
this survey are reported in chapter 8.  
 
6.2 Shop surveys 
Between May and June 2004, the DSS area and Ifakara were searched for any kind 
of shops stocking drugs. This included pharmacies, drug stores, general retailers, 
wholesalers, kiosks or genge (temporary stalls). The shops were found with the help 
of local leaders and with an outlet-list which had been established during earlier shop 
surveys in 2001 and 2002 (Goodman 2004). Each outlet’s location was recorded 
using hand-held Global Positioning System (GPS) devices. A structured 
questionnaire was used in all shops to record the services and drugs offered (in 
particular the brands of antimalarials and antipyretics) and the shop keepers’ 
knowledge of malaria and its treatment. Results of this survey are reported in 
chapters 9 and 10. 
 
6.3 Mystery shoppers 
In a follow-up study to the shop survey in September and October 2004 the shop 
keepers’ behaviour in selling drugs and giving advice was assessed. For this purpose, 
we used simulated clients (“mystery shoppers”) in a sub-sample of approx. 10% of 
the outlets stocking drugs. Local villagers were hired and instructed to go to a nearby 
shop and ask for treatment for a fever/malaria episode. The mystery shoppers were 
identified by local DSS enumerators who lived in the villages and knew people who 
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could be trusted to do such a job. The shop visits were based on three standard case 
scenarios: 
(A) a child, aged 2-4 months, with fever/hot body for one day and problems with 
drinking/breastfeeding,  
(B) a child, aged 2-4 years, with recurring fever/hot body for 3 days (especially at 
night), problems with drinking and eating, diarrhoea and tiredness/not playing 
with friends as usual,  
(C) an adult, with recurring fever/hot body for 2 days, headache, dizziness and loss of 
appetite.  
Mystery shoppers were provided with money to buy the drugs in the outlets. After 
their visit to a shop, they were interviewed using a catalogue of questions on what 
they did and said during their visit and what advice and drugs they were given. 
Results of this study are reported in chapter 10. 
 
6.4 Demographic Surveillance System 
The DSS was used as an epidemiological framework for all studies, except for those 
carried out in Ifakara town. In the absence of a vital registration, trained field workers 
routinely record births, deaths, in- and out-migrations and socio-economic indicators 
for every household in the 25 DSS villages. Each of the approximately 17,000 
households (2004) is visited every four months.  
 
The DSS database served as sampling frame for the community-based studies on 
treatment-seeking. Furthermore, it provided basic demographic data, household GPS 
locations and socio-economic household data. DSS field workers also participated in 
the shop survey and mystery shoppers study creating a link to the local community.  
 
6.5 Data entry and analysis 
All quantitative data from treatment-seeking and shop surveys was double-entered 
and cleaned by the data unit of the IHRDC using Microsoft FoxPro or Access 
software. Qualitative data, such as narrative parts of the EMIC as well as mystery 
shoppers interviews were entered by ACCESS Programme staff using Microsoft 
Word.  
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Data analysis was performed with Intercooled Stata 8 and 9 (StataCorp, College 
Station, Texas, USA) for quantitative and MAXqda2 (VERBI GmbH, Marburg, 
Germany) for qualitative data. For spatial data, MapInfo Professional 7.0 (MapInfo 
Corporation, Troy, New York, USA) and ArcView GIS 3.3 Software (Environmental 
Systems Research Institute, Inc., Redlands, California, USA) was used.  
 
6.6 Ethics 
All studies presented here were reviewed as part of the ACCESS Programme 
proposal. Ethical clearance was granted by the Institutional Review Board of the 
IHRDC and the National Institute for Medical Research of the United Republic of 
Tanzania (NIMR/HQ/R.8a/Vol. IX/236, 16th September 2003). The author of this 
thesis was granted Research Permits by the Tanzania Commission for Science and 
Technology (2004-189-CC-2001-40, 17 August 2004; 2005-314-ER-2001-40, 31 
August 2005; 2006-265-ER-2001-40, 17 August 2006).  
 
All study participants were asked for oral informed consent prior to conducting the 
surveys and all participants were free to reject an interview. For obvious practical 
reasons this was not the case for shop keepers during the mystery shoppers study. 
For those cases in which names were recorded (e.g. for linkage with the DSS 
database), participants were assured that their data would be kept in confidence. 
Final reports did not mention any names of study participants and shop keepers 
names only appeared in connection with their shops location but not with the services 
offered. Confidential data such as names of participants or participants’ businesses 
were not revealed to authorities.  
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7.1 Abstract 
7.1.1 Background 
Malaria is still a leading killer in sub-Saharan Africa. Yet access to prompt and 
effective malaria treatment, a mainstay of the malaria control strategy, is insufficient 
in many settings. Little is known about obstacles to treatment and community-
effectiveness of case-management strategies. This research quantified illness 
models, treatment seeking behaviour and access to treatment in a highly endemic 
rural Tanzanian community. The aim was to provide in-depth understanding of 
obstacles to treatment access in order to develop practical and cost-effective 
interventions.  
 
7.1.2 Methods 
We conducted community-based treatment-seeking surveys with 226 recent fever 
episodes in 2004 and 2005. The local Demographic Surveillance System provided 
additional household information. A census of drug retailers and health facilities 
provided data on availability and location of treatment sources.  
 
7.1.3 Results 
After years of health education, the biomedical concept of malaria has largely been 
adopted by the community. Traditional illness models of severe malaria were not 
anymore a significant barrier to modern treatment. 87.5% (78.2-93.8) of the fever 
cases in children and 80.7% (68.1-90.0) in adults were treated with one of the 
recommended antimalarials (at the time SP, amodiaquine or quinine). However, only 
22.5% (13.9-33.2) of the children and 10.5% (4.0-21.5) of the adults received prompt 
and appropriate antimalarial treatment. Health facility attendance increased the odds 
of receiving an antimalarial (OR=8.1) but did not have an influence on correct dosage. 
The exemption system for under-fives in public health facilities was not functioning 
and drug expenditures for children were as high in health facilities as with private 
retailers. This information is highly relevant to improve access to malaria treatment in 
the community. 
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7.1.4 Conclusions 
A clear preference for modern medicine was reflected in the frequent use of 
antimalarials. Yet, quality of case-management was far from satisfactory as was the 
functioning of the exemption mechanism for the main risk group. Poor drug efficacy 
and quality may have further decreased effectiveness. Private drug retailers played a 
central role in complementing existing formal health services. Such health system 
factors need to be tackled urgently in order to translate the high efficacy of newly 
introduced artemisinin-based combination therapy (ACT) into equitable community-
effectiveness and health-impact.  
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7.2 Background 
Malaria is killing over one million people every year, mostly children under five years 
of age in sub-Saharan Africa (WHO & UNICEF 2005). After failed attempts to 
eradicate malaria in most parts of Africa, it was recognized that only integrated 
control programmes combining different approaches were likely to bring alleviation 
(Greenwood et al. 2005). One mainstay of the control strategy promoted by the World 
Health Organization is prompt access to effective treatment for episodes of malaria 
(WHO & UNICEF 2005). It is difficult to estimate how many people worldwide lack 
access to effective and affordable treatment. Yet, it can be safely assumed that of the 
2.4 billion people (2005) living in low-income countries (World Bank 2007), only few 
have access to high quality health-care. In the case of malaria, it has been shown 
that access to and quality of treatment is unsatisfactory in many settings (McCombie 
2002; Committee on the Economics of Antimalarial Drugs 2004), hence contributing 
significantly to the high death toll. Increased attention is currently being paid by 
donors and researchers to these issues. It is worth considering that lack of access is 
a complex issue that should be put into the context of poverty, vulnerability and 
livelihoods to be better understood (Obrist et al. 2007).  
 
Several strategies have been proposed and tested to improve access to malaria 
treatment, including scaling-up of home-based management (WHO 2005a; Gyapong 
& Garshong 2007), stronger involvement of the private sector (Marsh et al. 2004; 
TDR/WHO 2006), improving case-management in health facilities (Rowe et al. 2005) 
as well as integrated approaches (Nyarango et al. 2006). In addition, it is now widely 
acknowledged that no malaria-control strategy can be successful and sustainable 
without an increased investment in the local health systems through which the 
interventions can be channelled (Travis et al. 2004; Singh 2006; Feachem & Sabot 
2007).  
 
The studies presented here assessed knowledge of malaria, treatment seeking 
behaviour and access to malaria treatment in a rural Tanzanian community. The 
research was carried out in the frame of a comprehensive intervention programme to 
improve access to malaria treatment in rural Tanzania (ACCESS Programme) 
(Hetzel et al. 2007c).  
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In this context, the studies provided in-depth understanding of obstacles to treatment 
access which are crucial to develop practical and cost-effective interventions to 
improve access at community-level. The development of a generic access framework 
fitted in the context of livelihood insecurities also benefited from the quantitative 
information gained in this research (Obrist et al. 2007).  
 
Indicators to measure access and effectiveness have to be chosen carefully in order 
to provide relevant information. Commonly used measures such as “percentage of 
episodes treated with an antimalarial” may be convenient for monitoring purposes but 
might give a distorted picture of the reality. This research provided for the first time a 
quantified estimation of the community effectiveness of malaria treatment on the 
basis of different key access indicators.  
 
7.3 Methods 
7.3.1 Study setting 
Treatment seeking for fever episodes and availability of treatment services were 
studied in the districts of Kilombero and Ulanga, Morogoro Region, south-eastern 
Tanzania, in 2004 and 2005. The study area comprised the 25 villages of the local 
Demographic Surveillance System (DSS) (Armstrong Schellenberg et al. 2002) with a 
population of 74’200 in 2004, as well as the town of Ifakara (2001 population census: 
45,726 (United Republic of Tanzania 2003a)), the district capital of Kilombero. The 
area is predominantly rural and the malaria transmission is high and perennial 
(Drakeley et al. 2003; Killeen et al. 2007). In 2004, there were 14 health facilities (9 
public, 5 private/mission) in the DSS area, as well as one private clinic and one 
district hospital in Ifakara. Malaria accounted for roughly half of all outpatient visits in 
these health facilities. Government and private health facilities in Kilombero are 
running on a cost-sharing scheme. In Ulanga, no user fees are charged in 
government facilities and a Community Health Fund (CHF) offers a form of risk-
protection for members of the fund. A more detailed description of the study area can 
be found elsewhere (Hetzel et al. 2007c).  At the time of the study, the recommended 
first-line treatment for uncomplicated malaria was SP, the second line treatment 
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amodiaquine, and quinine was recommended as third-line treatment and for cases of 
severe malaria (MOH 2000). 
 
7.3.2 Treatment seeking surveys 
To investigate understanding of malaria and treatment seeking behaviour for recent 
fever cases, two surveys were carried out: 
1. a cross-sectional cultural-epidemiological community survey in the DSS area 
and Ifakara town  
2. a longitudinal study investigating treatment seeking during the farming season 
(shamba survey). 
 
For the cross-sectional community survey, we took a village-stratified random 
sample with the number of households per village weighed by total village-size. A 
total of 318 households were drawn from the registered 16’220 households in the 25 
DSS villages. Only households with at least one child under the age of five years 
were eligible. 
 
Sampled households were visited by a DSS interviewer between May and August 
2004, within the schedule of the routine DSS data collection. In all households which 
reported a fever episode in the previous 14 days, the patient or caretaker (if the 
episode was in a child younger than 12 years) was interviewed. Patients who had not 
yet recovered were not included but advised to seek care from a health facility.  
 
For Ifakara town no up-to-date household list was available as sampling frame. The 
local administrative structure was used to establish a list of households and to 
perform a two-stage random sampling of 223 households. The ward Ifakara 
comprises five villages (vijiji) with 17 hamlets (vitongoji). In each hamlet, groups of 
originally ten households are represented by a ten-cell leader (balozi). Every 
household in Ifakara was assumed to belong to one ten-cell leader. Through visits to 
village and hamlet leaders, a comprehensive list of all 329 ten-cell leaders in Ifakara 
ward was established. A random sample of 35 ten-cell leaders was then drawn and 
visited in order to establish a complete household list for their ten-cells. From these 
lists, six households per ten-cell were then randomly sampled. A household may only 
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have been missed if it was not recorded by any ten-cell leader. We tried to avoid 
double-listing of households claimed by several ten-cell leaders by cross-checking 
the names of the household heads. Sampled households in Ifakara were visited by 
two trained interviewers in May 2004. The same inclusion and exclusion criteria as in 
the DSS villages applied. 
 
Spatial data on household locations as well as socio-economic status calculations 
were obtained from the DSS database, which could provide such information for 70% 
of all interviewed cases.  
 
The longitudinal shamba survey (in Swahili, shamba = farm) was carried out 
between December 2004 and August 2005 to investigate treatment seeking during 
the farming season. It included a random sample of approx. 100 farming households 
from 10 randomly selected DSS villages which were followed-up during the main 
cultivation period. Every month, interviews were done for recent fever episodes in 
these households, applying the same inclusion and exclusion criteria as in the cross-
sectional community survey. However, as the sampling methodologies differed 
(cross-sectional vs. longitudinal, general population vs. farming households), the two 
surveys were not equally representative of the general population. For the analysis of 
people’s understanding of malaria we assumed that there would be no difference 
between the two samples and included both data. However, the treatment seeking 
and risk factor analysis for the shamba survey was done separately and presented 
elsewhere (Hetzel et al. 2007a).  
 
To interview patients and caretakers, field-workers used an Explanatory Model 
Interview Catalogue (EMIC) (Weiss 2001). The EMIC is a semi-structured 
questionnaire based on an explanatory illness model. It was developed on the basis 
of preceding focus-group discussions and further qualitative research on people’s 
understanding and experience of malaria (Hausmann Muela 2000; Minja et al. 2001; 
Mayombana 2004). Data collected with the EMIC comprised quantitative variables as 
well as narratives on reported signs and symptoms (“patterns of distress”), perceived 
causes of the illness as well as help seeking. Its aim was to elicit comprehensively 
the experience of illness and resulting treatment-seeking behaviour from the point of 
view of those affected.  
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Selection of cases was based on self-reported fever. This took into account that in 
absence of diagnostic tools, most episodes of fever suggestive of malaria are treated 
presumptively based on the reports given by the patient or the caretaker. The 
Integrated Management of Childhood Illness (IMCI) algorithms, which are 
implemented in the study area, advocate an assessment based on clinical signs and 
symptoms. The data analysis took into consideration the reported signs and 
symptoms as well as the name given to the illness by the respondent.  
 
Oral informed consent was obtained from all study participants prior to the interviews. 
Ethical clearance of was granted by the National Institute for Medical Research of the 
United Republic of Tanzania (NIMR/HQ/R.8a/Vol. IX/236, 16th September 2003).  
 
7.3.3 Availability of treatment services 
Access to treatment is, among other things, clearly a function of the availability of 
treatment sources. We geo-located 16 health facilities and 498 drug selling shops 
(DSS and Ifakara) in a cross-sectional survey in May – June 2004 (Hetzel et al. 2006). 
 
7.3.4 Statistical analysis 
Epi Info 6 was used for all random sampling procedures. Data were double entered 
using Microsoft FoxPro and Microsoft Access (Microsoft Corp.), and checked for 
coding errors and consistency. Statistical analysis was done with Intercooled Stata 9 
(College Station, Texas, USA). For spatial analyses, MapInfo Professional 7.0 
(MapInfo Corp., Troy, New York, USA) and ArcView GIS 3.3 (ESRI, Redlands, CA, 
USA) were used. 
 
For cultural-epidemiological data on patterns of distress and perceived causes, 
answers were given values according to whether they were reported spontaneously 
(value of 2) or upon probing (value of 1) and out of these, mean prominence values 
were calculated. The Kruskal-Wallis test was used for testing differences of the 
ranked outcomes between sub-groups of the sample. Chi2 and Fisher’s exact tests 
were used for testing associations.  
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Univariate and multivariate logistic models were fitted to assess the effect of several 
predictors on prompt and effective treatment, as defined below. Univariate analysis 
was done on all possible predictors on which data had been collected within the 
frame of the programme. For the multivariate models, predictors were chosen on the 
grounds of evidence from scientific literature, plausibility, as well as significance in 
the univariate analysis. Models were compared using the likelihood ratio test.   
 
For this paper, the analysis was limited to children under the age of five and 
adolescents and adults over 12 years. 
 
7.4 Results 
7.4.1 Study sample 
During the cross-sectional community survey, 154 recent fever cases were included 
in the study (approximately 28% of all sampled households). 80 (52%) cases were in 
children under 5 years of age and 57 (37%) in adolescents and adults over 12 years. 
The shamba survey added another 29 children under 5 years and 28 adults over 12 
years to the sample. Basic sample characteristics are summarized in Table 7.1. 
 
Table 7.1: 2004 Community survey sample characteristics (N=154) 
Characteristics 2004 community survey 
(N=154) 
2005 shamba survey (N=66) 
 Freq. Percentage Freq. Percentage 
Age (years) 
0-4 80 51.9 29 43.9 
5-9 12 7.8 6 9.1 
10-19 14 9.1 5 7.6 
20-29 11 7.1 13 19.7 
30-39 16 10.4 9 13.6 
40-49 12 7.8 2 3.0 
50+ 8 5.2 2 3.0 
Sex 
Female 85 55.2 30 45.5 
Male 69 44.8 36 54.5 
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Table 7.1 (continued) 
Residence 
Ulanga DSS villages 61 39.6 37 56.1 
Kilombero DSS villages 49 31.8 29 43.9 
Ifakara 44 28.6 NA NA 
Religion (of caretaker if patient <12 years) 
Muslim 63 40.9 24 36.4 
Christian 91 59.1 42 63.6 
Years of formal education (of caretaker if patient <12 years) 
Mean (years) 5.5 (95% CI 4.98, 5.96) 6.5 (95% CI 6.09, 6.94) 
Median (years) 7 53.9 7 78.8 
Household income regular and dependable 
Yes 75 48.7 40 60.6 
Possibly 18 11.7 3 4.6 
Uncertain 16 10.4 8 12.1 
No 45 29.2 15 22.7 
 
7.4.2 Local understanding of febrile illness 
The subsequent analysis of patterns of distress and perceived causes, all children 
under the age of five years (80+29) and adults over 12 years (57+28) were 
considered (194 in total).  
 
Based on the illness labels given by the interviewees, the fever cases were classified 
into three illness categories that roughly correspond with biomedical malaria (Table 
7.2): 
• malaria 
• homa (fever), and  
• degedege (convulsions, usually known as illness of young children) 
 
This classification is common in the population as has been described in detail in 
earlier qualitative studies from Tanzania (Makemba et al. 1996; Hausmann Muela 
2000; Mayombana 2004). Degedege-labelled cases were relatively rare and hence 
less significant for this analysis. The two cases in adults which were labelled 
degedege were not included in the analysis. Patterns of distress (PD) and perceived 
causes (PC) were ranked according to their prominence in the interviewee’s accounts 
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as described above. Similar PD and PC were grouped for analysis. A detailed list of 
PD and PC variables with prominence values can be found in the Appendix 2.  
 
Table 7.2: Illness labels for children under 5 years and adults over 12 years 
Illness label Children Adults 
 Freq. Percentage Freq. Percentage 
Malaria 68 62.4 54 63.5 
Homa 24 22.0 26 30.6 
Degedege 8 7.3 2 2.4 
Missing 9 8.3 3 3.5 
Total 109  85  
 
7.4.2.1 Patterns of distress (PD)  
In children, fever symptoms (hot head, hot body, etc.) were the most prominently 
mentioned symptoms, reflecting the fever-based case-definition. Signs and 
symptoms related to body strength were the second most prominently reported PD, 
with having “no strength” being significantly more prominent in the malaria compared 
to the homa category (P=0.023). Vomiting was also more prominent in the malaria 
compared to the homa category (P=0.033). It was more prominently reported than 
diarrhoea in all categories. Symptoms of convulsions (such as twitching, stiff body, 
“eyes turn white”, kicking of leg/arm, froth in the mouth, mouth twisted sideways, but 
also delirium, falling down, and being easily startled or frightened) were most 
prominent in the degedege category. Twitching was significantly more prominent in 
the degedege compared to the malaria (P=0.029) and the homa categories 
(P=0.022). Respiratory symptoms were less prominent in all categories (Figure 7.1). 
68 (62.4%) cases showed one or several of the aforementioned signs of convulsions. 
Of these, 44 (61.1%) were labelled malaria, 15 (20.8%) homa, and 7 (9.7%) 
degedege, showing clearly that many caretakers make a link between convulsions 
and malaria. 
 
In adults the same fever case definition applied as in child cases. Nevertheless, 
symptoms related to body strength or pain were more than or as prominent as fever. 
Specifically headache was prominent in both, the homa and the malaria categories. 
In the homa category, headache was considerably more prominent than “hot body”. 
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Diarrhoea and vomiting were equally frequent in the two categories. In both, nausea 
and vomiting were more prominent than diarrhoea. Difficult breathing or cough were 
less prominent in adults than in children. Convulsion-symptoms, such as twitching, 
etc. which are common in degedege in children were not probed – but also not 
mentioned spontaneously (Figure 7.1). Overall there was no clear difference between 
adult cases labelled homa and malaria with regard to reported PD.  
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Figure 7.1: Pattern of distress (PD) by illness category.  
Grouped (bars) and most prominent signs and symptoms. 
 
7.4.2.2 Perceived causes (PC) 
For cases in children, mosquito bites were the most prominent PC. Differences 
between malaria, homa and degedege categories were not statistically significant. 
Houseflies (nzi) were significantly more prominently mentioned in the degedege 
compared to the malaria category (P=0.027). A “bird or insect called degedege”, 
previously reported to be seen as a cause of degedege (Makemba et al. 1996) was 
not significantly associated with the degedege category or symptoms of convulsions. 
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PC related to fatigue, work, physical constitution were significantly more prominent in 
the homa than the malaria category (P=0.023), especially the illness being a "stage 
of child growth" (P=0.033). Cold weather as a cause was most prominent in the homa, 
and least prominent in the malaria category (P=0.044). Heat as well as cold weather, 
were the second most prominent PC in the degedege category, following mosquito 
bites. Supernatural causes (God, spirits, sorcery, etc.) were not mentioned very 
prominently altogether. However, in the malaria category, God was mentioned most 
prominently, just after “mosquito bites”. PC related to contamination, ingestion and 
diet were not very prominent in all categories (Figure 7.2). 
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Figure 7.2: Perceived causes (PC) by illness category.  
Grouped (bars) and most prominent PC. 
 
Also in adults, mosquito bites were the most prominent PC in both, the malaria and 
the homa categories. In the malaria category, mosquito bites were mentioned more 
prominently although this was not quite statistically significant (P=0.062). Other 
insects were only rarely mentioned. Fatigue, work, physical constitution related PC 
were more prominent in the homa category. Physical hard work was more prominent 
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in the homa than the malaria category, with borderline significance (P=0.057). PC 
related to contamination, especially sanitation/dirty environment (P=0.030) were 
significantly more prominent in the malaria category (P=0.040). Weather/climate 
related PC were more prominent in the homa than the malaria category with 
borderline significance (P=0.057). Of all supernatural PC, God was mentioned most 
prominently with no significant difference between the categories. Ingestion/diet 
related causes were not prominently mentioned in either of the two categories (Figure 
7.2). 
 
7.4.3 Help seeking for fever episodes 
The subsequent analysis of help seeking for a recent febrile illness episode was 
limited to the 2004 cross-sectional community survey data on 80 children under 5 
and 57 adults over 12 years.  
 
7.4.3.1 First action and differences between illness labels 
The most frequent first action taken by 79.0% (95% confidence interval [CI] 66.1-
88.6) of adults and 80.0% (70.0-88.1) of caretakers of children was the administration 
of antipyretics (Figure 7.3). Antimalarials were clearly less often administered as first 
action, with no significant difference between children (42.5%, 31.5-54.1) and adults 
(52.6%, 39.0-66.0). 
 
Even in child-cases labelled malaria, antipyretic administration (78.8%, 95% CI 65.3 
to 88.9) was more frequent as first action than administration of antimalarials (48.1%, 
34.0-62.4). Antimalarial administration was not significantly different between the 
illness labels or between cases with (44.7%, 29.9-59.4) or without convulsions 
(39.4%, 21.8-57.0). There was a significant difference between the areas of 
residence (P=0.007) with antimalarial being administered most frequently in Ulanga 
DSS (60%) and less frequently in Kilombero DSS (39%) and Ifakara (18%).  
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Figure 7.3: First help-seeking action.  
Error bars represent 95% confidence intervals. 
 
While also in adult cases, antipyretics were administered most frequently in both 
homa and malaria labelled cases, antimalarials were taken more frequently for 
malaria than for homa (P=0.028). The opposite was the case for antipyretics 
(P=0.039).  
 
Health facility attendance was the second most frequently mentioned first action for 
children (62.5%, 51.0-73.1), and this was significantly different from adult cases 
(33.3%, 21.4-47.1; P=0.001). Adults visited clearly less frequently a health facility 
than they used antipyretics or antimalarials. While health facility visits of children did 
not differ between the two districts or Ifakara, significantly more adults went to a 
health facility in Ifakara than in the DSS villages of Kilombero (P=0.041). In terms of 
health facility attendance rates, no significant difference was seen between the 
illness labels. 
 
Cooling one’s body through sponging or a cold bath was mentioned for over 30% of 
children and adults. For adults, a cold bath or shower was significantly more frequent 
in the malaria (51.4%, 34.0-68.6) than the homa (10.5%, 1.3-33.1) category 
(P=0.003). 
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Traditional medicine or divination was not common in children (11.3%, 5.3-20.3) and 
adults (7.0%, 2.0-17.0), but in children herbal medicine was significantly more often 
given to cases of degedege than to homa or malaria (P=0.02).  
 
7.4.3.2 Expenditures for antimalarials 
Information on expenditures for antimalarial drugs was available for 70 children and 
46 adults who had received an antimalarial. Expenditures for patients exclusively 
attending either a health facility or a drug store are presented in Table 7.3. Children 
and adults paid similar prices in health facilities and in drug stores. Although children 
should be treated free of charge in government health facilities, they paid on average 
540 Tanzanian Shilling (Tsh) (median price, interquartile range [IQR] 0-1100 Tsh) for 
antimalarial medicine obtained in health facilities. It was not possible to distinguish 
between private and public health facilities in this analysis. However, in households 
from villages without a private health facility, child treatments from health facilities 
were not significantly cheaper, suggesting that exemption mechanisms were indeed 
not properly implemented. Quinine (median price Tsh 570, IQR 0-1100) was sold 
frequently and was on average more expensive than SP (Tsh 300, IQR 0-500), 
contributing substantially to total drug expenditures.  
 
Table 7.3: Expenditures for antimalarials in health facilities and general shops 
(in TSh). US $1 = Tsh. 1,117 (July 2004)* 
 Children Adults 
 n Median 
expenditure 
(IQR) 
Range n Median 
expenditure 
(IQR) 
Range 
Health facility 35 540 (0-1100) 0 to 3000 15 500 (200-700) 0 to 2700 
Drug store 16 600 (400-900) 0 to 3600 21 540 (400-800) 60 to 2000 
* OANDA currency website (www.oanda.com) 
IQR = Interquartile range 
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7.4.4 Access to treatment and community effectiveness 
In order to estimate community effectiveness, a range of key indicators of access to 
malaria treatment were assessed (Table 7.4).  
 
Overall, an almost 100% usage of biomedical treatment was noted in adults and 
children. Antimalarial administration to children was common (88.8%) with the 
majority receiving quinine (53.8%). 34.9% of the children who received quinine, were 
given an injection or infusion. Less than half of the children and adults received the 
first-line drug SP. 28.8% (95% CI 19.2-40.0) of the children and 12.3% (5.1-23.7) of 
the adults were treated with more than one product, usually with two (P=0.022).  
 
Few episodes were treated with an antipyretic only, or with an antibiotic. Overall, 
children (76.3%, 65.4-85.1) were significantly more often brought to a health facility 
than adults (56.1%, 42.4-69.3; P=0.013). Children (53.8%, 42.2-65.0) were also more 
likely to receive their antimalarial from a health facility  than adults(29.8%, 18.4-43.4; 
P=0.005). Adults on the other hand opted significantly more frequently for non-
exclusive (P=0.04) or exclusive (P=0.055) home-management with antimalarials than 
children. Generally, drug stores were the most important source for home-treatment 
and adults were more likely to get their antimalarials from drug stores than children 
(P=0.007). However, of the 57 children who were brought to a health facility and 
received an antimalarial, 24.6% obtained the drugs from a source other than the 
facility.  
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Table 7.4: Key indicators for help seeking and access to malaria treatment in 
individuals with fever in the preceding two weeks 
Indicator Children Adults P 
 n % 95% CI TDHS2 n % 95% CI  
N 80    57    
Episodes treated 80 100 95.5-100  57 100 93.7-100  
Medications: 1 
Modern medicine 80 100 95.5-100  56 98.3 90.6-100 0.416* 
Antimalarial drug (AM) 71 88.8 79.7-94.7 
58.2 
(88.6) 
47 82.5 70.1-91.3 0.293§ 
 - SP 38 47.5 36.2-59.0 
23.7 
(33.8) 
25 43.9 30.7-57.6 0.673§ 
 - amodiaquine 10 12.5 6.2-21.8 
22.1 
(29.3) 
5 8.8 2.9-19.3 0.491§ 
 - quinine 43 53.8 42.2-65.0 
11.9 
(23.5) 
23 40.4 27.6-54.2 0.122§ 
 - other AM 2 2.5 0.3-8.7  1 1.8 0.0-9.4 1.000* 
Antipyretic only 9 11.3 5.3-20.3  9 15.8 7.5-27.9 0.438§ 
Antibiotic 8 10.0 4.4-18.8  2 3.5 0.4-12.1 0.194* 
Treatment sources: 1 
Health facility visit 61 76.3 65.4-85.1  32 56.1 42.4-69.3 0.013§ 
AM from health facility 43 53.8 42.2-65.0  17 29.8 18.4-43.4 0.005§ 
AM not from health 
facility 
28 35.0 24.7-46.5  30 52.6 39.0-66.0 0.040§ 
AM from drug store 19 23.8 15.0-34.6  26 45.6 32.4-59.3 0.007§ 
AM from general shop 8 10.0 4.4-18.8  4 7.0 2.0-17.0 0.761* 
AM from home stock (or 
relative/neighbour) 
10 12.5 6.2-21.8  6 10.5 4.0-21.5 0.723§ 
Exclusive home-
management with AM3 
14 17.5 9.9-27.6  18 31.6 19.9-45.2 0.055§ 
Delay in first (immediate) help-seeking: 
Antipyretic on day 1 51 79.7 67.8-88.7  32 71.1 55.7-83.6 0.301§ 
AM on day 1 16 47.1 29.8-64.9  15 50.0 31.3-68.7 0.814§ 
Health facility on day 1 24 48.0 33.7-62.6  5 26.3 9.2-51.2 0.103§ 
1One episode may be treated with several drugs from various sources; 2Tanzania Demographic and 
Health Survey 2004-05 (data for Morogoro Region in brackets); 3Episodes never brought to a health 
facility; *Fisher’s exact test; §Chi-square test 
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Generally, antipyretics were used more promptly than antimalarials in children and 
adult cases. Antipyretic use was also quicker than visits to a health facility. For the 
first actions taken, there was no significant difference between the delay observed in 
children and adult cases. However, for overall antimalarial use, 76.3% (65.4-85.1) of 
the children received an antimalarial on the day the fever started or the day after, 
while only 56.1% (42.4-69.3) of adults took the medication within that period 
(P=0.013). If adjusted for age class (adult/child), those who had their antimalarial 
from a health facility were more likely to receive it on the day the illness started 
(P=0.004).  
 
7.4.4.1 Community effectiveness 
Effectiveness of malaria treatment does not only depend on drug efficacy, but to a 
large extend on wide coverage and timely access to the drugs, provider compliance 
with treatment guidelines and adherence to the correct dosage by the patient.  
 
The access indicators measured in this research allowed an estimation of community 
effectiveness of malaria treatment which is shown in Figure 7.4. The main indicators 
shown in the figure (and explained below), illustrate clearly how dramatically 
community effectiveness is reduced because of weaknesses in the treatment chain.. 
 
1. Use of a recommended antimalarial (SP, amodiaquine or quinine) ? 
87.5% (78.2-93.8) of children and 80.7% (68.1-90.0) of adults received one of 
the antimalarials recommended by the national guidelines (MOH 2000). 
2. Use of a recommended antimalarial on the same or next day ? 
72.5% (61.4-81.9) of children and 56.1% (42.4-69.3) of adults received the 
recommended antimalarial on the day of onset of the symptoms or the day 
after.  
3. Use of a correctly dosed recommended antimalarial on the same or next 
day ? 
42.5% (31.5-54.1) of children and 36.8% (24.4-50.7) of adults received the 
timely administered antimalarial in the recommended dose. Dosage was 
assessed based on what people reported to have taken or administered to the 
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child. Due to a lack of detailed information, it was assumed that all injections 
were correctly dosed. Most wrong dosages were under-dosages.  
4. Use of a correctly dosed antimalarial, appropriate considering the 
reported symptoms, on the same or next day ? 
22.5% (13.9-33.2) of children and 10.5% (4.0-21.5) of adults received timely 
treatment with correctly dosed SP or amodiaquine for reported symptoms of 
uncomplicated malaria and quinine if severe symptoms (incl. difficult breathing, 
yellow eyes, convulsions, delirium (MOH 2000; Mackintosh et al. 2004)) were 
reported. 
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Figure 7.4: Estimated effectiveness of fever treatment modelled based on 
patients’ or caretakers’ accounts. 
Legend: 
?  Episode treated 
?  Drug administered 
?  Antimalarial administered 
?  Recommended antimalarial 
?  Recommended antimalarial on same or next day 
?  Recommended antimalarial on same/next day, in correct dose 
?  Recommended antimalarial on same/next day, correct dosage,  
 considering reported symptoms 
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In this study, antimalarial usage rates reached a satisfactory level of over 80%. 
However, mere usage rates are misleading. If drug dosage, delay, and reported signs 
and symptoms were taken into account, treatment effectiveness reached only 11% 
and 23% for adults and children, respectively.  
 
7.4.4.2 Factors related to prompt and effective treatment 
Three multivariate logistic models were fitted to assess predictors for the 
administration of a recommended antimalarial, as well as for timely and correctly 
dosed treatment (Figure 7.5). Models were fitted once for the DSS only and once for 
both the DSS and Ifakara households. Spatial information and SES were only 
available for the DSS households.  
 
Children sample (100%)
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AM correct dose (21%)
AM same / 
next day (73%)(18%)
Adult sample (100%)
AM (82%)
AM correct 
dose (35%)
AM same / 
next day (56%)(28%)
 
Figure 7.5: Graphical illustration of treatment indicators assessed in the 
multivariate models* 
* Circles are roughly proportional to the percentage of patients. AM = antimalarial 
 
The model assessing predictors for a recommended antimalarial in DSS households 
revealed that labelling the illness as a homa (fever) (OR=0.08, 95% CI 0.02-0.32), 
administration of traditional herbal medicine as first action (OR=0.08, 0.01-0.58) and 
the total number of people in the household (OR=0.78, 0.63-0.96) decreased the 
odds of receiving a recommended antimalarial. On the other hand, attending a health 
facility during the course of the illness (OR=8.09, 1.92-34.12) increased the odds of 
receiving a recommended antimalarial (Table 7.5). If this model was fitted with DSS 
and Ifakara households, only the effects of the homa-label and the number of people 
in the household were retained.  In the univariate analysis, recognising the illness in 
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the fields (shamba) and increased distance to the nearest antimalarial provider were 
also significantly correlated with less antimalarial administration, while reported 
diarrhoea or vomiting significantly increased the odds. Episodes in DSS households 
were less likely to receive a recommended antimalarial than those in Ifakara.  
 
The second model assessed predictors for timely treatment (i.e. on the day of illness 
onset or the day after) among all those receiving an antimalarial. None of the 
plausible predictors was significantly correlated with the outcome, with the exception 
of number of people in the household, which decreased the odds of receiving an 
antimalarial promptly (OR=0.81, 0.66-0.98). Neither the age of the patient, nor the 
distance to the nearest provider, nor prior treatment with other medicine was found to 
significantly predict the outcome (Table 7.6). 
 
The third model assessed predictors for correct dosage among those receiving SP or 
amodiaquine. This analysis did not consider quinine, as it was not possible to 
establish the accuracy of the dosage of quinine injections. It resulted that compared 
to adults, children’s odds of receiving the correct dose was significantly decreased 
(OR=0.26, 0.09-0.81). Cases from DSS households were more likely to receive a 
correctly dosed drug than those from Ifakara (OR=4.69, 1.26-17.43) (Table 7.7).  
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Table 7.5: Univariate and multivariate analyses of predictors for administration 
of a recommended antimalarial (SP, amodiaquine or quinine) 
 Univariate model* Multivariate model** 
Exposure variable Crude OR 95% CI P Adjusted  OR 95% CI P 
Age group 
Adult 1   1   
Child 1.67 0.66-4.26 0.280 0.65 0.12-3.57 0.619 
Total number of people in 
household 0.85 0.73-0.99 0.041 0.78 0.63-0.96 0.022 
Place of illness recognition 
Home 1   1   
Shamba 0.19 0.07-0.51 0.001 0.29 0.07-1.25 0.096 
Diarrhoea or vomiting reported 
No 1   1   
Yes 5.05 1.73-14.74 0.003 4.03 0.90-18.03 0.069 
Signs of severe malaria 
No       
Yes 2.48 0.78-7.88 0.125 2.84 0.44-18.28 0.272 
Illness label (self-defined) 
Malaria/ degedege 1   1   
Homa 0.10 0.04-0.29 0.000 0.08 0.02-0.32 <0.001
First action: Antipyretic 
No 1   1   
Yes 0.61 0.17-2.23 0.451 1.43 0.22-9.34 0.706 
First action: Traditional medicine 
No 1   1   
Yes 0.24 0.07-0.81 0.022 0.08 0.01-0.58 0.012 
Health facility attendance 
No 1   1   
Yes 4.46 1.69-11.78 0.003 8.09 1.92-34.12 0.004 
Antimalarial provider in village1 
No 1   1   
Yes 2.10 0.67-6.59 0.201 1.02 0.14-7.34 0.981 
Distance to nearest AM 
provider (km)***/1 0.01 0.00-0.43 0.017    
Study area 
Ifakara 1      
DSS 0.22 0.05-0.98 0.046     
* 137 observations; ** 136 observations; *** 76 observations; 1 Incl. health facilities, drug stores and 
general shops stocking antimalarials in mid-2004; AM = antimalarial 
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Table 7.6: Univariate and multivariate analyses of predictors for timely 
administration of a recommended antimalarial (on the day of illness onset or 
the day after) 
 Univariate model* Multivariate model** 
Exposure variable Crude OR 95% CI P 
Adjusted 
OR 95% CI P 
Age group 
Adult 1   1   
Child 2.11 0.87-5.12 0.097 1.91 0.69-5.31 0.215 
Total number of people in 
household 0.81 0.68-0.96 0.014 0.81 0.66-0.98 0.032 
Place of illness recognition 
Home 1   1   
Shamba 0.62 0.21-1.83 0.387 0.88 0.26-2.98 0.835 
Diarrhoea or vomiting reported 
No 1      
Yes 1.21 0.50-2.93 0.677 1.19 0.43-3.29 0.742 
Illness label (self-defined) 
Malaria/degedege 1   1   
Homa 1.79 0.48-6.64 0.387 2.16 0.53-8.79 0.283 
First action: Antipyretic 
No 1   1   
Yes 0.83 0.28-2.49 0.744 0.81 0.24-2.71 0.736 
First action: Traditional medicine 
No 1   1   
Yes 0.45 0.10-2.03 0.299 0.36 0.07-1.87 0.225 
Health facility attendance 
No 1   1   
Yes 1.29 0.50-3.37 0.597 1.61 0.55-4.77 0.386 
Antimalarial provider in village1 
No 1   1   
Yes 0.85 0.22-3.26 0.810 0.66 0.15-2.91 0.587 
Distance to nearest AM 
provider (km)***/1 0.10 0-18.57 0.382    
Type of nearest provider*** 
Shop 1      
Health facility 1.66 0.44-6.20 0.453    
Antimalarial source: Health facility 
No 1      
Yes 1.33 0.56-3.20 0.520    
Antimalarial source: Shop or home 
No 1      
Yes 0.75 0.31-1.80 0.519    
* 116 observations; ** 115 observations; ***616 observations; 1 Incl. health facilities, drug stores and 
general shops stocking antimalarials in mid-2004; AM = antimalarial 
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Table 7.7: Univariate and multivariate analyses of predictors for correct dosage 
of SP or amodiaquine  
 Univariate model* Multivariate model* 
Exposure variable 
Crude 
OR 
95% CI P 
Adjusted 
OR 
95% CI P 
Age group 
Adult 1   1   
Child 0.26 0.10-0.71 0.008 0.26 0.09-0.81 0.019 
Sex of patient 
Female 1   1   
Male 0.77 0.31-1.90 0.563 0.86 0.29-2.54 0.787 
Total number of people in 
household 1.07 0.90-1.27 0.444    
Education of 
patient/caretaker (years) 1.06 0.92-1.22 0.392 1.06 0.91-1.23 0.483 
Place of illness recognition 
Home 1      
Shamba 1.39 0.48-4.03 0.546    
Diarrhoea or vomiting reported 
No 1      
Yes 0.69 0.27-1.73 0.424    
Illness label (self-defined) 
Malaria/ degedege 1      
Homa 0.88 0.28-2.72 0.817    
Health facility attendance 
No 1   1   
Yes 0.49 0.18-1.38 0.178 1.13 0.22-5.73 0.886 
Antimalarial source: Health facility 
No 1      
Yes 0.55 0.22-1.39 0.207 0.46 0.11-2.01 0.305 
Study area 
Ifakara 1   1   
DSS 3.01 1.01-9.01 0.048 4.69 1.26-17.43 0.021 
* 75 observations 
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7.5 Discussion 
Access to prompt and effective malaria treatment can be investigated using different 
approaches. Depending on the perspective, the focus may be laid on the patient’s 
behaviour, the health system performance or the livelihood context; or, the three 
approaches may be combined, as elaborated by Obrist et al. (2007). This paper 
assessed treatment effectiveness mainly from the perspective of the patients. It 
considered only patients who recovered from their febrile illness. The results are from 
studies with a limited sample size, carried out in two districts with a long history of 
malaria-control and research activities. This needs to be considered when making 
inferences to other areas. However, the analysis revealed some important issues for 
the development of future malaria control strategies. 
 
The reliance on patients’ or caretakers’ accounts can result in misdiagnosis and 
misreporting. However, many illness episodes brought to rural health facilities are 
diagnosed based on the patient’s or caretaker’s reported symptoms rather than by 
proper clinical assessment and laboratory test (Font et al. 2001; Eriksen et al. 2007). 
Even the Integrated Management of Childhood Illness (IMCI) strategy which is 
implemented in the study districts advocates exclusive clinical assessment of patients 
in rural dispensaries in the absence of reliable diagnostic tools (WHO 1997). And 
more importantly, it is the patient’s perceived ill-health that triggers help-seeking, 
rather than a parasitological test or clinical diagnosis (McCombie 2002).  
 
It has been recognised fro a long time that understanding of malaria by the 
community as an illness which can be treated with modern medicine will determine 
successful implementation of effective case-management (WHO 1993). This 
research tried for a first time to quantify the distribution of reported signs and 
symptoms as well as perceived causes in relation to local illness labels. Different 
illness concepts that relate to malaria in Tanzania have been described in detail and 
special attention has been paid to degedege, a febrile convulsive illness often related 
to severe malaria. The concept of degedege was traditionally linked to spirits in the 
form of a bird or a moth and mainly herbal treatment would be administered by 
traditional healers (Makemba et al. 1996; Oberländer & Elverdan 2000). In our 
studies, fevers with convulsions were in most cases labelled malaria rather than 
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degedege. Studies done between 1995 and 1997 in the same area found that 
concepts of degedege and malaria were fuzzy; while degedege may have  been 
seen as a cause of severe malaria, only mild malaria would be related to mosquito 
bites (Minja et al. 2001; Hausmann Muela et al. 2002). In 2004 a clear change could 
be noticed with mosquito bites being the most prominently mentioned perceived 
cause, also in cases with convulsions or those labelled degedege. A more 
comprehensive analysis of degedege in particular is currently in preparation 
(citation?). 
 
In contrast to degedege which would be considered a severe and dangerous illness 
(Hausmann Muela et al. 2002), homa (usually translated as “fever”) was often 
regarded as a normal stage in child growth or was attributed to weather conditions. 
Homa was a febrile illness without vomiting or other more severe symptoms. Very 
similar findings have been reported from different areas in Tanzania (Mayombana 
2004). While for homa and malaria different symptoms were reported in children, this 
was not the case in adults where headache was predominant for both labels. Adult 
malaria was attributed to mosquito bites or a dirty environment while homa was 
rather seen as caused by weather conditions or hard work. Overall it appeared that 
malaria was most prominently associated with mosquitoes whereas homa was more 
often attributed to other causes as well. In earlier studies, homa has been described 
as a label for general malaise and aches, sometimes even in absence of fever 
(Winch et al. 1996; Hausmann Muela et al. 1998), which may to some extent explain 
why fever as a symptom was not most prominent in all homa cases. The implications 
local illness labels may have were uncovered by the risk-factor analysis: Those cases 
labelled homa were more than 12 times (OR=0.08, 0.02-0.32) less likely to receive 
an antimalarial than cases labelled malaria or degedege.  
 
A large overlap of the popular and biomedical concepts of malaria can be seen in 
part as a consequence and success of regular and intensive health education 
campaigns in the area, from the national “Mtu ni Afya” (Man is Health) campaign in 
the late 1970s (Hausmann Muela 2000) to the intensive KINET social marketing in 
the 1990s (Armstrong Schellenberg et al. 1999; Minja et al. 2001). Nevertheless, 
factual knowledge does not necessarily translate directly into improved behaviour, as 
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described by Hausmann et al. (2002). This is particularly true, since appropriate care-
seeking depends on several factors other than illness understanding.  
 
In contrast to what has been reported from earlier studies and other areas (von 
Seidlein et al. 2002; Amin et al. 2003; Nsungwa-Sabiiti et al. 2005), no fever episode 
remained untreated and antimalarial administration was very common. Even cases 
with convulsions (labelled degedege or malaria) were frequently treated with 
antimalarials (44.7% first action, overall 91.5%) and more rarely with traditional 
herbal medicine (17% first action). This is a major improvement in treatment seeking 
compared to the reported 35% herbal medicine and 2% antimalarial for degedege in 
1995-97 (Hausmann Muela 2000). It confirms from a different angle what has been 
found by de Savigny et al. (2004b) who reported 78.7% first use of biomedical care 
for cases of fatal malaria in Tanzania. Considering that first treatment with herbal 
medicine was correlated with less antimalarial use (OR 0.08, 0.01-0.58), 
discouraging herbal treatment may help to increase treatment with antimalarials.  
 
The first action taken was most frequently the use of an antipyretic and episodes 
considered to be homa were more likely to be treated with antipyretics only. Home-
management with antimalarials was not very common, especially for children. This 
reflects the fact that antimalarials are nowadays less readily available in shops 
(Hetzel et al. 2006) and that Tanzania is not actively promoting home-based 
management of malaria. Adult episodes were more frequently treated with 
antimalarials from the private sector while 76% of the cases in children were brought 
to a health facility. Under the given circumstances, health facility attendance is 
desirable, especially for young children. Severe diseases other than malaria, e.g. 
pneumonia or meningitis, may anyway be detected and treated only in health 
facilities. 
 
Attending a health facility during the course of the illness was associated with more 
use of a recommended antimalarial (OR=8.09, 1.92-34.12). However, the proportion 
of people receiving an appropriate antimalarial timely and correctly dosed (11% and 
23% for adults and children, respectively) as an approximation for community 
effectiveness was too low and too far from the 80% target set by the RBM 
Partnership for 2010 (RBM Partnership 2005). It also puts into perspective the 
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indicator used in the 2004/5 demographic and health survey which reported 51.1% 
use of a recommended antimalarial on the same or next day for Tanzania and 82.7% 
for Morogoro Region (National Bureau of Statistics 2005) 
 
Attending a health facility or obtaining the antimalarial from there was not associated 
with more appropriate drug dosage. More than half of the SP dosages from health 
facilities were incorrect considering the reported age of the patient. Children were 
almost four times less likely to receive an appropriate dose of SP or amodiaquine 
(OR=0.26, 0.09-0.81). Although this may in part be attributed to lack of provider 
compliance, poor patient adherence or reporting errors, quality of care seems to need 
considerable improvement. Limiting antimalarial sales largely to health facilities and 
drug stores (Hetzel et al. 2006) did apparently not result in an acceptable quality of 
case-management. The effect of the number of people in a household on (timely) 
antimalarial treatment may be a chance finding or related to intra-household relations 
(Molyneux et al. 2002). Yet it may also reflect that in larger families, child care is 
often delegated from parents to older siblings who may not well know how to handle 
an illness episode. In families with more children (or in addition old people), 
caretakers may be more busy and have less time devote to each one. 
 
In this context it is worth considering that all estimates presented here did explicitly 
exclude the issue of drug efficacy, while actual efficacy of SP in children in nearby 
Mlimba village was reported to be only 65.7% (adequate clinical and parasitological 
response at day 28) (Mugittu et al. 2005). Furthermore, 24 % of SP tablets and 40 % 
of quinine sulphate tablets collected in the study area did not meet USP 
specifications for the amount of active ingredient and were mostly under-dosed 
(Braun 2005; Hetzel et al. 2007c). Adding this into an effectiveness-model would 
result in even lower levels of community effectiveness than reported here. 
 
25% of child episodes seen at a health facility were treated with a shop-bought 
antimalarial. Since children under the age of 5 years are formally exempted from any 
charges at public health facilities (including for drugs), it would be desirable that they 
obtain their antimalarial from there. It might have been expected that resorting to the 
commercial sector for cases of childhood fevers would pose an additional and 
unnecessary burden on poor households since in the private sector no exemption 
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policy applies. Njau et al. reported significantly higher spending in drug stores (but 
not general shops) compared to government health facilities (Njau et al. 2006). 
However, data from this study suggests that in reality the exemption system was not 
functioning and that expenditures for drugs did not significantly differ between health 
facilities and drug stores. Treating a child in the private retail sector may even have 
been cheaper, since shops were closer to people’s homes, resulting in lower 
secondary costs for time and transport. This may result in higher facility usage and 
possibly more use of antimalarials by richer households, as has been reported 
elsewhere (Armstrong Schellenberg et al. 2003). This link could however not be 
proven in our study. An additional problem were stock-outs of SP, amodiaquine, and 
quinine which were repeatedly observed in the study area (Dillip et al. 2007). Patients 
may therefore be forced to purchase medicines in the commercial sector which 
consequently plays a pivotal role in providing life-saving drugs in the case of delivery-
failure of formal health facilities.  
 
In the ongoing process of rolling out highly efficacious Artemisinin-based combination 
therapy (ACT), special attention will have to be paid to the quality of prescription in 
formal health facilities, the ability and willingness of patients to comply with the 
treatment regimen, as well as to the channels through which these drugs are brought 
to the patients. It needs to be closely monitored whether restricting ACT to the formal 
health sector will result in increased community effectiveness (timely administration 
of correctly dosed ACT to all those in need) or in a decrease in treatment rates 
without an improvement in the administered drug regimens.  
 
7.6 Conclusion 
The local understanding of the biomedical concept of (mild and severe) malaria has 
improved after decades of continuous health education. Further education may have 
to focus on clear messages on how, when and where to treat a febrile illness instead 
of merely reiterating illness models. Availability of antimalarials has been largely 
limited to certified providers and health facility usage was very popular. Nevertheless, 
the quality of case-management was far from satisfactory. Decreased drug efficacy 
and sub-standard drug quality may have further decreased effectiveness at 
community level. Exemption mechanisms aim to facilitate treatment access for poor 
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and vulnerable groups but in our setting they did not seem to be properly 
implemented. Private drug retailers play a central role in the provision of timely 
malaria treatment, complementing the existing formal health services. All these 
issues can be attributed to a health system which is still too weak to deliver a growing 
number of increasingly complex health interventions. Such systems constraints need 
to be tackled urgently with an increased investment in the local health system in 
order to translate the high efficacy of newly introduced ACT into equitable 
community-effectiveness and health-impact.  
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8.1 Abstract  
8.1.1 Background 
The Kilombero Valley is a highly malaria-endemic agricultural area in south-eastern 
Tanzania. Seasonal flooding of the valley is favourable to malaria transmission. 
During the farming season, many households move to distant field sites (shamba in 
Swahili) in the fertile river floodplain for the cultivation of rice. In the shamba, people 
live for several months in temporary shelters, far from the nearest health services. 
This study assessed the impact of seasonal movements to remote fields on malaria 
risk and treatment seeking behaviour.  
8.1.2 Methods 
A longitudinal study followed approximately 100 randomly selected farming 
households over six months. Every household was visited monthly and whereabouts 
of household members, activities in the fields, fever cases and treatment seeking for 
recent fever episodes were recorded.  
8.1.3 Results 
Fever incidence rates were lower in the shamba compared to the villages and moving 
to the shamba did not increase the risk of having a fever episode. Children aged 1-4 
years, who usually spend a considerable amount of time in the shamba with their 
caretakers, were more likely to have a fever than adults (OR=4.47, 95% CI 2.35-
8.51). Protection with mosquito nets in the fields was extremely good (98% usage) 
but home-stocking of antimalarials was uncommon. Despite the long distances to 
health services, 55.8% (37.9-72.8) of the fever episodes were treated at a health 
facility, while home-management was less common (37%, 17.4-50.5). 
8.1.4 Conclusions 
Living in the shamba does not appear to result in a higher fever-risk. Mosquito nets 
usage and treatment of fever in health facilities reflect awareness of malaria. Inability 
to obtain drugs in the fields may contribute to less irrational use of drugs but may 
pose an additional burden on poor farming households. A comprehensive approach 
is needed to improve access to treatment while at the same time assuring rational 
use of medicines and protecting fragile livelihoods.  
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8.2 Background 
Malaria continues to be a major public health problem, particularly for young children 
in sub-Saharan Africa (Lopez et al. 2006). Malaria has often been linked with 
agricultural practices, especially irrigation. Environmental management, such as well-
designed irrigation schemes have been proposed as one of the means for reducing 
the burden of malaria in agricultural settings (van der Hoek 2004; Keiser et al. 2005).  
 
Research on malaria risk related to farming activities has so far mainly focused on 
vector abundance and malaria transmission in areas with artificial irrigation (Ijumba et 
al. 2002a; Sissoko et al. 2004; Diuk-Wasser et al. 2007). Linkages between malaria 
and agriculture were found to be complex and specific to the local setting. Cultivation 
of rice may encourage the proliferation of malaria-transmitting Anopheles mosquitoes 
(Sogoba et al. 2007; Diuk-Wasser et al. 2007). Yet, due to lower density of human 
hosts in the fields in some areas, or zoophilic feeding behaviour of some vector 
species in others (Mutero et al. 2004), an increase in the number of mosquitoes does 
not necessarily translate into higher parasite prevalence in the human population. 
Research done in northern Tanzania reported lower malaria transmission in villages 
with irrigated crop production compared to adjacent savannah villages without 
irrigation. This was attributed to a higher standard of living and better health care in 
the studied irrigation schemes and has been referred to as the “paddies paradox” 
(Ijumba et al. 2002a).  
 
By contrast, an analysis of the spatiotemporal patterns of malaria transmission in 
Thailand provided some evidence that the farming season and the movement of 
people to the location of their crops were associated with higher risk of malaria 
(Childs et al. 2006). Socio-cultural aspects were investigated in a study in Côte 
d’Ivoire which indicated that socio-economic transformations and changes in gender-
specific tasks and responsibilities induced by the intensification of inland valley rice 
cultivation lead to a reduction of the capacity of women to manage disease episodes 
(De Plaen et al. 2003). Overall, no simple and clear association has so far been 
found between irrigated rice cultivation and malaria transmission (Ijumba & Lindsay 
2001).  
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The Kilombero Valley in south-eastern Tanzania is a well-described highly malaria-
endemic tropical wetland dominated by subsistence agriculture (Zehnder et al. 1987; 
Smith et al. 1993; Drakeley et al. 2003; Killeen et al. 2007). The valley’s climatic and 
ecological characteristics are favourable for high and perennial malaria transmission. 
During the rainy season, large parts of the valley are flooded by the Kilombero River. 
The majority of the valley’s farming residents take advantage of this natural flood 
irrigation to cultivate rice, which is the main staple food and the most important cash 
crop in the area. Only very few artificial irrigation schemes are in place. While artificial 
schemes may be established based on knowledge of water management and 
mosquito ecology (Keiser et al. 2005), there is little opportunity to influence the 
natural flooding of a vast floodplain such as the Kilombero Valley.  
 
The geographical and ecological patterns of the Kilombero Valley lead to distinct 
seasonal movements of the local farming population. The valley’s villages with their 
entire infrastructure are situated along the main roads on the edges of the flood plain. 
All health care providers, such as health facilities, drug stores or general shops 
selling drugs are located in the villages. Farming sites (shamba in Swahili) are often 
located at a considerable distance from people’s homes in the fertile lower wetland. 
Due to the standing water, farms can often be accessed only by walking long 
distances and wading through water. During the main cultivation period, families 
therefore often move from the villages to the farms where they stay in temporary 
shelters, usually fabricated with branches and straw and often built on stilts to protect 
them from water and wild animals (Figure 8.1 a and b).  
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Figure 8.1: Shamba houses (A & B) and main house in a village (C) 
 
The rainy season and hence main cultivation period occurs between February and 
June. It is considered a period of high vulnerability for the farming population 
because of recurring food insecurity (empty stocks before the harvest), labour stress 
(intensive work on the farm), poor access to preventive and curative health services 
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as well as family support due to the remoteness of the farms, little time for child care 
and poor access to clean water and adequate sanitation in the fields. Malaria 
transmission, fever incidence and mortality in the community show seasonal 
variations with a peak during the same season. It has therefore been speculated that 
the seasonal movement of parts of the population to their distant fields results in an 
increased risk of and vulnerability to malaria. Long distances from the farming sites to 
the next village and health facility can furthermore contribute to delayed and 
inappropriate care-seeking which may in part be compensated by more frequent use 
of home-stocked drugs. Eventually, disease episodes during the cultivation period 
may result in lower crop yield and consequently lower income with considerable 
impact on household economies, as was shown in a study conducted in Côte d’Ivoire 
(Girardin et al. 2004).  
 
Hardly any of the literature published so far has focused on the impact of these 
seasonal movements on malaria incidence or the ability of people to cope with 
disease episodes, and it is unclear, how common such movement patters are on the 
African continent. We provide a qualitative and quantitative assessment of risks, 
access to health services and treatment-seeking related to fever episodes that 
occurred in farming households during the main cultivation period.  
 
8.3 Methods 
This longitudinal study was carried out between January and August 2005 within the 
frame of a research and intervention project to understand and improve access to 
effective malaria treatment (ACCESS Programme), which is described in detail 
elsewhere (Hetzel et al. 2007c). 
 
8.3.1 Study area and study population 
The study was conducted in the area of a Demographic Surveillance System (DSS), 
in the districts of Kilombero and Ulanga, Tanzania. In mid-2005, the DSS had a 
population of 75,120. There is a short rainy season from October to December and a 
long one from February to June. Annual rainfall ranges from 1200 to 1800 mm and 
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annual mean temperature is around 26° C (Armstrong Schellenberg et al. 2002). The 
details of the study area have been described elsewhere (Hetzel et al. 2007c).  
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Figure 8.2: Study area with Demographic Surveillance System (DSS), ten 
sampled villages (villages centres shaded grey), main houses and shamba 
locations 
 
For the initial visit in January 2005, ten out of a total of 25 DSS villages were chosen 
at random (Figure 8.2). Out of 5912 households that had previously reported to have 
a farming plot (shamba), a two-stage random sample of 159 households was drawn, 
proportional to the relative size of the villages. To compensate for 77 (54.7%) 
households which reported not to have a shamba anymore in 2005, an additional 
sample of 80 households was added to the study in March using the same sampling 
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strategy. Of these, another 40 (50%) households did not have a shamba anymore or 
did not cultivate it that year. The total number of households visited per round is 
reported in Table 8.1. 
 
Table 8.1: Number of households (main residencies and shamba houses) 
visited in each round 
Round Time Main houses Shamba Total** 
1 15-29 Jan 72 N/A 72 
2 2-20 March 25 47 72 
2b* 29 Mar-4 Apr 40 N/A 40 
3 6-27 Apr 35 67 102 
4 12-23 May 32 69 104 
5 11-27 Jun 28 69 98 
6 23 Jul-1 Aug 61 26 87 
* additional sample to compensate for losses to follow-up, as explained in the text 
** in round 4 and 5, the differences between the sum of the two locations and the total value are due 
to missing information on the interview location 
N/A = Not applicable 
 
8.3.2 Data collection 
Data was collected monthly from all households included in the study. Baseline data 
collection started in January 2005 in the main residences in the villages. The 
subsequent visits (rounds) took place in the shamba unless all family members were 
in the main residence at the time of the monthly visit. The sixth and last visit was 
done in July 2005 or earlier if the family had completely moved back from the fields to 
their main house. At every visit, two data collection tools were used:   
 
A) Household-level questionnaire 
During each round, the same structured questionnaire was applied to record each 
household member’s whereabouts in the four preceding calendar weeks (day-time 
and night-time), activities performed on the farms, use of mosquito nets and number 
of recent fever episodes. The location of the main house and the shamba were 
recorded using hand-held GPS devices (Garmin® e-Trex®, Garmin Ltd.).  
 
B) Treatment-seeking questionnaire (EMIC) 
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For those fever episodes which had occurred in the preceding two weeks, an in-
depth interview was carried out to elicit detailed information on treatment seeking. 
Interviews were done with patients of 12 years and above and with caretakers of 
children under the age of 5 years. Cases that had not recovered the day of the 
interview were not interviewed and advised to seek care from a qualified provider. An 
Explanatory Model Interview Catalogue (EMIC) was used for data collection. EMICs 
are semi-structured questionnaires designed to collect quantitative and qualitative 
information (narratives) on the experience of illness and resulting treatment-seeking 
behaviour from the point of view of those affected (Weiss 2001). The EMIC was 
developed based on preceding focus-group discussions (Hetzel et al. 2007c) and 
further qualitative research on people’s understanding of malaria (Hausmann Muela 
2000; Minja et al. 2001; Mayombana 2004). The same forms had already been used 
in a previous treatment-seeking survey in the same area (Hetzel et al. 2007d).  
 
In addition, information on the socioeconomic ranking of the households in the study 
was obtained from the DSS database. Each year, information is collected on proxy 
markers of socioeconomic status such as main sources of income, household 
ownership of assets, housing characteristics and water and sanitation facilities for all 
of the households in the DSS area. The 2005 survey collected information on 15,396 
households.  
 
8.3.3 Data entry and analysis 
Data was double-entered at the Ifakara Health Research and Development Centre 
(IHRDC) data unit using Microsoft Access or FoxPro software (Microsoft Corp., 
Seattle, USA). Statistical analysis was done in Intercooled Stata 9 (StataCorp, 
College Station, Texas, USA) and mapping using MapInfo Professional 7.0 (MapInfo 
Corp., Troy, New York, USA) and ArcView GIS 3.3 (ESRI, Redlands, CA, USA).  
 
An individual level and a household level model were fitted to quantify the effect of 
risk factors for a fever episode.  
 
A logistic model was fitted at the individual level to quantify the effect of age and 
proportion of weeks spent in the shamba overnight on fever incidence. The outcome 
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variable at individual level was derived from the EMIC interviews. As EMICs were 
only done for recovered episodes (excluding acute cases), the outcome indicator 
represented only a proportion of the overall fever incidence. In the five cases in which 
more than one episode was recorded on the same person, one episode was chosen 
at random. At the household level, a logistic model with outcome variable “reported 
fever episode in the household in the past two weeks” was fitted to quantify the effect 
of household mosquito net ownership and use. In the final individual and household 
models, no account was taken of the clustering within individuals and households. 
Comparing the models with and without clustering using the likelihood ratio test 
revealed no evidence of significant between-individual or between-household 
variance (results not shown). 
 
A descriptive analysis of household data on net ownership and drug home stocking 
was carried out. Averages were calculated over all rounds with no weighting since in 
each round approximately the same number of households was interviewed. Net 
usage average was weighed by number of observations (persons) per round. 
 
Treatment seeking indicators were assessed at an individual level using EMIC data. 
All estimates derived from this retrospective study relied on self-reported help-
seeking behaviour. Logistic models were fitted to assess the effect of likely predictors 
on several treatment seeking indicators.  
 
Principal components analysis (PCA) was used to define the weights of a relative 
index of socioeconomic status (SES). The first principal component was chosen, 
since it summarises the largest amount of information common to the asset 
(Armstrong Schellenberg et al. 2003; Vyas & Kumaranayake 2006). The index was 
constructed for 14,603 out of 15,396 (94.8%) households in the DSS area from the 
following dichotomous variables: living in a rented accommodation (10% of the 
households), having income from any sort of business (11%), ownership of bike 
(49%), radio (57%), chicken (59%), and other animals (4%); presence of iron roof 
(30%), concrete/brick wall (44%), cemented floor (12%), toilet (91%) and toilet wall 
(12%) in the house. In addition, the following variables were measured on an ordinal 
scale: hectares of land owned (5% had no land, 30% up to one hectare, 31% more 
than one and up to two hectares, 17% had more than two and up to three hectares 
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and 17% had more than three hectares), number of rooms in the house (30% had 
one bedroom, 42% had two, and 28% had three or more) and number of mosquito 
nets owned (6% had none, 32% had one, 34% had two and 28% had three or more). 
 
The first principal component accounted for 22% of the variability. Greatest weight 
was given to ownership of tin roof (0.39), the presence of concrete/brick walls (0.35), 
cemented floor (0.33), ownership of bikes (0.30), lighting by candles or petrol lamp 
(0.30), ownership of nets (0.29), number of bedrooms (0.28), wall around the toilet 
(0.27), and ownership of a radio (0.26). Households were classified into wealth-
quintiles with mean indices of -2.25, -1.23, -0.32, 0.83, and 2.97. Households from 
the study were assigned their SES index and category from the analysis performed 
on the entire DSS database.  
 
8.3.4 Ethical considerations 
Study participants were informed about the study framework, aim and purpose and 
oral informed consent was obtained. Village authorities were informed about the 
activities prior to their onset. The study was granted ethical clearance as part of the 
ACCESS Programme by the institutional review board of the IHRDC and the 
Tanzanian National Medical Research Coordinating Committee 
(NIMR/HQ/R.8a/Vol.IX/236). 
 
8.4 Results 
8.4.1 Sample characteristics  
In each round, between 72 and 104 households were visited (Table 8.1). Over the six 
rounds 575 household visits were carried out and information was collected on 703 
individuals. On average there were 5.92 (SD 2.46) members in each household. The 
sample comprised 24 infants (age <1 year), 82 children aged 1 to <5 years, 150 
children aged 5 to <12 years, 66 adolescents aged 12 to <16 years and 354 adults 
(age 16 years and above). For 27 individuals no age was recorded. The age structure 
corresponded closely with the national age structure as reported in the 2002 
population census (United Republic of Tanzania 2003a). The distribution of the 
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study-households in SES quintiles was as follows: 16% poorest, 21% second poorest, 
26% middle, 23% second richest, 14% richest. 
 
8.4.2 Exposure in the shamba 
The field sites were on average located at a median linear distance of 7.3 km 
(interquartile range [IQR] 3.7-12.1) from the main houses. Main houses were closer 
to the nearest health facility (median distance 2.2 km; IQR 0.8-5.6) than shamba 
locations (7.9 km; IQR 6.0-10.1) (Wilcoxon rank-sum test W=-9.28, P<0.001). Actual 
travel distances and times between main house and shamba or to the next health 
facility did not only depend on the distance but also on the condition of the trails, the 
available means of transport (such as motorbike, bicycle, or canoe), and water levels. 
This was reflected in a parallel study in the same area in which distances to the next 
health facility of up to 19 km along people’s walking paths were measured 
(Mayumana 2007). 
 
Analysis of the reported whereabouts of people each week showed that depending 
on the activities performed in the fields, large parts of the households moved to the 
shamba for overnight stays. During the weeding (mid-February to mid-March) and 
harvesting seasons (May), the proportion of household members who spent days and 
nights in the fields peaked. Throughout the study period, going to the shamba only 
for the day was less frequent than staying overnight, which reflects the long distances 
and difficult accessibility of the field sites. However, at the beginning of the farming 
season when the crops were planted (January – mid February) a higher percentage 
of household members only spent the day in the fields and moved back to their main 
residence overnight (Figure 8.3). This proportion decreased in the following months. 
Over the whole study period, adults (over 16 years) and children below five years 
were most frequently found to spend the nights in the shamba, while children 
between 5-16 years (i.e. about school age) were most frequently permanently in the 
main house (Figure 8.4). Over the whole study, people spent, on average, 40.0% of 
the weeks in the shamba overnight. 
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Figure 8.3: Percentage of members of visited households in the shamba each 
week 
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Figure 8.4: Percentage of time (weeks) spent in the shamba or at home over 
entire study period. Error bars are 95% confidence intervals. 
 
8 – Malaria in the paddies of Kilombero 115
8.4.3 Preventive measures 
Overall, coverage and usage rates of mosquito nets were extremely high. On 
average, there was a mosquito-net in 93.6% of the main houses (95% confidence 
interval [CI] 89.9-96.2) and in 96.8% (93.9-98.5) of the shamba huts. Household 
ownership of nets treated with insecticide (ITN) was lower with 58.9% (52.7-64.9) and 
59.2% (43.2-65.0) in the main house and the shamba, respectively. Averaged over 
the study period, 97.9% (95.2-100) of the people sleeping in the shamba reported to 
have used a mosquito net (treated or not) the preceding night 
 
Over the whole study period, 50.5% (40.2-60.8) of the households reported to stock 
drugs in their shamba hut, varying from 21.2% to 34.0% between the rounds. 
Antipyretics were found most frequently (43.3% of all households; 33.3-53.7), while 
only few households stocked antimalarial drugs (6.2%; 2.3-13.0) (Figure 8.5). 
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Figure 8.5: Drug home stocking in the shamba huts. Error bars are 95% 
confidence intervals. 
 
8.4.4 Fever incidence 
Over the study period 29% of households visited reported fever cases in the 
preceding two weeks. Some households (n=27 over all rounds) reported more than 
one fever episode. At an individual level, averaged over the whole study period, this 
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accounts for a two-week incidence rate of 6.1% which is lower than the 13% 
(7,102/55,514) reported routinely from the DSS for that period (Table 8.2) 
 
In total 58 of these fever cases were followed up with an EMIC interview. However, 
one person was followed up on three consecutive occasions and three individuals on 
two consecutive occasions, leaving 52 independent EMIC interviews for the analysis 
at individual level (27 persons of 12 years and above, and 25 children under 5 years). 
 
Table 8.2: Number of individuals and households visited in each round and 
reported two-week fever incidence  
HH level Individual level 
Fever Fever 
Round 
N 
% n** 
N 
% n** 
1 72 59 30 (/51) 390 13.9 41 (/293) 
2 72 28 20 409 6.4 26 
2b* 40 42 14 (/33) 209 8.7 17 (/195) 
3 102 24 24 (/101) 584 4.7 32 (/596) 
4 104 26 27 596 5.4 32 
5 98 19 18 547 3.5 19 (/541) 
6 87 29 26 489 5.5 27 
Overall 575 29 158 (/545) 3224 6.1 189 (/3103) 
* additional sample to compensate for losses to follow-up, as explained in the text 
** numbers in brackets denote the denominator excluding missing values 
 
8.4.5 Risk factor analysis at individual level 
Results from the univariate model (Table 8.3) fitted at individual level showed 
evidence of a very slight increase in the odds of fever for every 10% increase in 
weeks spent overnight in the shamba (OR=1.09; 1.02-1.17).  However, the effect was 
confounded by age and once this was accounted for in the multivariate model the 
effect of time spent in the shamba lost its significance. Age was a very strong 
independent predictor of fever incidence (likelihood ratio test [LRT] of inclusion chi-
square=34.62, P<0.001). The odds of children aged 1 to under 5 years having a 
fever were 4.47 times the odds of adults (2.35-8.51). No evidence could be found of 
an increased risk for infants, although this may have been due to lower sample size 
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in this age group. There was no evidence of an interaction between the effect of age 
and time spent at the shamba overnight (LRT of inclusion chi-square=6.13, P=0.101).  
 
Table 8.3: Univariate and multivariate analyses of the relationship between 
fever incidence and risk factors (logistic regression) 
Risk factors Univariate Multivariate 
 n OR 
(95% CI) 
P* n 
 
Adjusted OR 
(95%CI) 
P* 
% weeks at  
shamba overnight  
(10% increase) 
688 1.09 
(1.02 to 1.17) 
0.013 667 1.06 
(0.98 to 1.14) 
0.142 
Age (years) 676     <0.001 
 0-0.9  
24 
2.63 
(0.83 to 8.27) 
 
0.098 
 
23 
2.51 
(0.79 to 8.01) 
 
0.119 
 1-4.9 82 4.53 
(2.38 to 8.58) 
<0.001 82 4.47 
(2.35 to 8.51) 
<0.001 
 5-11.9 150 0.64 
(0.27 to 1.51) 
0.317 150 0.71 
(0.30 to 1.71) 
0.448 
 12-15.9 66 0 0.026 65 0 n/a 
 16+ 354 1 - 347 1 - 
* Wald test of significance of effect, LLR test of significance of variable in the model  
 
8.4.6 Risk factor analysis at household level 
Analysis of the crude effect of location of the interview showed a significant decrease 
in the odds of fever in households for which the interview was carried out at the 
shamba rather than in the main house (OR=0.53, 0.36-0.77). However, once 
corrected for the number of households in each round this effect was longer 
significant. The analysis at the household level showed no association of reported 
fever cases and net ownership (treated or untreated) or use. Given the consistently 
high level of net use, this was not surprising. No association was found between 
number of household members and fever incidence. However, households with a 
higher SES score were found to be more likely to report a fever case (OR=1.16, 1.01-
1.32) (Table 8.4). This slight positive association may be attributed to a reporting bias. 
However, a chance finding cannot be ruled out as no association could be found 
when the same analysis was repeated for the entire DSS population (OR=1.02, 0.76-
1.36).  
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Table 8.4. Univariate analysis of the relationship between reported fever case in 
a household and household factors (logistic regression)* 
Household risk factors n Odds ratio 
(95% CI) 
P 
Interview at the shamba 542 0.79 (0.50 to 1.23) 0.300 
Net ownership in the household 542 0.78 (0.34 to 1.79) 0.564 
Number of nets owned 543 1.08 (0.89 to 1.30) 0.439 
Number of treated nets 541 1.01 (0.86 to 1.19) 0.873 
Number of people sleeping under 
a net 
545 1.00 (0.94 to 1.06) 0.963 
SES index 479 1.16 (1.01 to 1.32) 0.032 
Number of household members 545 0.99 (0.91 to 1.06) 0.820 
* adjusted for number of households in each round 
 
8.4.7 Treatment seeking 
In total, 90.4% (79.0-96.8) of the followed-up fever cases were treated with one or 
more of the recommended antimalarials (55.8% sulphadoxine-pyrimethamine [SP], 
28.9% amodiaquine, 13.5% quinine). 25.0% (14.0-38.9) of these antimalarials were 
administered on the same day, 71.2% (56.9-82.9) on the same or the next day. 
53.8% (39.5-67.8) attended a health facility during the course of their illness, while 
36.5% (23.6-51.0) practised exclusive home-management with shop-bought or 
leftover drugs from home stocks.  
 
There was no statistically significant difference in these indicators between children 
and adults or between socio-economic groups. Treatment with a recommended 
antimalarial within two days was found to be slightly more frequent in under-fives 
(84.0%, 63.9-95.5) than in adolescents and adults above five years of age (59.3%, 
38.8-77.6), with borderline significance (P=0.056). Whether the episode was first 
recognised in the shamba or the main house had no effect on whether it was treated 
with an antimalarial, treated within one or two days, or brought to a health facility 
(Table 8.5).  
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Table 8.5: Treatment indicators for fever episodes recognised at home and in 
the shamba 
Indicator Home Shamba P 
 Percentage (95% CI) Percentage (95% CI)  
N 22 30  
Treated with any drug 95.8% (78.9 to 99.9) 97.1% (84.7 to 99.9) 0.803 
Antimalarial (AM)* 95.8% (78.9 to 99.9) 88.2% (72.6 to 96.7) 0.290 
AM on day 1 or 2* 62.5% (40.6 to 81.2) 76.5% (58.8 to 89.3) 0.252 
AM on day 1* 16.7% (4.7 to 37.4) 32.4% (17.4 to 50.5) 0.171 
Health facility visit 58.3% (36.6 to 77.9) 55.8% (37.9 to 72.8) 0.853 
Exclusive HMM‡ 37.5% 18.8 to 59.4) 32.4% (17.4 to 50.5) 0.685 
* Recommended antimalarial (AM): SP, amodiaquine or quinine 
‡ Home-management 
 
In the multivariate analysis, longer distance to the nearest health facility seemed to 
be associated with less exclusive home management (OR=0.79, 0.63-1.00) i.e. 
paradoxically, households whose shamba was far from a facility were less likely to 
administer an antimalarial without ever attending a health facility. No other significant 
predictors were found (Table 8.6). In reverse, visiting a health facility was slightly 
more likely if households were located further away from a facility (OR=1.40, 1.03-
1.89). 
 
The same analysis for non-exclusive home management (i.e. treatment with an 
antimalarial not obtained from a health facility, irrespective of whether a health facility 
was attended or not) as outcome did not reveal a significant effect of distance to the 
nearest health facility. However, non-exclusive home-management was more likely if 
the nearest provider was a drug store rather than a health facility or general shop 
(OR 8.95, 1.23-65.19). Hence, it appeared as if antimalarials would rather be 
obtained from outside a health facility if a drug store was close - but without 
preventing people from visiting a facility at some stage. 
 
No significant predictors for administration of an effective antimalarial within one or 
two days were found in this analysis.  
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Table 6: Multivariate analysis of factors related to exclusive home management 
(logistic regression) 
Risk factors Univariate Multivariate 
 n OR 
(95% CI) 
P n Adjusted OR 
(95% CI) 
P 
Age group       
 12+ years 27 1  19 1  
 <5 years 25 0.68  
(0.22-2.14) 
0.514 24 0.49  
(0.10-2.49) 
0.391 
Illness recognised       
 Home 22 1  18 1  
 Shamba 30 0.72  
(0.23-2.26) 
0.576 25 2.09  
(0.36-12.04) 
0.409 
Type of closest 
provider 
      
 Health facility 15 0.82  
(0.23-2.90) 
0.760 16 1  
 General shop 18 0.36  
(0.10-1.33) 
0.126 15 0.33  
(0.05-2.45) 
0.281 
 Drug store 12 1.32  
(0.35-4.96) 
0.675 12 1.25  
(0.18-8.79) 
0.821 
Distance to health 
facility (km) 
42 0.83  
(0.68-1.00) 
0.050 43 0.79  
(0.63 to 1.00) 
0.046 
Distance to nearest 
provider (km) 
42 0.82  
(0.69-0.98) 
0.029 43 - - 
Location       
 Kilombero 24 1  18 - - 
 Ulanga 28 0.33  
(0.10-1.08) 
0.066 25   
SES score 47 0.93  
(0.64-1.35) 
0.694 43 0.79  
(0.46-1.36) 
0.395 
* Wald test of significance of effect 
 
8.5 Discussion  
The seasonal movement of people to distant field sites is a prevailing pattern in the 
Kilombero Valley of Tanzania, and a major determinant of the lives of entire 
households. To which extent this pattern is common in the rest of sub-Saharan Africa 
is unclear, given the scarcity of data on this issue. Household members spend a 
considerable part of the farming season living in very basic shelters under difficult 
conditions. During the harvesting period, over 60% of the members of the farming 
households moved to the fields from where access to health services and other 
infrastructure is more difficult. Walking distances of up to 19 km are a reality in some 
areas (Mayumana 2007). Conversely, this also means that during the farming season 
a large part of the local population is difficult to reach with health services, messages 
and campaigns. Adults who bear the heaviest burden are those most frequently 
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spending the nights in the shamba houses. Young children who are most at risk of 
contracting malaria and generally more vulnerable are often accompanying their 
parents and therefore exposed to the same adverse conditions. Only school-aged 
children were spending most of the time in the villages, since school-attendance is 
compulsory for 7 years. 
 
Adverse conditions in the shamba are clearly recognised by the local population. 
Extremely high (98%) mosquito-net usage rates reflect the immense nuisance posed 
by mosquitoes as well as the success of health education and social marketing in 
promoting the use of ITNs (Armstrong Schellenberg et al. 1999). However, many 
mosquito nets are not treated with insecticide calling for interventions to increase re-
treatment rates or the implementation of long-lasting insecticidal nets (LLIN). 
Preparedness for malaria illness episodes is rather poor with only 6% of the 
households stocking antimalarials in the shamba, which may to some extent reflect 
the lower availability of the first-line treatment SP in shops in the study area (Hetzel 
et al. 2006). Better availability of appropriate antimalarial drugs close to people’s 
homes could potentially promote prompt treatment of malaria episodes (WHO 2005a; 
Gyapong & Garshong 2007). Currently, registered drug stores and health facilities do 
not reach the shamba locations and this is unlikely to rapidly. Alternative approaches 
to provide people in the shamba with appropriate treatment should therefore be 
explored. 
 
While accessibility to treatment services is clearly more difficult from the shamba, 
spending time there did not increase the odds of having a fever overall. Fever rates 
observed in the shamba were even lower than those in the main houses or rates 
derived from routine DSS reports. Similar findings have been reported from other 
places in Tanzania (Ijumba et al. 2002b). Estimates of entomological inoculation 
rates (EIR) in the Kilombero Valley did not reveal elevated malaria transmission in 
the shamba compared to village locations (Killeen et al. 2007). Lower malaria 
transmission fever incidence in the shamba could be attributed to lower population 
density in the fields and different feeding behaviour and transmission capacity of 
vectors, potentially leading to less transmission (Ijumba et al. 2002a). Yet, it may also 
be influenced by human behaviour. As shamba houses are very scattered, there is 
little opportunity for social life after dusk. People would therefore retreat to their huts 
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and go to bed earlier than in the villages and with the high mosquito net usage rates, 
most people would be effectively protected against Anopheles bites. Other 
explanation for the lower fever incidence in the shamba could not be found.  
 
The analysis of treatment-seeking behaviour showed that most fever episodes were 
treated with an antimalarial and 56.9% of the episodes reached a health facility at 
some stage. Despite the long distance to the nearest facilities, few episodes were 
exclusively managed at home. This is supported by the findings of a related study 
which found that episodes from even the most distant shamba were eventually 
treated at a health facility (Mayumana 2007). No significant differences could be seen 
between episodes which were first recognised at the shamba or at the main house. 
This may on one hand be due to the small sample size. On the other hand, it was 
often observed that in case of an illness episode, household moved back to their 
main house from where treatment-seeking action would then be started.  
 
From this study, the considerable distance between farming sites and health services 
did not appear to lead to a delay in treatment-seeking. However, the use of 
quantitative methods - a semi-structured questionnaire - may also have influenced 
this result. Mayumana (2007) investigated treatment delay in more detail in a 
qualitative study on livelihoods and health care. It appeared from his study that most 
cases occurring in the families’ main houses were treated within 24 hours while 
episodes in the shamba only after three to five days. 
 
Surprisingly, home management was less common the further away the nearest 
health facility was. This may be related to the fact that few households stocked 
antimalarial drugs in the shamba and households far from health facilities were also 
far away from drug stores or general shops stocking drugs. Hence, there was little 
opportunity to purchase antimalarials from alternative providers. Nevertheless, home 
management was still more frequent in this shamba survey (37.5%) than in a cross-
sectional community survey done in 2004 in the same area. In that study, 23.4% of 
fever episodes were exclusively treated at home. At the same time, health facility 
attendance was higher with 76% children under 5 years of age and 56% adults being 
brought to a health facility (Hetzel et al. 2007d). This supports the assumption that 
access to health facilities is in fact more difficult for families staying in the fields 
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compared to the population in general. Episodes which occur in the shamba would 
therefore demand greater efforts (in terms of money and time) for families to obtain 
the preferred treatment and care at health facilities. Home-management with drugs 
provided to the households in or close to the shamba would most likely facilitate 
timely access to appropriate treatment but would need to be coupled with education 
of care-takers and training of drug-providers (Gyapong & Garshong 2007). However, 
any implementation strategy would have to take into account the draw-backs of low 
population densities and widely dispersed households in the fields. 
 
8.6 Conclusions  
Seasonal movements of households to farming sites located at a considerable 
distance from their main residences are very common in the Kilombero Valley. 
Despite high malaria endemicity in this area, no increased fever incidence could be 
detected in people who spend days and nights in temporary shelters on their rice 
fields. Individual protection with mosquito nets was very high but preparedness for 
malaria episodes rather poor. Inability to obtain antimalarials easily from nearby 
drugs stores forced people to seek help from distant health facilities. On the one 
hand, this may facilitate the implementation of good quality case-management and 
rational prescription of drugs. However, each episode occurring in the shamba may 
well become a heavier social and economic burden than under normal circumstances. 
In such a situation, a comprehensive approach is needed to improve timely access to 
affordable treatment and care, while at the same time assuring rational use of 
medicines. 
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9.1 Abstract  
9.1.1 Background 
Malaria control strategies emphasize the need for prompt and effective treatment of 
malaria episodes. To increase treatment efficacy, Tanzania changed its first-line 
treatment from chloroquine to sulphadoxine-pyrimethamine (SP) in 2001. The effect 
of this policy change on the availability of antimalarials was studied in rural south-
eastern Tanzania. 
 
9.1.2 Methods  
In 2001 and 2004, the study area was searched for commercial outlets selling drugs 
and their stocks were recorded. Household information was obtained from the local 
Demographic Surveillance System.  
 
9.1.3 Results 
From 2001 to 2004, the number of general shops stocking drugs increased by 15% 
and the number of drug stores nearly doubled. However, the proportion of general 
shops stocking antimalarials dropped markedly, resulting in an almost 50% decrease 
of antimalarial selling outlets. This led to more households being located farther from 
a treatment source. In 2004, five out of 25 studied villages with a total population of 
13,506 (18%) had neither a health facility, nor a shop as source of malaria treatment.  
 
9.1.4 Conclusions  
While the change to SP resulted in a higher treatment efficacy, it also led to a 
decreased antimalarial availability in the study area. Although there was no apparent 
impact on overall antimalarial use, the decline in access may have disproportionately 
affected the poorest and most remote groups. In view of the imminent policy change 
to artemisinin-based combination therapy these issues need to be addressed 
urgently if the benefits of this new class of antimalarials are to be extended to the 
whole population.  
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9.2 Background 
The first and foremost malaria control strategy promoted by the World Health 
Organization (WHO) and adopted by most African countries emphasizes the need for 
treatment of malaria episodes with an efficacious drug within 24 hours after onset of 
symptoms (MOH 2002; WHO & UNICEF 2005). African heads of state agreed at the 
Abuja summit in April 2000 to ensure that by 2005 at least 60% of those suffering 
from malaria have access to affordable, appropriate and timely treatment (Roll Back 
Malaria/World Health Organization 2000). 
 
However, in most areas of sub-Saharan Africa, this target is still far from being 
reached. Many malaria patients do not receive prompt and effective treatment for 
malaria, even if efficacious drugs are available on the local market (von Seidlein et al. 
2002; Committee on the Economics of Antimalarial Drugs & Board on Global Health 
2004; Nsungwa-Sabiiti et al. 2005) or at health facilities (Zurovac et al. 2005). A fever 
episode, especially in a child, often prompts action and very high treatment rates 
(over 90%) have been reported (McCombie 2002). On the other hand, household 
surveys in 28 African countries have shown that on average only 42% of children 
under five years of age with fever were treated with an antimalarial. In 80% of these 
cases chloroquine was used, which can not be considered any more an efficacious 
treatment in most areas (WHO & UNICEF 2003). While in case of a malaria attack 
many factors influence care seeking behaviour (McCombie 2002), one of the 
prerequisites for successful treatment of a malaria episode is the availability of 
effective antimalarial drugs close to where the episode occurs.  
 
Self-treatment at home is often the first response to a malaria episode. In many of the 
studies reviewed by McCombie (1996) self-treatment was frequent in response to an 
episode of fever or malaria (44% of the self-treatment rates in published studies were 
reported to be above 50%). The same review found that almost half of all malaria 
episodes were exclusively treated outside the formal health care sector. Hamel 
(2001) reported from a study in Kenya that 32% of caretakers treated their children’s 
fever exclusively at home, with an antimalarial. Data recently collected in our field site 
in southern Tanzania suggest that exclusive home treatment is less common, with 
76% of recently feverish children attending a health facility during their illness. 
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However, not all of those children receive an antimalarial when visiting the health 
facility.  
 
Reliance on home management and self-treatment raises crucially the issue of 
availability of antimalarials. In this context, the private retail sector has been shown to 
play an important role in the provision of drugs close to people’s homes (McCombie 
1996; Goodman et al. 2004). Shops are often preferred as first treatment choice 
because of better accessibility, shorter waiting times, more reliable drug stocks and 
lower costs (Brugha & Zwi 1998). The role of the retail sector in improving access to 
prompt malaria treatment has been recognized by WHO through its home-
management of malaria (HMM) strategy (WHO 2005a). 
 
The national drug policy in Tanzania was strengthened in 2003 when the Tanzania 
Food, Drugs and Cosmetics Act established the Tanzania Food and Drugs Authority 
(TFDA) as executive agency (United Republic of Tanzania 2003b). Since then the 
TFDA has been responsible for all regulatory aspects of drugs and other medical 
products in the country. The private retail sector for drugs includes two types of 
licensed drug shops as well as general stores. Mobile drug sellers are not common in 
most parts of Tanzania. Fully-fledged Part I pharmacies are headed by a pharmacist 
and are allowed to sell all registered prescription-only (Part I) and over-the-counter 
(Part II) drugs. In 2003, there were 344 Part I pharmacies in Tanzania, 60% of which 
were located in Dar es Salaam, and the rest scattered over other major towns 
(Battersby et al. 2003). Part II drug stores (known as Duka la Dawa Baridi) need to 
be staffed with a medically trained vendor and are allowed to sell over-the-counter 
drugs such as analgesics/antipyretics. However, in practice they sell a much wider 
variety of drugs. 5,666 Part II drug stores had been registered in 2003 (Battersby et 
al. 2003). According to Goodman (2004), general shops were formally not allowed to 
stock any drugs in 2003 but were in practice permitted to sell common OTC drugs, 
such as painkillers. However, the legal position of drugs in these outlets has been 
unclear.  
 
Until 2001, chloroquine was the first line antimalarial and it was designated a Part II 
drug, available over-the-counter at Part II drug stores. In practice, chloroquine was 
also tolerated in general stores, where it was widely available (Goodman et al. 2004). 
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Since the 2001 policy change to sulphadoxine-pyrimethamine (SP) as first-line 
treatment and amodiaquine as second-line treatment, the first line antimalarial (but 
not the second-line) is prescription-only. Hence, SP can only be purchased legally in 
Part I pharmacies, besides being available in health facilities. In many parts of the 
country, SP has also been tolerated in Part II drug stores but not in general shops. 
These inconsistencies in applying legal regulations to the use and availability of SP 
have resulted in some level of confusion between government departments and in 
the development of malaria control strategies.  
 
The change to SP aimed at increasing the effectiveness of malaria treatment and 
hence to decrease the malaria burden.  However, little is known so far about the 
impact of this policy change in terms of availability of antimalarial drugs through 
different providers. Treatment effectiveness at community level is a function of many 
interlinked factors, not just the efficacy of the first line drug. In particular treatment 
must be available and accessible to the target population. This analysis assessed the 
change in availability and accessibility of antimalarial drugs in the private sector 
following the change of first-line treatment in Tanzania. The surveys were carried out 
in a rural Tanzanian setting in the frame of two projects on (1) access to malaria 
treatment (ACCESS Programme) and (2) deployment of antimalarial combination 
therapy (Interdisciplinary Monitoring Project for Antimalarial Combination Therapy in 
Tanzania – IMPACT-Tz). 
 
9.3 Methods  
9.3.1 Study area 
In 2001 and 2004, we conducted studies on antimalarial drug availability in the area 
of a Demographic Surveillance System (DSS) in the Kilombero and Ulanga Districts 
in south-eastern Tanzania (Figure 9.1). The DSS area covers 25 villages (13 in 
Kilombero and 12 in Ulanga) with almost 74,000 people (2004) in a highly malaria 
endemic floodplain, the Kilombero Valley (INDEPTH Network 2002). Malaria 
transmission in the area is intense and perennial with over 300 and in some areas up 
to 1,000 infective bites per person per year but with seasonal fluctuations depending 
on rainfall patterns (Smith et al. 1993) (Killeen, personal communication). Malaria is 
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the predominant cause of morbidity and mortality, accounting for about 50% of 
outpatient diagnoses at rural health facilities (INDEPTH Network 2002). There were 
seven health facilities in the DSS area of Ulanga and another seven in the DSS area 
of Kilombero District in 2001 and 2004. 
 
 
Figure 9.1: Map of Kilombero and Ulanga districts showing Ifakara town and 
the Demographic Surveillance System (DSS). 
 
In 2004, the area of Ifakara town was also included in our studies. This semi-urban 
headquarters of the Kilombero District lies in the midst of the floodplain outside the 
DSS area. The population included in our studies was 45,700 in 2002 (United 
Republic of Tanzania 2003a). Malaria transmission is lower here, with a reported 
average of 29 infective bites per year (Drakeley et al. 2003) and a decrease in clinical 
incidence in recent years observed at the Designated District Hospital (Schellenberg 
et al. 2004). The study area is described in detail elsewhere (Tanner et al. 1991; 
Armstrong Schellenberg et al. 1999). 
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9.3.2 Shop surveys  
From May to September 2001, the DSS area was searched for commercial outlets 
selling drugs, with the help of DSS field staff familiar with the study area and an outlet 
inventory from a previous study (Goodman et al. 2004). All outlets were then visited 
by interviewers who recorded the outlets’ locations and their drug stocks. Survey 
methods are described in detail elsewhere (Goodman 2004). Data collection was 
completed before the new antimalarial drug policy with SP as first line drug was 
implemented in the area.  
 
A further survey was done 3 years after the policy change, in May – June 2004. The 
outlet list was updated after consulting village leaders and DSS field staff. All outlets 
were visited again by interviewers who geo-located them using a hand-held GPS unit 
(Garmin® e-Trex®, Garmin Ltd.) and administered a questionnaire on drugs stocked, 
and other parameters not presented in this paper. In each survey, the questionnaires 
contained a checklist for common drug brand names obtained during pilot studies in 
local shops. Drugs were recorded as “in stock” only if the interviewer was shown the 
stock. Field supervisors checked the completed questionnaires and helped to resolve 
any queries. In 2004, the survey was extended to Ifakara town, where the outlets 
were identified with the help of local community leaders.  
 
9.3.3 Follow-up on SP availability 
A follow-up study was done in November 2004 to find the reasons for the low 
availability of the first-line antimalarial SP. For this purpose, 50 general shops were 
randomly sampled from all general shops that had stocked drugs or had sold drugs 
previously (n=474), weighted by the total number of shops in each of the three 
sampling units: Kilombero DSS, Ulanga DSS and Ifakara town. A second set of 50 
shops was sampled as backup for shops temporarily or completely closed down. The 
shops were visited and a semi-structured questionnaire was administered to record 
stock of SP drugs, customer demand and wholesale sources for antimalarial drugs; if 
no SP was stocked, the reasons for this were elicited. 
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9.3.4 Household and health facility information 
Demographic data as well as household GPS coordinates were derived from the core 
DSS database. Since 1997 DSS field workers have collected basic household 
information (births, deaths, migrations) three times per year, i.e. every household is 
visited every four months. Locations of DSS households and health facilities were 
recorded during routine DSS data collection and ACCESS Programme activities. 
While precise population data were available for all years, GPS locations of 
households had been recorded only once in 2001 and not updated since. GPS data 
were available for 12,005 households (total of all households in 2004: 16,220). 
 
9.3.5 Ethical approval and informed consent 
Ethical approval for the studies done within the ACCESS Programme and IMPACT-
Tz was received from the institutional review board of the Ifakara Health Research 
and Development Centre and the Tanzanian National Medical Research 
Coordinating Committee (NIMR/HQ/R.8a/Vol.IX/236). In addition, IMPACT-Tz was 
approved by the review board of the U.S. Centers for Disease Control and Prevention. 
Participation was voluntary and interviewees were informed about the purpose and 
nature of the research. Oral informed consent was obtained prior to the interviews. 
Village authorities of the study area were informed about all research activities before 
their onset.  
 
9.3.6 Data entry and analysis 
Data were double entered using Microsoft FoxPro and Microsoft Access (Microsoft 
Corp. Seattle, USA) and checked for coding errors and consistency. Intercooled 
Stata 8.0 (Stata Corp., College Station, TX, USA) was used for analysis. Mapping of 
shops and households was done using MapInfo Professional 7.0 (MapInfo 
Corporation). 
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9.4 Results 
9.4.1 Drug stocking outlets 
In 2001, 350 shops from an initial list of 439 outlets (80%) were interviewed, of which 
287 stocked drugs on the day of the visit; these comprised 10 Part II drug stores and 
277 general shops, but no Part I pharmacy. Of those not interviewed, 86 had closed 
permanently, 1 was temporarily closed, 1 refused, and for 1 no reason was recorded. 
 
In 2004, 758 commercial outlets were visited, which were either listed in 2001 or 
reported by the community to have opened since then. In 625 (82%) of them, the 
shop-keeper was interviewed. 123 shops had closed down completely, another eight 
temporarily. Two shop keepers refused the interview.  A total of 195 interviewed 
shops were in Ifakara and 430 in the DSS area. The interviewed shops ranged from 
little shacks with a grass-thatched roof to nicely furnished shops with brick walls and 
display cabinets made of glass. 
 
In the DSS area in 2004 we recorded 19 Part II drug stores and 318 general shops 
stocking any type of drugs on the day of the visit (78% of interviewed shops). A 
further 16 outlets reported having sold drugs during the last month but were out of 
stock the day of the interview. As in 2001, there was no Part I pharmacy in these 
villages. 
 
In Ifakara town, there were 10 Part II drug stores and 142 general shops stocking 
drugs in 2004. One Part I pharmacy and the hospital pharmacy of St. Francis 
Designated District Hospital were not included in the survey. An additional 7 general 
shops had sold drugs during the last month but were out of stock on the day of the 
interview. 
 
Between 2001 and 2004, the total number of drug-selling shops increased in the 
DSS area. There were 15% more general shops stocking drugs (277 vs. 318) and the 
number of drug stores nearly doubled, from 10 to 19. In both years the absolute 
number of shops was higher in Kilombero than in Ulanga District, and the increase 
varied also considerably between the two districts: The number of general shops 
stocking drugs increased 4% in Ulanga and 23% in Kilombero. The number of drug 
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shops doubled in Kilombero but remained almost unchanged and low in Ulanga 
(Table 9.1). An analysis of these data in relation to population numbers is shown 
below. 
 
Table 9.1: Number of shops selling drugs and antimalarials 
Location Population 
General shops 
stocking drugs Drug Stores 
General shops 
stocking AM 
Total of AM 
stocking shops 
 2001 2004 2001 2004 Δ (%) 2001 2004 Δ (%) 2001 2004 Δ (%) 2001 2004 Δ (%)
Ulanga DSS 
Idunda 1736 1837 6 5 -17 0 0  1 0 -100 1 0 -100 
Igota 1419 1533 6 6 0 0 0  2 0 -100 2 0 -100 
Igumbiro 2056 2311 9 10 11 0 0  1 2 100 1 2 100 
Iragua 3547 3704 6 8 33 0 1  1 1 0 1 2 100 
Kichangani 3119 3103 13 13 0 0 0  1 0 -100 1 0 -100 
Kidugalo 1695 2539 7 3 -57 0 0  4 0 -100 4 0 -100 
Kivukoni 5634 5612 22 25 14 1 0 -100 4 3 -25 5 3 -40 
Lupiro 3591 4009 24 23 -4 1 1 0 0 2  1 3 200 
Mavimba 2268 2417 11 15 36 0 0  1 1 0 1 1 0 
Milola 1277 1282 3 5 67 0 1  1 0 -100 1 1 0 
Minepa 1955 1964 9 7 -22 0 0  2 1 -50 2 1 -50 
Nakafulu 1079 919 6 7 17 0 0  0 0  0 0  
Sub-total 29376 31230 122 127 4 2 3 50 18 10 -44 20 13 -35 
Kilombero DSS 
Idete 4657 4661 9 18 100 1 1 0 1 0 -100 2 1 -50 
Igima 3210 3793 17 21 24 1 4 300 12 3 -75 13 7 -46 
Ikule 1571 2244 10 12 20 1 3 200 4 0 -100 5 3 -40 
Kisegese 1113 1370 5 9 80 0 0  3 2 -33 3 2 -33 
Lukolongo 3526 3821 9 6 -33 0 0  1 1 0 1 1 0 
Mbingu 4928 5380 14 24 71 1 1 0 7 5 -29 8 6 -25 
Mchombe 4006 4452 30 37 23 2 3 50 9 0 -100 11 3 -73 
Miwangani 1446 1702 7 9 29 0 0  2 2 0 2 2 0 
Mkangawalo 4426 4675 15 16 7 1 1 0 9 0 -100 10 1 -90 
Mngeta 3218 3399 14 13 -7 0 2  2 1 -50 2 3 50 
Mpofu 1673 1897 1 1 0 0 0  0 0  0 0  
Namawala 2799 3675 19 19 0 1 1 0 5 0 -100 6 1 -83 
Njagi 1597 1678 5 6 20 0 0  2 0 -100 2 0 -100 
Sub-total 38170 42747 155 191 23 8 16 100 57 14 -75 65 30 -54 
Total DSS 67546 73977 277 318 15 10 19 90 75 24 -68 85 43 -49 
Ifakara*  45726  142   10   5   15  
Δ (%) = Change in number of shops 2001-2004 in percent 
Data for the DSS villages of Kilombero and Ulanga Districts and Ifakara town. Ifakara population: 
National census 2002. 
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9.4.2 Availability of antipyretics and antimalarials in general shops 
In 2001 and 2004, 99% of general shops stocking drugs in the DSS had 
antipyretics/analgesics in stock. In 2004, the main products stocked in these outlets 
were paracetamol generics (93%), aspirin (79%) or co-formulations of paracetamol 
and another antipyretic/analgesic compound (25%). One particular paracetamol 
generic made in Tanzania (Sheladol™, Shelys Pharmaceuticals Ltd.) was found in 
205 (64%) general shops.  
 
In 2001, of the 277 general shops stocking drugs, 75 (27%) had an antimalarial in 
stock. All of these stocked chloroquine, while only 1% of all general shops stocked 
SP and less than 1% amodiaquine or quinine. None stocked injectable antimalarials. 
 
In 2004, of the 318 general shops stocking drugs only 24 (8%) had an antimalarial in 
stock. 5% stocked amodiaquine, 3% SP and 1% quinine. One general shop had 
injectable quinine in stock.  
 
In Ifakara in 2004, all except one of the 142 general shops stocking drugs had 
antipyretics/analgesics in stock. Paracetamol generics (89%) and co-formulations of 
paracetamol and another antipyretic/analgesic compound (49%) were more 
frequently stocked than aspirin (13%). Only five (4%) general shops stocking drugs 
had an antimalarial in stock, all of them amodiaquine.  
 
Hence, within 3 years of the policy change from chloroquine to SP, the number of 
general shops that stocked antimalarials decreased by 68%, despite an increase in 
the number of general shops stocking drugs. The decrease was more marked in 
Kilombero (75%) than in Ulanga DSS area (44%). The proportion of shops stocking 
drugs that had antipyretics/analgesics remained unchanged. This resulted in a 
considerable increase in the number of general shops offering treatment for fever – 
but no cure for malaria. 
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9.4.3 Availability of antipyretics and antimalarials in drug stores 
All Part II drug stores in the DSS area stocked antipyretics/analgesics as well as 
antimalarial drugs in 2001 and 2004. In 2004, they all stocked paracetamol generics 
and 84% stocked aspirin and diclofenac, a non-steroidal anti-inflammatory drug. 
 
In 2001, the antimalarials stocked by the 10 drug stores in the DSS area were 
chloroquine (80%), SP (70%), quinine (70%) and amodiaquine (60%). 80% stocked 
also an injectable antimalarial. 
 
In 2004, the 19 drug stores stocked mainly amodiaquine (95%), SP (90%), and 
quinine (74%). 68% stocked an injectable antimalarial, usually quinine.  
 
In Ifakara in 2004, all of the 10 drug stores stocked paracetamol, 70% diclofenac 
generics and 40% aspirin. All drug stores had SP and amodiaquine and 80% had 
quinine in stock. 30% stocked an injectable antimalarial. Other antimalarial drugs, 
such as mefloquine or artesunate were only rarely found (Table 9.2).  
 
In 2001, the then first-line drug chloroquine was the most frequently stocked 
antimalarial in both drug stores and general shops in the DSS area. In 2004, however, 
the second-line drug amodiaquine was more readily available than the first-line drug 
SP. The percentage of drug stores with the first-line drug in stock was nevertheless 
higher in 2004 (90% SP) than in 2001 (80% Chloroquine). In 2004, antimalarial 
injections were less frequently stocked than in 2001. 
 
Table 9.2: Products stocked by drug stores and general shops in the study 
area in 2004 
(a) Drug stores Number of drug stores with product in stock (percentage) 
Location SP AQ QU ART Other INJ Any AM Any AP 
Ulanga DSS (N=3) 3 (100) 3 (100) 3 (100) 0 (0) 0 (0) 3 (100) 3 (100) 3 (100)
Kilombero DSS (N=16) 14 (88) 15 (94) 11 (69) 0 (0) 1* (6) 10 (63) 16 (100) 16 (100)
Total DSS villages (N=19) 17 (89) 18 (95) 14 (74) 0 (0) 1 (5) 13 (68) 19 (100) 19 (100)
Ifakara (N=10) 10 (100) 10 (100) 8 (80) 2 (20) 1** (10) 3 (30) 10 (100) 10 (100)
Total (N=29) 27 (93) 28 (97) 22 (76) 2 (7) 2 (7) 16 (55) 29 (100) 29 (100)
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Table 9.2 (continued) 
(b) General shops Number of general shops with product in stock (percentage) 
Location SP AQ QU ART Other INJ Any AM Any AP 
Ulanga DSS (N=127) 5 (4) 5 (4) 0 (0) 0 (0) 0 (0) 0 (0) 10 (8) 125 (98)
Kilombero DSS (N=191) 5 (3) 10 (5) 3 (2) 0 (0) 0 (0) 1 (1) 14 (7) 188 (98)
Total DSS villages (N=318) 10 (3) 15 (5) 3 (1) 0 (0) 0 (0) 1 (0) 24 (8) 313 (98)
Ifakara (N=142) 0 (0) 5 (4) 0 (0) 0 (0) 0 (0) 0 (0) 5 (4) 141 (99)
Total (N=460) 10 (2) 20 (4) 3 (1) 0 (0) 0 (0) 1 (0) 29 (6) 454 (99)
SP = Sulphadoxine-pyrimethamine or sulphalene-pyrimethamine; AQ = Amodiaquine; QU = Quinine; 
ART = Artesunate; CQ = Chloroquine; INJ = Antimalarial injection; AM = Antimalarial; AP = 
Antipyretics/analgesics. *Chloroquine; **Includes mefloquine and dihydroartemisinin tablets 
 
9.4.4 Overall access to antimalarials 
From 2001 to 2004, the total number of shops with antimalarials in stock (including 
drug stores and general shops) decreased in the DSS area by almost 50%, from 85 
to 43. In 2004, more drug shops than general shops stocked antimalarials in the 
Kilombero DSS area and in Ifakara. By contrast, in the Ulanga DSS area, general 
shops stocking antimalarials outnumbered the few drug shops. The geographical 
distribution of antimalarial selling shops in 2001 and 2004 is displayed in Figure 9.2. 
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Figure 9.2: Study area with households (small dots) and number of shops 
stocking antimalarials, per village, in 2001 and 2004. 
Data for Ifakara town only available for 2004 
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9.4.5 Reasons for not stocking SP  
Of the 50 general shops stocking drugs that were re-visited in the follow-up study, 
one had SP and amodiaquine, and one only amodiaquine in stock the day of the re-
visit. Shops without SP stated no permission to sell (65%), lack of demand (39%), or 
inability to buy the drugs (23%) as reasons for not stocking SP.  In total 92% of the 
shop-keepers were aware that they were not allowed to sell SP and 31% of shops 
without SP had actually tried to buy SP but could not, usually because they did not 
have an appropriate drug store license. These findings suggest that the respective 
legislation was implemented quite effectively. 
 
Only after specific probing did 5 shop keepers (10%) mention the bad reputation or 
perceived side effects of SP as reasons for not stocking it.  Given that shop-keepers 
did report customer demand for antimalarials (51% for SP, 31% for amodiaquine, 
24% for quinine and 16% for chloroquine) it is obvious that there are other 
determinants for stocking antimalarials than only customer demand.  
 
9.4.6 Location of antimalarial selling points 
While small general shops were found everywhere in the study area, shops stocking 
drugs were clustered in larger centres along with other resources such as permanent 
markets and health facilities. Linear regression analysis of the DSS data showed a 
significant correlation between the population of the villages and the number of shops 
stocking drugs (2001: R2 = 0.46, P < 0.001; 2004: R2 = 0.55, P < 0.001) as well as 
shops stocking antimalarials (2001: R2 = 0.21, P = 0.02; 2004: R2 = 0.28, P = 0.006). 
Whether or not there was a drug store in a village was significantly correlated with the 
size of the village in 2001 (likelihood ratio χ2 = 13.14, P < 0.001) and 2004 (likelihood 
ratio χ2 = 7.62, P = 0.006). In both years, there was no such correlation for general 
shops stocking antimalarials, even though the number of general shops varied with 
the size of the village. 
 
The distance of households to outlets stocking antimalarials was influenced by the 
change in the number of outlets from 2001 to 2004. The increase in number of drug 
stores resulted in slightly more households living within a 2 km range of a drug store 
(43 vs. 46%) (Figure 9.3). However, the number of households within 2 km of any 
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shop selling antimalarials decreased (Figure 9.4) as well as the number of 
households living near any source of antimalarials - shops or health facilities (Figure 
9.5).  This resulted in more households being located at a farther distance from a 
treatment source (Table 9.3).  
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Figure 7.3: Cumulative percentage of households within given distance to 
nearest drug store 
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Figure 7.4: Cumulative percentage of households within given distance to 
nearest shop stocking antimalarials (general shops and drug stores) 
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Figure 9.5: Cumulative percentage of households within given distance to any 
source of antimalarials (general shops / drug stores / health facilities) 
 
Table 9.3: Household distance to source of antimalarials 
 Number of households (percentage) 
 Drug Store Drug store and general 
shop stocking AM 
Health facility and 
shops stocking AM 
Distance (km) 2001 2004 2001 2004 2001 2004 
0-2 5191 (43) 5571 (46) 8976 (75) 7671 (64) 9254 (77) 8479 (71) 
>2-10 5766 (48) 5309 (44) 3013 (25) 4044 (32) 2735 (23) 3379 (28) 
>10 1048 (9) 1125 (9) 16 (0) 290 (2) 16 (0) 147 (1) 
 
In the DSS area the average population per shop stocking drugs decreased slightly 
from 235 in 2001 to 220 in 2004 due to the increase in number of shops. Similarly, 
the population per drug store decreased from 6’755 to 3’894, although it remained 
very high in Ulanga DSS (10,410 in 2004). The average for Kilombero DSS and 
Ifakara in 2004 was under the national average of about 6’060 persons per shop 
selling drugs (calculated on the basis of (Battersby et al. 2003; United Republic of 
Tanzania 2003a)). The population per shop stocking antimalarials increased 
considerably from 795 to 1,720 in the Kilombero DSS where the numbers of general 
shops stocking antimalarials had dropped most markedly. Adding health facilities to 
this calculation on the assumption that they have antimalarial drugs in stock does not 
change these ratios significantly (Table 9.4).  
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Table 9.4:  Population per shop 
 
Kilombero  
DSS 
Ulanga  
DSS 
Total  
DSS 
Ifakara 
 2001 2004 2001 2004 2001 2004 2004 
Population 38170 42747 29376 31230 67546 73977 45726 
Population per shop stocking 
drugs (GS & DS) 
234 207 237 240 235 220 301 
Population per drug store 4771 2671 14688 10410 6755 3894 4573 
Population per shop stocking AM 
(GS & DS) 
587 1425 1469 2402 795 1720 3048 
Population per source of AM, 
including shops and HF 
530 1155 1088 1562 682 1298 2690 
GS = General shop; DS = Drug store; AM = Antimalarial; HF = Health facility 
 
In 2001, of the 25 DSS villages, 12 had a health facility and a shop stocking 
antimalarials, 11 villages had only a shop. In 2 villages with a total population of 
2,752 (4% of DSS) there was no antimalarial selling point at all. In 2004, 10 of the 
DSS villages had a health facility and a shop stocking antimalarials, eight had only a 
shop and two only a health facility. The number of villages without either of the two 
increased to five, with a total population of 13,506 (18% of total DSS population). 
 
9.5 Discussion & conclusion 
In 2001, Tanzania embarked on a malaria treatment policy change from chloroquine 
to SP to increase the efficacy of malaria treatment. Four years later, the number of 
retail outlets stocking antimalarials had dropped to almost half the number in 2001. 
Furthermore, these outlets did not primarily stock the first-line antimalarial (SP) but 
rather the second-line drug amodiaquine. On the basis of access measures such as 
population per antimalarial outlet, number of villages with at least one antimalarial 
stockist, and distance to antimalarial stockists, availability of treatment has declined 
in 2004 compared to 2001.   
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This decrease did not affect all outlets equally. The number of Part II drug stores 
actually increased and in these outlets the first line drug SP was more often stocked 
in 2004 than chloroquine in 2001. Anecdotal evidence that some Part II drug stores 
opened after 2003 were running on the margins of legality was not investigated in the 
frame of this research, although we noticed that all except one drug seller we 
interviewed reported to have undergone some form of medical training. Most of them 
were nurse assistants with one year or less of medical training. From a regulatory 
point of view, the restriction to drug stores must be seen as a positive development, 
considering the risks of distributing antimalarials through general shops (Goodman et 
al. 2004). From a public health point of view, this development means that the overall 
number of antimalarial stocking outlets fell substantially and this bears its own risk.  
 
Changes in availability did not equally affect the two Districts. While the relative 
decrease was larger in the Kilombero DSS area, the Ulanga DSS area had a lower 
number of shops stocking antimalarials, leaving as many as five out of 12 villages 
(42%; 32% of the population) without a single antimalarial retailer in 2004. Smaller 
villages in both districts were more at risk of losing their antimalarial retailer, as they 
were more likely to be served only by a general shop. However, the unit “village” may 
not always be absolutely adequate for such calculations, as some villages are 
clustered and distances between villages vary (unpublished observations). A 
household on the edge of one village may for example have a shop relatively close in 
the neighbouring village.  
 
In Ulanga DSS in 2004, general shops stocking antimalarials outnumbered the few 
drug stores. The opposite was the case for the Kilombero DSS area and Ifakara, 
which might result in better rates of appropriate treatment in these areas - under the 
hypothesis that drug stores provide better services than general shops. This 
assumption, however, does not take into account people’s perception of the different 
types of shops and their services, and its impact on utilisation.  
 
The high percentage of general shops stocking antipyretic drugs (74%) suggests a 
considerable consumer demand for drugs against pain or fever. In addition, over 50% 
of general shops not stocking antimalarials reported customer demand for SP drugs. 
This unmet demand may be related to temporary non-availability of services and 
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drugs at health facilities and/or longer distances to the closest facility or drug store. 
However, a generally good availability of SP in health facilities has been reported 
since the policy change (NMCP 2005), but stock-outs occurred recently in health 
facilities in the both Kilombero and Ulanga Districts. 
 
Interestingly, chloroquine was still requested by patients who may appreciate its 
antipyretic effect (lacking in the case of SP). However, in 2004 only one shop was 
found to stock chloroquine, which was officially banned after the introduction of SP. 
Recent data on treatment seeking collected by the ACCESS Programme does 
support the observation that chloroquine has been effectively banned.  
 
Lack of availability of antimalarials, particularly SP in general shops is clearly a result 
of the new drug regulations. The negative perceptions of SP because of the fear of 
severe side-effects, as described for Tanzania by Nsimba (Nsimba 2006), could not 
be found in our studies. Interestingly, shops without antimalarials reported more 
demand for SP than for amodiaquine, although other shops stocked more of the 
latter. This may reflect the prescription-free (OTC) status of amodiaquine. 
Amodiaquine has never been put on the list of prescription-only drugs, so it may still 
be available through non-pharmacy distribution channels.  
 
Other antimalarial drugs than the ones recommended as first-, second- or third-line 
treatment were basically not available at retailer level. Undoubtedly, the much higher 
prices of these drugs limits their availability in rural areas. In contrast to Dar es 
Salaam (Kachur et al. 2006a), artemisinin-containing monotherapies are not (yet) 
frequently sold in our rather remote rural study area. This is encouraging in view of 
the introduction of artemisinin-based combination therapy (ACT), as widespread use 
of monotherapies could foster resistance development (WHO 2001b).   
 
As with every cross-sectional study, our surveys have the limitation of capturing a 
certain situation of one point in the year, ignoring seasonal changes. However, data 
from the follow-up survey on reasons for not stocking SP, done in November 2004, 
suggest that the survey data are quite representative. And since the 2001 and 2004 
surveys were done in the same season, the data are at least comparable over time. 
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As a result of decreased availability of antimalarials, the National Malarial Control 
Programme’s goal of improving prompt access to effective treatment may be difficult 
to achieve, considering the importance of the private sector in providing drugs 
(McCombie 1996; Hamel et al. 2001; WHO 2005a). Home-treatment of malaria with a 
(mostly) shop bought antimalarial was shown to be done more rapidly than bringing a 
child to a health facility in an area with good availability of antimalarials in shops 
(Hamel et al. 2001). With antipyretic drugs being available far closer to people’s 
homes than antimalarials, the initial treatment is more likely to be done with 
antipyretics, potentially delaying the administration of an effective drug against 
malaria. This is supported by community survey data from the DSS villages and 
Ifakara, where on the day of illness onset, 64% of recent fever cases in children were 
treated with an antipyretic but only 53% with an antimalarial.  
 
However, the interpretation of our data is complicated by the fact that data from 
household surveys conducted in the same areas and time periods did not show a fall 
in antimalarial use between 2004 and 2001 (IMPACT-Tz collaboration, unpublished 
data, personal communication S. Patrick Kachur). There was a (non-significant) fall in 
the proportion of general store users obtaining an antimalarial for febrile illness (27% 
to 13%), but the overall probability of obtaining an antimalarial showed a (non-
significant) increase (46% to 54%). This reflected mainly an improvement in 
antimalarial utilisation for government facility users, and the relatively small role of 
general stores in antimalarial provision in 2001. The relatively unimportant role of 
general stores was documented by data on antimalarial volumes in 2002, which 
showed that general stores accounted for only 7% of all antimalarials dispensed in 
the DSS areas (Goodman 2004). Although poorer people in these areas are no more 
likely to use general stores (Njau et al. 2006), it is possible that poorer groups were 
more affected by the change in antimalarial availability, as they were more likely to 
live in the most remote locations. Njau et al. (Njau et al. 2006) showed that it is the 
better-off who get better treatment for fever episodes. However, they spend 
significantly more money for the treatment they obtain from the more expensive non-
governmental organisation facilities and from drug stores. Changing to better quality 
but also more expensive treatment sources may consequently not be an option for 
the poorest, unless exemption mechanisms (theoretically in place in public health 
facilities) increase affordability of treatment and care.  
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The regulatory environment that was created after the introduction of SP as first-line 
treatment does not support well the promotion of home-based management of 
malaria. This problem is likely to be further exacerbated by the imminent policy 
change in Tanzania with the introduction of a highly efficacious artemisinin-based 
combination therapy (ACT). The potential advantages of supplying ACT as 
prescription-only drugs through skilled providers, such as prevention of fast 
development of resistance and limiting irrational drug-use (D'Alessandro et al. 2005), 
need to be carefully weighed against the disadvantages of limiting ACT distribution to 
few suppliers, which may not easily be accessed by a considerable part of the 
population.  
 
The Accredited Drug Dispensing Outlets (ADDO) Project which is currently being 
piloted in a few Tanzanian districts by TFDA and Management Sciences for Health 
may contribute to the solution to this problem (Mbwasi 2005). Its goal is to improve 
access to affordable quality drugs and services in drug retail outlets in rural or peri-
urban areas. Activities include promoting and assisting in the establishment of new 
drug stores even in remote areas, and in training drug sellers and shop owners to 
dispense a limited range of prescription-only drugs. This initiative could increase the 
number of shops licensed to sell antimalarials and/or ACT in the frame of a quality 
service provision. A big question at this time is the high price of ACTs and hence the 
need for subsidies to make them affordable in poor rural areas.  
 
To assure prompt and appropriate malaria treatment, availability of effective drugs 
close to people’s homes is essential, combined with appropriate prescription 
practices and improved compliance on the patient’s side. In case of the imminent 
policy change to ACT, these issues need to be taken into consideration. A pre-
requisite for this is a good coordination of the efforts of the drug regulatory and the 
malaria control authorities. The aim must be to guarantee that the new drugs reach 
all those who need them in time. A precious chance would be missed if regulatory 
mechanisms prevented people from having prompt access to life-saving malaria 
treatment with ACT. 
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10.1 Abstract 
10.1.1 Background 
Throughout Africa, the private retail sector has been recognised as an important 
source of antimalarial treatment, complementing formal health services. However, 
the quality of advice and treatment at private outlets is a widespread concern, 
especially with the introduction of artemisinin-based combination therapies (ACTs). 
As a result, ACTs are often deployed exclusively through public health facilities, 
potentially leading to poorer access among parts of the population. Documenting the 
performance of the retail sector is urgently required to improve and broaden delivery 
channels for life-saving drugs.  
 
10.1.2 Methodology/Principal Findings 
Using data from a shop census and an innovative mystery shoppers approach, we 
assessed knowledge and practice of shop keepers in private retail outlets in two rural 
Tanzanian districts. Shop keepers in drug store knew more about malaria and its 
treatment than their peers in general shops. In drug stores, 52% mentioned the 
correct child-dosage of sulphadoxine-pyrimethamine (SP) compared to only 3% in 
general shops. In drug stores, mystery shoppers were more likely to receive an 
appropriate treatment (OR=9.6), but at a higher price. Overall, adults were more 
often sold an antimalarial than children (OR=11.3). On the other hand, general shop 
keepers were often ready to refer especially children to a higher level if they felt 
unable to manage the case.  
 
10.1.3 Conclusions/Significance 
The quality of malaria case-management in the retail sector is not satisfactory. Drug 
stores should be supported and empowered to provide correct malaria-treatment with 
drugs they are allowed to dispense. At the same time, the role of general shops as 
first contact points for malaria patients needs to be re-considered. Interventions to 
improve availability of ACTs in the retail sector are urgently required within the given 
legal framework. 
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10.2 Background 
Treatment-seeking behaviour for malaria in sub-Saharan Africa is complex, often 
involving several steps and actors, depending on the local health system, society and 
culture (McCombie 1996; Obrist et al. 2007). As a result of poor access to and often 
poor performance of formal health services, presumptive treatment of malaria 
episodes at home has become a widespread option (McCombie 2002; Gyapong & 
Garshong 2007). The home-management of malaria (HMM) strategy of the WHO is 
promoting interventions to improve antimalarial drug use outside the formal health 
services as a complementary option to improve access to prompt and effective 
treatment at community level (WHO 2005a).  
 
In most places, the private retail sector has been identified as an important source of 
drugs close to people’s homes (Foster 1991; Snow 1992; Goodman et al. 2004). 
However, patients obtaining drugs from private retailers may not receive an 
antimalarial drug, even if it would be appropriate (Kachur et al. 2006b). If 
antimalarials are dispensed, dosages are often inappropriate, especially for more 
complex dosage regimens (Slutsker et al. 1994; Abuya et al. 2007). In order to 
improve community-wide effectiveness of antimalarial treatment, the popularity of 
home-management and the quality of treatment obtained from commercial shops 
need to be better addressed. Considerable improvement in case-management has 
been shown to be possible as a result of training private retailers in general shops 
(Marsh et al. 2004) and in drug stores (Mbwasi 2005).  
 
The retail sector for drugs in Tanzania includes two types of licensed drug stores as 
well as general shops. Fully-fledged pharmacies are allowed to sell all prescription 
medicines and need to be headed by a pharmacist. Yet in 2003, 60% of the 344 
existing pharmacies were located in Dar es Salaam and the rest in other larger towns 
(Battersby et al. 2003). Part II drug stores (Duka la Dawa Baridi) need to be headed 
by a person with basic medical or health-related training and can be found also in 
larger villages. These shops are allowed to sell all over-the-counter (OTC) drugs (e.g. 
analgesics/antipyretics). In practice however, they dispense a much wider variety of 
medicines, including prescription-only antimalarials. In 2003, 5666 registered part II 
drug stores were operating in Tanzania (Battersby et al. 2003). General shops are 
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not legally allowed to sell prescription drugs. However, they often sell common OTC 
medicines, such as painkillers (Figure 10.1). 
 
 
Figure 10.1: Part II drug store (left) and general shop (right) selling antimalarial 
treatment in rural Tanzania 
 
The studies presented here applied a mixed methods approach to compare factual 
knowledge with every-day practices of private drug retailers in treating cases of 
malaria in two Tanzanian districts. We included retailers in drug stores as well as 
general shops in order to get a comprehensive picture of the quality of treatment and 
advice that can be obtained from the private retail sector.  
 
This research provides valuable information in the light of ongoing discussions on the 
distribution channels for highly efficacious antimalarial drugs, such as artemisinin-
based combination therapies (ACT). The work was carried out within the frame of a 
project to improve access to prompt and effective malaria treatment in rural Tanzania 
(ACCESS Programme) (Hetzel et al. 2007c).  
 
10.3 Methods 
10.3.1 Study setting 
A systematic shop census and a complementary qualitative study using mystery 
shoppers were conducted in the districts of Kilombero and Ulanga, Morogoro Region, 
south-eastern Tanzania. The study area comprised the 25 villages of the local 
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Demographic Surveillance System (DSS) (Armstrong Schellenberg et al. 2002) and 
the town of Ifakara, 20 km to the east of the DSS. The mid-2004 population of the 
DSS was 74,200 and Ifakara had a population of 45,726 in the 2001 population 
census (United Republic of Tanzania 2003a).  
 
Malaria is highly endemic in the area, accounting for roughly half of all outpatient 
visits in rural health facilities. The study area is described in more detail elsewhere 
(Hetzel et al. 2007c). Previous studies in the same setting found a range of easily 
accessible commercial outlets frequently selling drugs for fever episodes (Goodman 
et al. 2004). In 2004, 29 part 2 drug stores and 460 general shops stocking drugs 
were counted and chloroquine was found to be completely replaced on the market by 
sulphadoxine-pyrimethamine (SP) and amodiaquine (Hetzel et al. 2006). 
 
At the time of the surveys, SP was the recommended first-line treatment for 
uncomplicated malaria; amodiaquine and quinine were second-line and third-line 
treatment, respectively. Quinine was the drug of choice for severe malaria (MOH 
2000). All antimalarials were prescription-only medicines and could therefore legally 
be sold only in the one registered pharmacy located in Ifakara town. However, part II 
drug stores which were found in some villages were generally tolerated to stock and 
sell antimalarials. General shops were not allowed to stock any prescription drugs, 
which was reflected in the low availability of antimalarials reported elsewhere (Hetzel 
et al. 2006). 
  
10.3.2 Shop census 
Between May and June 2004, all commercial outlets in the DSS area and Ifakara 
town were visited in order to investigate the availability of antimalarial drugs in the 
retail sector. The detailed methodology of this census, as well as the results on drug 
availability have been published elsewhere (Hetzel et al. 2006). This paper makes 
use of additional information on shopkeepers’ knowledge of malaria and its treatment, 
collected during the same survey. During the shop-visits, the shop keepers were 
asked to mention signs and symptoms of malaria. Then, they were asked what the 
recommended treatment was for uncomplicated malaria in a two-year-old child and 
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an adult. In addition, the interviewers recorded information on the estimated number 
of customers per day. 
 
10.3.3 Mystery shoppers 
The results of the census were complemented in September and October 2004 by 
“mystery shoppers”, simulated clients who purchased drugs for predefined malaria 
case-scenarios.  
 
From a preliminary list of outlets stocking drugs in 2004 (n=510), a sample of 111 
general shops (approx. 20%) was chosen at random. The sample was drawn per 
village and weighed by village size. A back-up sample was drawn to compensate for 
shops that would be closed or could not be visited for other reasons. In addition, all 
19 drug stores from the DSS area and 10 from Ifakara town were added to the 
sample.  
 
Three case scenarios were randomly assigned to each shop: 
(A) child aged 2-4 months, with fever/hot body for one day and problems with 
drinking/breastfeeding 
(B) child aged 2-4 years, with recurring fever/hot body for 3 days (especially at night), 
problems with drinking and eating, diarrhoea and tiredness/not playing as usual 
(C) adult, with recurring fever/hot body for 2 days, headache, dizziness and loss of 
appetite.  
Symptoms for all scenarios did explicitly exclude signs of convulsions or 
unconsciousness. For the child-scenarios, the mystery shoppers would carry their 
children when visiting the shops, if at all possible. 
 
Local DSS field staff identified suitable mystery shoppers from the villages in which 
the respective shops were located. On the day of the study, the mystery shoppers 
were explained the aim of the exercise and instructed by project staff. Mystery 
shoppers were asked to visit one selected shop and ask for treatment based on the 
aforementioned case-scenario. Each mystery shopper received 2,000 Tanzanian 
shilling (TSh) (US $1.80) to buy drugs. After completing their assignment, they were 
interviewed by project staff about what exactly happened when they visited the shops, 
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what they had told the shop keeper, and what advice and drugs they were given. 
Interviews were tape-recorded and later transcribed. Drugs and remaining money 
were collected, types and amount of drugs recorded, and the mystery shoppers were 
paid a small fee for their collaboration.  
 
10.3.4 Data entry and analysis 
Generic and brand names (if possible), as well as amount and price of the drugs 
obtained by the mystery shoppers were entered in a Microsoft Access database 
(Microsoft Corp., Seattle, USA). Interviews with the mystery shoppers were entered 
with word processing software in an RTF file and imported into MAXqda software 
(VERBI GmbH, Marburg, Germany) for analysis. Statistical analysis was done with 
Intercooled Stata 9 (StataCorp, College Station, Texas, USA).  
 
10.3.5 Ethics 
While mystery shoppers were fully informed and asked for informed consent, the 
nature of this study did not allow informing the shopkeepers in advance and asking 
them for consent to participate. To protect shopkeepers’ privacy, no names of staff 
were recorded and names of shops were never mentioned in connection with the 
study’s results. For the shop census, informed consent was obtained from 
shopkeepers as described in detail in the aforementioned publication. 
 
The shop survey and mystery shopper study were granted ethical clearance as part 
of the ACCESS Programme proposal by the institutional review board of the Ifakara 
Health Research and Development Centre and the Tanzanian National Medical 
Research Coordinating Committee (NIMR/HQ/R.8a/Vol.IX/236). 
 
10.4 Results 
10.4.1 Shop census 
The sample for this analysis included interviews with shopkeepers of 29 Part 2 drug 
stores (Duka la Dawa Baridi) and 460 general shops, all of which stocked drugs the 
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day of the interview. General shopkeepers had on average a lower education than 
their peers in drug stores (7 vs.10 years, P<0.001).  A shop keeper with medical or 
health-related qualifications was found in 93% of the drug stores and 1.5% of the 
general shops (P<0.001). Shopkeepers reported the number of customers buying 
drugs per day to be on average 19 (95% CI 14 to 24) in drug stores and 10 (9 to 11) 
in general shops (P<0.001).  
 
10.4.1.1 Knowledge of malaria symptoms and treatment 
Shopkeepers of drug stores most frequently mentioned fever, headache and vomiting 
(86.2% each) as symptoms of malaria (not specified whether in children or adults). In 
general shops, fever (60.4%), headache (40.2%) and joint pains (38.9%) were most 
frequently mentioned (Table 10.1). Generally, shopkeepers of general shops seemed 
to be significantly less aware of malaria symptoms. They mentioned all of the 
recorded symptoms less frequently than shopkeepers of drug stores. Out of 15 
symptoms associated with malaria, shopkeepers in drug stores mentioned on 
average 4.8 (95% CI 4.1 to 5.5), while in general shops they mentioned only 2.4 (2.3 
to 2.5) (P=0.005). If asked for “severe malaria” (malaria kali), a similar picture arose. 
The symptoms most often mentioned by general shop keepers were high fever 
(43.7%) and weakness (17.9%), while in drug stores, shop keepers most often 
mentioned high fever (79.3%) and convulsions (degedege) (51.7%) (Table 10.1).  
 
In drug stores, most shopkeepers knew that an antimalarial drug was the 
recommended treatment for malaria in a two year-old child (89.7%) and in an adult 
(93.1%). In general shops, shopkeepers most frequently said that the child should be 
referred to a health facility (34.3%) while adults should take an antimalarial drug 
(53.7%). Shopkeepers of drugs stores had significantly better knowledge of malaria 
treatment, as shown in Table 10.2. In drug stores, 65.5% mentioned SP as the 
recommended treatment for a child aged 2 years and 79.3% for an adult. In general 
shops this percentage was significantly lower. Of those who mentioned SP, 78.9% 
knew the correct child dose in drug stores and 26.8% in general shops (P<0.001). No 
shopkeeper mentioned traditional treatment, or that the episode should not be 
treated at all. 
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Table 10.1: Malaria symptoms mentioned most frequently by shopkeepers 
(N=489)  
 Drug store General shop  
symptom % (95% CI) % (95% CI) P* 
N 29 460  
What are symptoms of malaria? 
Fever 86.2 (68.3-96.1) 60.4 (55.8-64.9) 0.006 
Headache 86.2 (68.3-96.1) 40.2 (35.7-44.9) 0.000 
Joint pains 62.1 (42.3-79.3) 38.9 (34.4-43.5) 0.014 
Vomiting 86.2 (68.3-96.1) 32.5 (28.2-37.0) <0.001 
Malaise 31.0 (15.3-50.8 19.6 (16.1-23.5) 0.138 
Feeling cold 17.2 (5.8-35.8) 16.3 13.0-20.0) 0.895 
Poor appetite 20.7 (8.0-39.7) 9.8 (7.2-12.9) 0.063 
Weakness 27.6 (12.7-47.2) 7.2 (5.0-10.0) <0.001 
Diarrhoea 27.6 (12.7-47.2) 5.9 (3.9-8.4) <0.001 
Dizziness 13.8 (3.9-31.7) 3.9 (2.3-6.1) 0.013 
Don’t know 0.0 (0.1-11.9) 11.5 (8.7-14.8) 0.053 
What are symptoms of severe malaria? 
Changed behaviour 24.1 (10.3-43.5) 17.0 (13.7-20.7) 0.326 
Unconsciousness / coma 17.2 (5.8-35.8) 7.4 (5.2-10.2) 0.059 
Weakness 34.5 (17.9-54.3) 17.9 (14.5-21.7) 0.027 
Anaemia  10.3 (2.2-27.4) 0.7 (0.1-1.9) <0.001 
Convulsions (degedege) 51.7 (32.5-70.6) 10.0 (7.4-13.1) <0.001 
Splenomegaly (bandama) 3.4 (0.1-17.8) 0.2 (0.0-1.2) 0.008 
High fever 79.3 (60.3-92.0) 43.7 (39.1-38.4) <0.001 
Don't know 3.4 (0.1-17.8) 27.1 (23.1-31.5) 0.005 
* Wilcoxon rank sign test 
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Table 10.2: Shopkeepers’ understanding of the recommended treatment of 
uncomplicated malaria (N=489) 
 Drug store General shop  
Treatment‡ % (95% CI) % (95% CI) P* 
N 29 460  
Child aged two years with uncomplicated malaria 
Referral to health facility 3.4 (0.1-17.8) 34.3 (30.0-38.9) 0.001 
Antipyretic 55.2 (35.7-73.6) 30.9 (26.7-35.3) 0.007 
Antimalarial 89.7 (72.6-97.8) 31.7 (27.5-36.2) <0.001 
- SP 65.5 (45.7-82.1) 12.2 (9.3-15.5) <0.001 
- SP + PCM 34.5 (17.9-54.3) 4.6 (2.8-6.9) <0.001 
- SP correct dose 51.7 (32.5-70.6) 3.3 (1.8-5.3) <0.001 
- SP correct dose + PCM 31.0 (15.3-50.8) 0.9 (0.2-2.2) <0.001 
Adult with uncomplicated malaria 
Referral to HF† 0 (0-11.9) 23.7 (19.9-27.9) 0.003 
Antipyretic 55.2 (35.7-73.6) 43.9 (39.3-48.6) 0.237 
Antimalarial 93.1 (77.2-99.2) 53.7 (49.0-58.3) <0.001 
- SP 79.3 (60.3-92.0) 35.0 (30.6-39.6) <0.001 
- SP + PCM 48.3 (29.4-67.5) 15.7 (12.5-19.3) <0.001 
- SP correct dose 75.9 (56.5-89.7) 28.9 (24.8-33.3) <0.001 
- SP correct dose + PCM 44.8 (26.4-64.3) 14.3 (11.3-17.9) <0.001 
SP = Sulphadoxine-pyrimethamine; PCM = Paracetamol 
* Wilcoxon rank sign test 
‡ Double-mentioning possible 
† one-sided, 97.5% confidence interval 
 
In a multivariate logistic regression analysis adjusted for shop type, number of 
customers and shop location, higher general education was a significant predictor of 
knowing SP as recommended treatment for adults (OR=1.15, 95% CI 1.02-1.30; 
P=0.020). A health-related qualification was a strong predictor of knowing SP as a 
child treatment (OR=12.36, 2.45-62.20; P=0.002). Correctly dosed SP for adults - but 
not for children - was correlated with higher education (OR=1.15, 1.01-1.30; 
P=0.032) and a health-related qualification (OR=4.80, 1.08-21.34; P=0.039). 
Generally, there seemed to be better knowledge of the appropriate treatment among 
shopkeepers in Ulanga DSS villages, compared to Kilombero DSS and Ifakara town. 
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10.4.1.2 Referral 
Shop keepers were asked for situations in which they would refer a customer to 
another outlet or a health facility. In drug stores, 19 or 65.5% of the shop keepers 
said they would refer customers if they showed signs of severe malaria, in general 
shops this was indicated by 259 or 56.3%. Of the general shop keepers, 56 or 12.6% 
said they would never refer somebody to another outlet or a health facility, while this 
was never mentioned by shop keepers of drug stores.  
 
10.4.2 Mystery shoppers 
A total of 20 Part 2 drug stores and 98 general shops were visited by mystery 
shoppers. General shops comprised all sorts of outlets, from permanent modern 
shops to temporary stalls. Case-scenarios were distributed as shown in Figure 10.2.   
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general shops
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obtained:
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Obtained:
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Figure 10.2: Flow-chart of mystery shoppers study  
Case scenarios: A = child, aged 2-4 months; B = child, aged 2-4 years; C = adult. 
(Refer to main text for details.) 
 
10.4.2.1 Drug sale 
Mystery shoppers obtained drugs in 53 (54.1%, 95% CI 62.1-96.8) general shops 
and 17 (85.0%, 43.7-64.2) drug stores (P=0.01) (Table 10.3). 
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Table 10.3: Number of shops that dispensed drugs to mystery shoppers 
 Drug store General shop Total 
Area n (%) n (%) n (%) 
Ulanga DSS 2/2 (100) 23/30 (76.7) 25/32 (78.1) 
Kilombero DSS 10/10 (100) 20/44 (45.5) 30/54 (55.6) 
Ifakara 5/8 (62.5) 10/24 (41.7) 15/32 (46.9) 
Total 17/20 (85.0) 53/98 (54.1) 70/118 (59.3) 
 
Out of the 17 drug stores that sold drugs, 88.2% (63.6 to 98.5) dispensed an 
antipyretic and the same percentage of 88.2% (63.6 to 98.5) an antimalarial (Table 
10.4). SP, amodiaquine and quinine were sold six times each. Once, SP and quinine 
were sold together. All drug stores sold SP together with paracetamol, as 
recommended in the national guidelines (MOH 2000). Quinine was always, and 
amodiaquine in most cases sold together with paracetamol.  
 
No antimalarials other than SP, amodiaquine or quinine were dispensed. Two drug 
stores sold an antibiotic, together with amodiaquine or quinine + paracetamol. In the 
Kilombero DSS villages, Vitamin B was sometimes dispensed together with 
antimalarials. 
 
Of the 53 general shops, 84.9% (72.4 to 93.3) sold an antipyretic, usually 
paracetamol and 18.9% (9.4 to 32.0) sold an antimalarial, either SP or amodiaquine. 
3 out of 5 times, SP was dispensed together with paracetamol. 2 out of 4 times, 
amodiaquine and paracetamol were dispensed together. Twice, general shop sold an 
antibiotic (Table 10.4). 
 
On average, drug shops sold more products per client than general shops, which 
often had only paracetamol on offer. Drug stores most frequently sold two products 
(to 44% of the mystery shoppers) (mean 2.9 products, 95% CI 2.0 to 3.8). General 
shops most often sold only one product (66% of the mystery shoppers) (mean 1.5 
products, 1.2 to 1.8). 
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Table 10.4: Types of medicines sold to mystery shoppers 
 Drug stores 
(N=17) 
General shops 
(N=53) 
Type of drugs n (%) n (%) 
Antimalarials   
  SP 6 (35.3) 5 (9.4) 
  Amodiaquine 6 (35.3) 4 (7.6) 
  Quinine 4 (23.5) 0 
  Any antimalarial 15 (88.2) 10 (18.9) 
Antipyretics   
  Paracetamol 14 (82.4) 39 (73.6) 
  Any antipyretic 15 (88.2) 45 (84.9) 
Other drugs   
  Antibiotic 2 (11.7) 2 (3.8) 
  Vitamin B complex 5 (29.4) 0 
Combinations   
  SP & paracetamol 6 (35.3) 3 (5.7) 
  Amodiaquine & paracetamol 4 (23.5) 2 (3.8) 
  Quinine & paracetamol 4 (23.5) 0 
  SP & quinine 1 (5.9) 0 
  Antimalarial & antibiotic 2 (11.7) 0 
 
10.4.2.2 Predictors of drug sale 
Univariate and multivariate models were fitted to assess factors related to obtaining 
an antimalarial and obtaining an antimalarial treatment according to Tanzanian 
guidelines.  
 
Adjusted for the confounding effect of age group (i.e. case scenarios A, B, C, as 
described above), visits to a drug store resulted significantly more often in obtaining a 
drug than visits to a general shop (OR=6.02, 95% CI 1.57 to 23.10) and shopkeepers 
in the DSS were more likely to sell a drug than their counterparts in Ifakara (OR=2.53, 
1.04 to 6.18).  
 
In drug stores, mystery shoppers were significantly more likely to receive an 
antimalarial (OR=76.47, 13.07 to 447.50) (Table 10.5). Adults were more likely to be 
sold an antimalarial compared with infants (OR=9.30, 1.70 to 50.92) and compared 
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with the two child scenarios (OR=11.27, 2.36 to 53.81) (not in table). There was no 
significant difference in this outcome between shops located in the villages or in 
Ifakara town. 
 
In order to assess whether the observed difference in antimalarial dispensing was 
due to a lower availability of drugs in general shops, the same analysis was carried 
out only with shops that had dispensed any drugs at all. It resulted that drug stores 
were again more likely to dispense an antimalarial than general shops (OR=70.71, 
9.38 to 533.10). If a drug was sold, mystery shoppers were in both types of shops 
equally likely to receive an antipyretic drug.  
 
Table 10.5: Univariate and multivariate logistic regression analysis of the 
relationship between (any) antimalarial drug obtained and selected predictors 
(all visited shops) 
  Univariate model Multivariate model 
Predictor n Odds Ratio 
(95% CI) 
P* Odds Ratio 
(95% CI) 
P* 
Case scenario      
- Child 2-4 months 43 1  1  
- Child 1-4 years 33 0.85 
(0.22-3.30) 
0.815 0.62 
(0.09-4.00) 
0.612 
- Adult 42 3.43 
(1.18-9.98) 
0.024 9.30 
(1.70-50.92) 
0.010 
Shop type      
- General shop 98 1  1  
- Drug store 20 26.40 
(7.91-88.10) 
<0.001 76.47 
(13.07-447.50) 
<0.001 
Location      
- Ifakara 32 1  1  
- DSS 86 0.95 
(0.35-2.53) 
0.911 1.65 
(0.41-6.66) 
0.480 
* Wald test of significance of effect 
 
Adjusted for the same confounders as listed in Table 10.5, mystery shoppers visiting 
a drug store were more likely to receive the recommended first-line antimalarial SP 
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(OR=9.62; 1.53 to 60.53) or even SP together with paracetamol (OR=16.40; 2.28 to 
117.99) than those who went to a general shop.  
 
Again, the same analysis was carried out only for those shops that had dispensed an 
antimalarial. In this case, drug stores did not dispense SP (or SP with paracetamol) 
more often than general shops. 
 
10.4.2.3 Price 
In drug stores, mystery shoppers paid a median price of TSh 1000 or US $0.90 
(interquartile range [IQR] 0.50-1.53) for drugs, while in general shops they spent only 
TSh 140 or US $0.13 (IQR 0.09-0.29, equality-of-medians test P<0.001). 
 
Table 10.6: Linear regression model of predictors of higher expenditures for 
antimalarial drugs 
  Univariate model Multivariate model 
Risk factors n Estimated effect 
(95% CI) 
P* Estimated effect 
(95% CI) 
P* 
Case scenario      
- Child 2-4 months 20 1  1  
- Child 1-4 years 22 -0.12  
(-0.42 to 0.18) 
0.423 -0.16  
(-0.37 to 0.05) 
0.124 
- Adult 26 -0.15 
(-0.44 to 0.13) 
0.285 -0.25  
(-0.45 to -0.06) 
0.012 
Number of products 68 0.19  
(0.11 to 0.27) 
<0.001 0.12  
(0.05 to 0.19) 
0.001 
Shop type      
- General shop 50 1  1  
- Drug store 18 0.75 
(0.56 to 0.95) 
<0.001 0.59 
(0.38 to 0.80) 
<0.001 
Location      
- Ifakara 15 1  1  
- DSS 53 -0.11  
(-0.39 to 0.17) 
0.434 -0.06  
(-0.24 to 0.13) 
0.548 
*Wald test of significance of effect 
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In a multivariate linear regression model we assessed the effect of the age group 
(case scenario A, B, C), the number of products sold, the shop type and the location 
(Ifakara vs. DSS) on the price charged to the mystery shoppers. Significantly less (-
25%) money was spent for adult cases (case scenario C) compared to children aged 
2-4 months (case scenario A) (P=0.012) and 59% more in drug stores than in general 
shops (P<0.001). Obviously, more money was spent if more drugs were sold (12% 
more per additional product; P=0.001) (Table 10.6). 
 
10.4.2.4 Dosage and advice 
The accuracy of the dosages was judged from the amount of drugs the mystery 
shoppers obtained and from their accounts of the advice they were given by the 
shopkeepers.  
 
10/11 (90.9%) SP doses were tablets, one was a suspension. 4/10 (40.0%) 
amodiaquine doses were tablets and 6 were suspensions. Quinine was sold 2/4 
(50%) times as tablets, and twice as syrup.  
 
10/11 (90.9%) SP dosages (incl. the suspension) and 4/10 (40%) amodiaquine 
dosages (2 tablets, 2 suspensions) were correct, considering the amount sold and 
the advice given. For two amodiaquine doses, no dosage information was available. 
Quinine tablets and syrup doses were all wrongly dosed. With the low number of 
samples no relevant comparison could be made between the appropriateness of the 
dosages and the shop types. Yet it should be noted that in general stores, all SP 
dosages tablet were correct, while in the drug stores, 1/6 was under-dosed (adult 
case). On the other hand, all amodiaquine dosages which were sold in drug stores 
(and for which the dosage information was available) were correct while those sold in 
general shops were under-dosed. 
 
3 (15.0%) drug stores and 29 (29.6%) general shops did not sell any drugs to the 
mystery shoppers although they would have had drugs in stock (Figure 10.1). In all of 
these drug stores the mystery shoppers were advised to seek treatment or advice 
from a health facility. In the general shops, 86.2% (25/29) of the shopkeepers 
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referred the mystery shoppers to a higher level: 62.1% (18/29) to a health facility and 
31.0% (9/29) to a drug store (some of them to both).  
 
10.5 Discussion 
The private retail sector plays a central role in the provision of malaria treatment in 
Tanzania. In rural areas, 68% of the population live within 5km of a health centre or a 
dispensary (98% in urban areas) (United Republic of Tanzania 2005). Yet, poor 
quality of care, shortage of skilled providers, stock-outs of essential drugs, and long 
waiting times (Mamdani & Bangser 2004; Dillip et al. 2007) are challenges which may 
drive patients to seek care (or at least buy drugs) from more expensive private or 
mission facilities, or from drug stores. The private retail sector can complement 
health facility services where the facilities are unable to deliver (Hetzel et al. 2007d).  
 
In the studies presented here, drug stores reported to have significantly more 
customers for drugs than general shops, reflecting the relative importance of these 
types of outlets in the provision of antimalarial medicines. In an earlier study, general 
shops have been described as being important treatment sources for fever/malaria, 
with 29% of fever cases using this source of treatment. Yet, in terms of drug volumes, 
general shops accounted for only 6-7% of all antimalarial doses dispensed in the two 
study districts (Goodman 2004).  
 
General shops are important first contact points of patients with a network of 
treatment providers. They are numerous even in small villages and often more easily 
accessible than drug stores or health facilities (Hetzel et al. 2006). While general 
shops are not legally allowed to dispense antimalarial drugs, they are recognised in 
the national policy as one component of the health care delivery structure (MOH 
2000; MOH 2002). Providers in general shops are generally less knowledgeable 
about malaria and its appropriate treatment, supporting the ban of antimalarial drugs 
from these outlets. Surprisingly, only 60% of general shopkeepers mentioned homa 
(fever) as a symptom of malaria. In part, this may be explained by the parallel use of 
homa as a term to describe a less severe febrile illness or general malaise (Winch et 
al. 1996; Hausmann Muela 2000). Knowing the correct treatment was clearly a 
function of the shopkeeper’s education, which in general shops was lower than in 
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drug stores. Only 3.3% of the shop keepers in general shops were able to mention 
the correct SP dosage for children and 28.9% for adults. However, they did not seem 
to be completely unaware of their limitations, as 34.3% of the general shop keepers 
mentioned referral to a health facility as the correct action for a 2 year-old child with 
malaria.  
 
Drug stores on the other hand are the lowest level of providers which is generally 
tolerated to dispense prescription-only antimalarial drugs. Unfortunately, they often 
do not reach out into small villages or remote areas (Hetzel et al. 2006). Shop 
keepers in drug stores were more knowledgeable about malaria-related symptoms 
and malaria treatment than their counterparts in general shops. Knowledge of 
antimalarial treatment was strongly correlated with basic medical or health-related 
training, a prerequisite for shop keepers of licensed part II drug stores (United 
Republic of Tanzania 2003b). Yet, their performance was still not very satisfactory, 
with only 51.7% mentioning SP in the correct dosage as recommended treatment for 
children. 
 
Knowledge vs. practice 
In order to get a realistic picture of drug-sellers' performance, we used mystery 
shoppers; an approach which is innovative and has been used in only few occasions 
in African private sector settings (Tavrow et al. 2003; Nyazema et al. 2007). The 
main challenge of applying this methodology in a rural setting, which is to find un-
suspicious and capable mystery shoppers within a certain village, was tackled with 
the help of knowledgeable village-based DSS field staff.  
 
Daily shopkeepers’ practices clearly reflected their level of understanding of 
appropriate treatment, the current drug regulations, as well as the low antimalarial 
availability in general shops (Hetzel et al. 2006). Antipyretics were frequently sold in 
drug stores and general shops. Most drug stores (88.2%) also sold antimalarials to 
the mystery shoppers, usually in combination with paracetamol. In contrast, during a 
study conducted elsewhere in Tanzania in which shop keepers were under 
observation, only 17.1% of febrile patients had received an antimalarial (Kachur et al. 
2006b). In general shops, 18.9% of the mystery shoppers were sold an antimalarial. 
This was slightly more than would have been expected based on the shop census in 
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which 8% of all general shops that had drugs in stock also stocked an antimalarial 
(Hetzel et al. 2006).  
 
While many shop keepers in drug stores knew that SP was the recommended 
treatment for children and adults, in practise, amodiaquine and quinine were sold as 
often as SP. This may to some extent reflect that amodiaquine was slightly more 
readily available in drug stores and, according to anecdotal evidence, quinine was 
popular as it was often regarded a strong and powerful medicine  (Hetzel et al. 2006). 
Overall, it was more likely that a mystery shopper received an antimalarial or even 
SP in a drug store. However, drug stores did not adhere better to the guidelines than 
general shops. This may in part be attributed to the fact that in general shops there 
were fewer different antimalarial products available and therefore less opportunity to 
diverge from the first-line regimen. Mere non-availability may also be a reason why 
no other antimalarials than SP, amodiaquine and quinine were sold, along with the 
fact that with the cash provided by the researchers, the mystery shoppers would not 
have been able to purchase expensive drugs such as artemisinin mono therapies or 
ACT (Kachur et al. 2006a).  
 
Altogether, adults would more readily be dispensed an antimalarial than children. 
This is interesting in the light of findings from a cross-sectional community-survey in 
which adults would be treated more frequently with shop bought drugs while children 
were more often brought to a health facility (Hetzel et al. 2007d). This may give some 
indications of provider-side influences on treatment-seeking behaviour.  
 
Treatments for adults were 25% cheaper than treatments obtained for very young 
children and drug stores were more expensive than general shops. The latter was 
also found in another study in the same area, where more expensive treatments 
were obtained from non-governmental organisation (NGO) facilities and drug stores, 
usually by people from the better-off socio-economic stratum (Njau et al. 2006).  
 
Private retailers may commonly be perceived as being mainly business-driven in their 
behaviour. In this study we found that in theory, more than half of all shop keepers 
said they would refer severely ill patients and general shopkeepers commonly 
regarded referral as best option for young children. In practice, 15% (3/20) of drug 
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stores and 30.5% (25/82) of general shops did not sell any medicines but referred the 
simulated patients to a higher level of care – although they would have had drugs in 
their shops. The awareness of shopkeepers that certain cases need to be dealt with 
at a higher level may be a good entry point for interventions targeted at the retailer 
level. Several projects targeting private drug retailers, have already counted on the 
ability and willingness of shopkeepers to refer severe or complicated cases to an 
appropriate facility (Marsh et al. 1999; Mbwasi 2005).  
 
Implications for policy and interventions 
The importance of the retail sector as a source of malaria treatment and care 
complementary to health facility has been recognised internationally (TDR/WHO 
2006) and within Tanzania (MOH 2002). However, the major concern regarding the 
private sector has been inadequacy of the treatments offered by often untrained (or 
not sufficiently trained) shopkeepers (Marsh et al. 1999; Brugha et al. 1999; 
McCombie 2002). This issue has re-emerged in the discussions about appropriate 
delivery channels for ACTs. Defining the role of each type of retailer present in a 
health system within the frame of their capabilities and the given legal context is an 
important first step in improving quality and access.  
 
Fully-fledged pharmacies only reach 17% of the Tanzanian population and are hence 
not sufficient to meet the demand for essential drugs (Ndomondo-Sigonda et al. 
2005). Part II drug stores which are the largest network of licensed drug-retailers in 
Tanzania (Battersby et al. 2003) are licensed to sell only OTC drugs, to which none 
of the recommended antimalarials belongs. Kachur et al. showed that patients at 
drug stores are as likely to be infected with malaria as patients seeking care at health 
facilities (Kachur et al. 2006b). Considering this demand for antimalarial treatments, 
there is a need to make efficacious antimalarial drugs available in drug stores. In 
reality this is usually tolerated by the authorities who recognise the lack of 
alternatives. In order to improve the quality of services in drug stores, specialised 
training for drug vendors may be a valid option for improving management of malaria-
cases, as has been shown in other areas (Marsh et al. 2004). The mere definition of 
educational prerequisites as currently the case for Part II shops may only lure health 
workers away from health facilities to a more profitable business in the retail sector. 
Yet, training alone is unlikely to improve performance if not coupled with appropriate 
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means of rewarding the shopkeepers for good practices (Brugha & Zwi 1998; Brugha 
et al. 1999). These approaches are combined in a project that upgrades Part II shops 
to Accredited Drug Dispensing Outlets (ADDO) and that is currently being 
implemented in selected districts in Tanzania (Mbwasi 2005; Ndomondo-Sigonda et 
al. 2005). 
 
The role of general shops should not be the dispensing of prescription medicines. Yet, 
due to their importance as easily accessible first contact point for malaria patients, 
they should not be completely left aside when targeting the private sector. There are 
several options to strengthen their role in the health sector. Firstly, they could be 
upgraded to drug retailers (e.g. ADDOs) if appropriately trained, thereby increasing 
the population coverage with antimalarial providers. Secondly, general shop keepers 
could be trained on the appropriate first aid for malaria cases with OTC medicines 
and subsequent referral to a higher level. Considering that general shops may 
manage malaria cases only with antipyretics, particularly in places where they are the 
nearest provider, targeted information or training may decrease the number of 
inappropriately managed cases at the lowest level. The social pressure exerted on 
shopkeepers by communities’ expectations on their performance should not be 
under-estimated. In our study, a considerable number of shopkeepers did without 
business in favour of referring the patient to a drug store or a health facility.  
 
Including all levels of formal and informal health care providers is feasible within the 
existing legal framework and guided by the national malaria control policy. Alternative 
approaches including lowest level shops may be a step forward in improving access 
for people living in remote areas or deprived villages which so far lack any provider of 
antimalarial medicines (Hetzel et al. 2006).  
 
10.6 Conclusion 
Private retailers play an important role in the provision of prompt and effective 
malaria treatment, complementing the services of formal health facilities. Yet, the 
quality of case-management in the retail sector leaves much room for improvement. 
Drug stores should be empowered and encouraged to provide correct malaria-
treatment with drugs they are legally allowed to dispense. At the same time, the role 
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of general shops as important first contact points for malaria patients needs to be re-
considered within the given legal framework.  
 
Interventions on shop-level should consider all types of private retailers. While 
antimalarial medicines, such as ACTs ought to be dispensed only by qualified 
personnel, general shop keepers may acquire sufficient knowledge to properly 
recognise malaria cases and refer them to a trained provider.  
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11.1 Abstract 
Universal and equitable access to quality health care is not only a health but also a 
development issue. To improve access, novel community approaches have to better 
align health care services with the resources of the poor. This article suggests a 
framework linking social science and public health research with broader livelihood 
approaches to poverty alleviation and exemplifies the approach with research 
findings and interventions of the ACCESS Programme in Tanzania. Such an 
approach examines access as a critical factor in a double sense: people 1) need 
access to household and community assets in order 2) to be able to access health 
care services. It thus illuminates a neglected aspect of the illness-poverty trap: While 
it is true that illness reduces people’s productive capability and medical costs deplete 
their livelihood resources, people may in fact not even gain access to health services 
because they lack access to the required household and community assets. This 
insight not only opens up new lines of scientific inquiry, it also calls for access 
policies and interventions that reach beyond health services.     
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11.2 Introduction 
Access to health care is a major health and development issue. Most governments 
declare that their citizens should enjoy universal and equitable access to good quality 
care. However, even within the developed world, this goal is difficult to achieve, and 
there are no internationally recognized standards on how to define and measure 
“equitable access” (Oliver & Mossialos 2004). Evidently, big disparities exist between 
the poor and the better off with respect to access to health care services and health 
status (Gwatkin 2001; Victora et al. 2003; Gwatkin 2005). Gaps in child mortality 
between rich and poor countries are wide, as well as between the wealthy and the 
poor within most countries. Poor children are not only more likely than their better off 
peers to be exposed to health risks and have less resistance to disease, they also 
have less access to preventive and curative interventions. Even public subsidies for 
health frequently benefit rich people more than poor people. Clearly, more of the 
same is not enough (Victora et al. 2003): To improve equitable access, innovative 
and community-based approaches are needed to better align health care services 
with poor people’s needs, expectations, and resources. 
 
This article presents a framework for analysis and action to explore and improve 
access to health care in resource-poor countries, especially in Africa. The framework 
links social science and public health research with broader development approaches 
to poverty alleviation. It was developed in the frame of the ACCESS Programme, 
which focuses on understanding and improving access to prompt and effective 
malaria treatment and care in rural Tanzania as an empirical case study (Hetzel et al. 
2006; Hetzel et al. 2007c). The article first provides a brief outline of three 
approaches to investigating health care access, focusing either on health seeking, 
health services, or livelihoods. It then presents a framework that combines the three 
approaches, exemplified with research findings and interventions of the ACCESS 
Programme. 
 
11.3 Access to health care from three perspectives 
Health-seeking studies focus on people (Suchman 1965; Chrisman 1977; Kleinman 
1980; Mackian et al. 2004). They apply pathway models and follow sick persons step 
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by step from the recognition of symptoms through different types of help seeking until 
they feel healed or capable of living with their condition. Health-seeking studies 
provide a deeper understanding of why, when, and how individuals, social groups, 
and communities seek access to health care services, and investigate interactions 
between lay persons and professionals (Montgomery et al. 2006). In this perspective, 
social actors are the potential driving force for improving access to effective and 
affordable health care, but they are often constrained by politics and the economy on 
national and international levels (Singer & Baer 1995; Baer et al. 1997; Farmer 1999). 
 
Health service studies concentrate on factors influencing access to health care, 
which they commonly define as utilization rates (Penchansky & Thomas 1981; 
Fiedler 1981; Andersen 1995). They apply determinants’ models and consider 
access as a general concept summarizing a set of more specific dimensions, such as 
availability, affordability, accessibility, adequacy, and acceptability. Although they 
take into account demographic characteristics of health service users, their 
knowledge about the disease, and, more recently, wealth as measured by household 
assets, health services studies tend to pay more attention to the supply than the 
demand side (Gulliford et al. 2002; Ensor & Cooper 2004). They search for policy 
interventions to reduce supply barriers and improve the delivery of services, including 
availability of health facilities, equipment, and qualified staff, staff skills, protocols of 
diagnosis, treatment, and quality of care. Moreover, they are less oriented towards 
health-seeking processes. Interventions on the demand side are commonly limited to 
information, education, and communication (IEC) campaigns. 
 
Livelihood approaches—as the name implies—emphasize assets (including material 
and social resources) and activities needed to gain and sustain a living under 
conditions of economic hardship (Chambers 1989; Chambers & Conway 1991; 
Chambers 1995; Carney et al. 1999; DFID 2001; Hussein 2002). Access is a key 
issue for sustainable livelihoods (De Haan & Zoomers 2005). Recent studies applying 
the Sustainable Livelihood framework of the United Kingdom Department for 
International Development to study HIV/AIDS (Seeley & Pringle 2002) and malaria (J. 
Chuma, unpublished PhD thesis) demonstrate the many difficulties people face in 
gaining access to household and community assets and how this constrains their 
strategies to cope with the disease. In other words, not only possession, but 
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mobilization of household and community assets is a critical factor influencing 
people’s access to health care and other health-related services. Interventions target 
communities and social groups, emphasize solidarity and empowerment, and try to 
improve livelihood conditions. 
 
11.4 Access to health care with a livelihood focus 
The Health Access Livelihood Framework combines health service and health-
seeking approaches and situates access to health care in the broader context of 
livelihood insecurity (Figure 11.1). 
 
Figure 11.1: The Health Access Livelihood Framework 
Once people recognize an illness and decide to initiate treatment, access becomes a critical 
issue. Five dimensions of access influence the course of the health-seeking process: 
Availability, Accessibility, Affordability, Adequacy, and Acceptability. What degree of access 
is reached along the five dimensions depends on the interplay between (a) the health care 
services and the broader policies, institutions, organizations, and processes that govern the 
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services, and (b) the livelihood assets people can mobilize in particular vulnerability contexts. 
However, improved access and health care utilization have to be combined with high quality 
of care to reach positive outcomes. The outcomes can be measured in terms of health status 
(as evaluated by patients or by experts), patient satisfaction, and equity. 
 
11.4.1 Five dimensions of access 
Access becomes an issue once illness is recognized and treatment seeking is 
initiated. Five dimensions of access influence the course of the health-seeking 
process: Availability, Accessibility, Affordability, Adequacy, and Acceptability (see 
Table 11.1). 
 
Table 11.1: Five dimensions of access to health care services 
Dimension Questions 
Availability: 
The existing health services and 
goods meet clients’ needs. 
What types of services exist? Which organizations offer these 
services? Is there enough skilled personnel? Do the offered 
products and services correspond with the needs of poor 
people? Do the supplies suffice to cover the demand?  
Accessibility: 
The location of supply is in line 
with the location of clients. 
What is the geographical distance between the services and the 
homes of the intended users? By what means of transport can 
they be reached? How much time does it take? 
Affordability: 
The prices of services fit the 
clients’ income and ability to pay. 
What are the direct costs of the services and the products 
delivered through the services? What are the indirect costs in 
terms of transportation, lost time and income, bribes, and other 
“unofficial” charges?  
Adequacy: 
The organization of health care 
meets the clients’ expectations. 
How are the services organized? Does the organizational set up 
meet the patients’ expectations? Do the opening hours match 
with schedules of the clients, for instance the daily work 
schedule of small-scale farmers? Are the facilities clean and well 
kept?  
Acceptability: 
The characteristics of providers 
match with those of the clients. 
Does the information, explanation, and treatment provided take 
local illness concepts and social values into account? Do the 
patients feel welcome and cared for? Do the patients trust in the 
competence and personality of the health care providers? 
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A review of literature from Tanzania found, for instance, that people considered the 
availability of essential drugs a prerequisite to the credibility of health services 
(Mamdani & Bangser 2004). Problems of accessibility, including long distances to 
nearest dispensary or health center, scarce public transport, and lack of bicycles and 
other private means continued to be major access barriers. Issues related to 
affordability were also major obstacles: complaints about fees were frequent, and 
even if official fees were exempted (e.g., for children under fives) or waived (e.g., for 
persons temporarily unable to pay), people often ended up paying for drugs, small 
charges, kerosene, and even ambulance transport. Poor people had to resort to 
short-term coping strategies like selling critical assets such as crops to pay for health 
care, especially in times of emergencies. Adequacy and acceptability in terms of 
people’s judgment of quality of care also played an important role. 
 
What degree of access is reached along the five dimensions depends on the 
interplay between (a) the health care services and the broader policies, institutions, 
organizations, and processes (PIOP) (SDC/NADEL 2006) that govern the services, 
and (b) the livelihood assets people can mobilize and combine in particular 
vulnerability contexts. Hence, access improves as health care services become 
better aligned with clients’ needs and resources. 
 
11.4.2 The health care services and the PIOP 
Sick persons and caregivers seek help not only in health facilities or private practice, 
but also in drug shops and pharmacies as well as from healers representing a wide 
array of medical traditions. Access to these health care service providers is governed 
by cultural norms, policies, laws and regulations, which themselves are influenced by 
broader trends in society, global health policy, research, and development. 
 
In malaria control, for instance, the World Health Organization has increasingly 
recognized the role of the private retail sector in improving access to prompt malaria 
treatment, since self-treatment at home is often the first response to a malaria 
episode (WHO 2005a). The National Malaria Control Programme of Tanzania also 
acknowledges the importance of shops for home management of malaria (MOH 
2002). A shop survey of the ACCESS Programme showed, however, that the 
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proportion of general shops with antimalarials in stock had dropped from 27% in 2001 
(Goodman et al. 2004) to 8% in 2004 (Hetzel et al. 2006). The reduced availability of 
antimalarials in general shops was largely due to a change in the policy of the 
Ministry of Health. Until 2001, chloroquine was the first-line antimalarial and was 
treated as an over-the-counter drug; Part II drug stores—a category of shops below 
pharmacies—were allowed to sell chloroquine and, in practice, chloroquine was also 
tolerated in general shops, where it was widely available (Goodman et al. 2004). 
After the policy change from chloroquine to sulphadoxine-pyrimethamine (SP) as the 
first-line antimalarial in 2001, SP remained classified as prescription-only. The 
Tanzania Food and Drugs Authority (TFDA), which is responsible for all regulatory 
aspects of drugs and other medical products in the country, did not reclassify SP as 
an over-the-counter drug. Hence, SP could only be legally sold in pharmacies (Part I 
drug shops). In many parts of the country, SP was also tolerated in Part II drug stores, 
though not in general shops. In the study area, the TFDA regulations were enforced, 
and while the change in malaria policy resulted in a higher treatment efficacy, it also 
led to an almost 50% decrease in the availability of antimalarials. To improve the 
availability of antimalarials for home management of malaria, the ACCESS 
Programme decided to collaborate with a TFDA-supported program that upgrades 
Part II shops and enables them to sell antimalarials and other essential drugs 
(Mbwasi 2005; MSH 2006). 
 
11.4.3 Livelihood assets and the vulnerability context 
Whether people actually recognize an illness and seek treatment in drug shops or 
through other health care services depends to a large extent on their access to 
livelihood assets of the household, the community, and the wider society. These 
livelihood assets comprise human capital (local knowledge, education, skills), social 
capital (social networks and affiliations), natural capital (land, water, and livestock), 
physical capital (infrastructure, equipment, and means of transport) and financial 
capital (cash and credit) (DFID 2001). The availability of these assets is influenced by 
forces over which people have little control, for instance economy, politics or 
technology, climatic variability or shocks like floods, draughts, armed conflicts or 
epidemics. Such factors may be referred to as their vulnerability context. 
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In the study area of the ACCESS Programme, the Kilombero Valley in southeastern 
Tanzania, the natural environment increases people’s vulnerability to health risks 
(Hetzel et al. 2006). Malaria is highly endemic, transmission is intense and perennial, 
and malaria is the predominant cause of morbidity and mortality. Large parts of the 
valley are flooded during the rain season from November to May. Most of the 
517,000 people living in the 109 villages (2002) rely on subsistence agriculture. 
Labor-intensive rice farming on distant fields in the floodplain forces many families to 
move to their farming sites during the cultivation period (Hetzel et al. 2007a). Already 
in the village, families face many difficulties in gaining access to the resources 
necessary for malaria prevention and case management, but even more so in the 
farming sites (Mayumana et al. 2007).  
 
For nearly all members of the study communities, land is the backbone of their 
livelihood (natural capital) (Mayumana 2007). To raise cash for renting bicycles, 
buying drugs, or paying treatment expenses (financial capital), farmers have to tap 
household savings, sell food stock, borrow from local money lenders, and work as 
causal laborers. Family members and relatives take sick children to health care 
services, buy drugs, and provide practical and moral support (social capital). Bicycles 
feature prominently as an asset enabling treatment seeking (physical capital). 
Popular and biomedical concepts of malaria nowadays overlap (human capital), 
probably as a consequence of regular and intensive IEC and social marketing 
campaigns. During its first phase (2003–2007), the ACCESS Programme invested in 
social marketing to increase knowledge and awareness of malaria and to promote 
prompt and appropriate treatment seeking from reliable sources (Hetzel et al. 2007c). 
For the second phase starting in 2008, additional initiatives to facilitate access to 
livelihood assets are planned, such as support to community health funds and 
provision of microcredits. 
 
11.4.4 Health care utilization and quality of care 
Depending on access to health care services and to livelihood assets, people 
develop multiple and changing health care utilization strategies. They may take no 
action at all or use different service providers simultaneously or in sequence. 
However, even if they gain access and health care utilization takes its course, the 
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outcome in terms of health status (as evaluated by experts or by patients), patient 
satisfaction, and equity (defined as equal access to health care by those in equal 
need (Oliver & Mossialos 2004)) is subject to the technical quality of care. In a broad 
sense, technical quality of care includes provider compliance and diagnostic 
accuracy, safety of the product, and patient compliance (or adherence; see Figure 
11.1). 
 
An ACCESS Programme study to determine the effectiveness and promptness of 
fever treatment based on caregivers’ accounts highlights the impact of quality of care 
(Hetzel et al. 2007d). A community survey of a random sample of 318 household 
identified 80 children under five years of age who had a fever (considered as a proxy 
for malaria) during the 14 days preceding the interview. The results show that 100% 
of the sick children were treated with a pharmaceutical drug (an antipyretic or 
antimalarial), 88% were treated with the recommended antimalarial, 76% received 
the recommended antimalarial on the same day or the day after the fever started, 
43% got the recommended antimalarial on the same day or the day after the fever 
started in the correct dosage, and only 23% were given the recommended 
antimalarial on the same day or the day after the fever started, in the right dosage, 
considering also age and the reported symptoms. The multivariate analysis showed 
that access to and use of a health facility during the course of the fever increased the 
chance of receiving one of the recommended antimalarials (SP, amodiaquine, or 
quinine, according to national guidelines) (p = 0.004). On the other hand, 
antimalarials from health facilities were not more accurately dosed than those 
obtained from shops. To improve quality of care in health facilities, the ACCESS 
Programme supported the Council Health Management Teams of the two districts in 
carrying out refresher training in malaria case-management for health facility staff, 
followed by strengthening of routine supportive supervision and the implementation 
of a quality management scheme in all health facilities (Hetzel et al. 2007c). 
 
11.5 Conclusion 
Even the most powerful diagnostic tests, drugs, and vaccines have little public health 
impact if they do not reach the poor. Providing the goods, as well as the services to 
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deliver them, and ensuring that goods and services are of high quality, are major 
challenges by themselves, especially in a resource-poor setting. But unless additional 
efforts are made to enable poor people to gain access to these goods and services, 
as well as to more basic livelihood assets required to initiate treatment seeking, 
equitable access remains an empty formula of politicians and experts. This is an 
aspect of the illness–poverty trap that is often overlooked. While it has been 
increasingly acknowledged that ill-health contributes to poverty because health costs 
deplete people’s meager resources, it is hardly recognized that people often cannot 
even gain access to health services because they cannot mobilize critical livelihood 
resources. This article presents an innovative framework that pulls together the 
strength of social sciences, public health research, and development studies. 
Through this combination of perspectives and expertise, a more comprehensive, but 
structured analysis of access to health care in resource-poor settings can be 
achieved, which will lead to the identification of key entry points and targeted action 
for health and poverty alleviation in horizontal community-based approaches. 
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PART 4 
DISCUSSION AND RECOMMENDATIONS 
 
 
 
On a shamba in Ulanga District 
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12 DISCUSSION 
The present thesis investigated factors influencing access to prompt and effective 
malaria treatment in a highly malaria-endemic area of rural Tanzania. The aim of this 
research was to contribute to a better understanding of access to treatment in order 
to inform the development of targeted interventions. In addition, the findings should 
feed into a more general model of access which could be used for conceptual and 
analytical purposes. This chapter starts with a review of the methodological 
approaches, followed by a discussion of the main research findings with reference to 
the original objectives described in chapter 4 and the frameworks developed within 
the ACCESS Programme. Finally, the implications for malaria control interventions 
and health policy are discussed and recommendations for further research on access 
are made.  
 
12.1 Methodological issues 
The research for this thesis was carried out within a rural DSS area and the nearby 
semi-urban centre of Ifakara. The local DSS offered a unique opportunity to integrate 
community-based studies into a well-established data-collection routine. At the same 
time, the DSS provided demographic data which could be used as sampling frame 
and as denominator for community-level indicators. Last but not least, the DSS which 
has been operational since 1996 (Armstrong Schellenberg et al. 2002), has built a 
solid bridge between the researchers at IHRDC and the community, via village-based 
DSS field-interviewers. Most of the studies were also conducted in Ifakara town, 
which is situated outside the DSS. Sampling of households was more challenging 
there and demographic data was only available from the 2002 national population 
census (United Republic of Tanzania 2003a).  
 
Operationally, carrying out the research in the DSS was a big advantage and some 
information could not have been collected without this system. Thanks to the DSS, 
research results could be compared to data from earlier studies conducted in the 
same area. And other projects, such as IMPACT-Tz, which were simultaneously 
taking place within the DSS, provided valuable additional information which was not 
collected directly through ACCESS activities (e.g. chapter 9). Nevertheless, certain 
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trade-offs need to be considered when interpreting the research results. The long-
standing presence of researchers in the area may have influenced the way people 
answered to survey questions. Every household in the DSS is visited three times a 
year by a field-interviewer and it is possible that people become tired of repeatedly 
answering the same or similar questions. On the other hand, villagers may appreciate 
the visits of DSS staff as courtesy and opportunity to share their problems and 
concerns. In fact, both situations have been reported from the field. The 
understandable request of the community for some kind of return for their continuous 
collaboration should be met by an investment into activities that improve health and 
welfare in the area on the basis of the acquired knowledge. 
 
The possibility of a “Hawthorne effect” also needs to be considered (Roethlisberger & 
Dickson 1939; Last 2001). Respondents may adapt their responses (or their 
behaviour) as a consequence of the increased attention paid to them by the DSS 
staff. In concrete terms this could mean that somebody either reports a more 
adequate care-seeking behaviour or even takes more appropriate actions as a result 
of knowing that he or she is being studied. Consequently, observations made by 
researchers may not accurately reflect the situation in the community (as it would be 
without the researchers’ attention). Yet, the actual behaviour of the residents of the 
study area is likely to be influenced not only by the DSS but to a larger extent by 
previous intensive malaria control activities that had been going on in the area, 
particularly the KINET social marketing for ITNs (Armstrong Schellenberg et al. 1999; 
Armstrong Schellenberg et al. 2001).  
 
Whether and how the findings can be extrapolated to the rest of Tanzania or even 
further may be different for each component of the present research. It is likely that 
awareness of malaria and its appropriate prevention and treatment is higher in the 
study area than in the rest of Tanzania. For example, in 2004-05, the DHS-reported 
household ownership of mosquito nets was 46% for Tanzania mainland, while 
Morogoro Region, in which the study area is located, reported 65% - the highest 
rates outside Dar es Salaam (National Bureau of Statistics 2005). In the DSS, a 
mean net usage of 75% was reported (Killeen et al. 2007), while the Tanzanian 
average was 31% (National Bureau of Statistics 2005). Similarly, the reported 
antimalarial usage by under-fives with a recent fever in Morogoro Region (89%) was 
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higher than the Tanzanian average (58%). IPTp on the other hand, a more recent 
intervention, was not better implemented in the study area (51% of women received 
SP during their last pregnancy) than in the rest of the country (54%) (National Bureau 
of Statistics 2005). It may be concluded that the results related to malaria prevention 
and treatment presented in this thesis display a more optimistic situation than what is 
the reality in other parts of the country.  
 
The high use of mosquito nets may to a certain extent also be the result of the 
enormous nuisance posed by the many mosquitoes (not only Anopheles) which 
proliferate in the humid environment of the Kilombero Valley (Killeen et al. 2007). The 
seasonal movement of families to their farming sites within the valley (see chapter 8) 
is another special feature of the study area. It is unclear how widespread such 
movements patterns are in other regions and hence how results which are related to 
this particularity can be projected to other places.  
 
Generally, in extrapolating the research findings, the health system context, including 
for example the way health services are financed, should also be taken into 
consideration. Concretely, the Kilombero District operates on a cost-sharing scheme, 
while Ulanga District has a community health fund. In both districts, a pull-system for 
drug delivery to health facilities is in place, i.e. facilities order drugs according to their 
estimated needs. In certain other Tanzanian districts, health facilities are still supplied 
with a standard drug-kit. Across Africa, treatment-seeking patterns may vary 
considerably, as a comparison with the findings of Granado (2007) reveals. She 
found high use of traditional medicine by adults in Abidjan, while in rural Kilombero 
Valley, traditional medicine use was the exception (Granado et al. 2006).  
 
These examples just highlight a few issues that need to be considered when 
projecting the results of this thesis to other settings.  
 
Most ACCESS studies presented in the previous chapters used a mixed methods 
approach, combining qualitative and quantitative methods of data collection in 
different ways. This thesis put the main emphasis on the analysis of the quantitative 
aspects, but without loosing sight of the contributions and results of the qualitative 
data.  
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The main instrument used in the treatment-seeking surveys (chapters 6 and 7) was 
the Explanatory Model Interview Catalogue, or EMIC (Weiss 1997). Though rooted in 
the study of stigma and disease in India (Weiss 2001), the EMIC has subsequently 
been used in several occasions as an interview-tool in cultural epidemiological 
research of malaria (Ahorlu et al. 2005; Granado 2007). The EMIC differs from 
classical epidemiological questionnaires by the way it is developed and structured: 
qualitative studies (in our case mainly focus-group discussions) provide the basis for 
the development of an illness model as defined by those affected by the condition. 
The importance of high-quality exploratory qualitative research needs to be stressed 
at this point. Open-ended questions and screening queries on pre-defined categories 
of answers allow an in-depth assessment of the representation and aetiology of this 
illness model, its frequency and associated actions taken by the affected. While 
criticized by some as too superficial (Waldram 2006), the EMIC provides an 
opportunity to study the distribution of a perceived illness model without (1) the 
disadvantages of small-scale ethnographic studies, or (2) the application of a purely 
biomedical definition which is not necessarily shared by the community. Thanks to 
this approach, a quantitative estimation of the distribution of signs and symptoms as 
well as perceived causes of fever cases was possible. However, due to the 
comprehensiveness of the EMIC, interviews may become rather long and field-
workers need sufficient training and practice to be able to satisfactorily complete the 
form. In the community survey (chapter 6) this was challenging since the forms were 
filled by DSS field-interviewers, each of whom had only few fever-cases to interview. 
As they were working on their own, the recommended setup with one interviewer and 
one recorder could not be implemented. Several times, recorded narratives were kept 
very short and provided only limited additional information. Occasionally, the 
lengthiness of the interview might even have discouraged interviewers to complete a 
form when they were short of time. A better approach was applied in Ifakara where a 
permanent team of interviewers collected the data. They always worked in pairs and 
did not have any other tasks alongside. Unfortunately, applying the same approach in 
the DSS area would have interfered with DSS routine data collection activities. For 
our purpose, it would seem advisable to shorten the EMIC to the most important 
questions without loosing its main cultural epidemiological characteristics, while at 
the same time refining the sections on help-seeking actions. 
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The shop survey or shop census (chapters 8 and 9) used existing questionnaires that 
had previously been applied in the same area (Goodman et al. 2004; Goodman 
2004). The questionnaire was adapted to the specific research questions of this 
study and harmonised with the new drug policy (e.g. new recommended antimalarial 
treatment after 2001). In an attempt to find proxy-indicators for the size and structure 
of retail outlets, a pilot study recorded information on products sold, building structure, 
staffing and measures of the shop size. Unfortunately, no indicators could be found 
that were significantly correlated with the size, type, or building structure of the shop 
(M. Hetzel and C. Lengeler, unpublished data). Several field-interviewers who had 
been involved in the previous shop surveys carried out by Goodman and colleagues 
(Goodman et al. 2000) could be recruited again, including an experienced field 
supervisor. An experienced and well trained field team was important in order to 
establish good relations with the shopkeepers who would be asked rather private 
questions on their businesses. In some occasions, it was a challenge to convince 
shopkeepers that the interviewers had not been commissioned by the revenue 
authorities.  
 
The mystery shoppers study (chapter 9) applied a more innovative approach. So far, 
mystery shoppers (simulated clients) have only rarely been used to assess the 
performance of retail outlets in Africa. Two studies, one in Kenya and one in 
Zimbabwe, assessed drug shop keepers’ performance using mystery shoppers 
(Tavrow et al. 2003; Nyazema et al. 2007) and in few occasions, the approach was 
applied to assess reproductive health services (Harrison et al. 1998; Stanback & 
Janowitz 2003). In research conducted in industrialised countries mystery shoppers 
are more widely used (Sykes & O'Sullivan 2006; Gosselt et al. 2007; Alte et al. 2007). 
Compared to classical observational studies on performance of treatment providers, 
there are several advantages in the mystery shoppers approach. Firstly and most 
important, the shopkeepers are not aware that they are being studied. While this may 
be criticised from an ethical point-of-view, it is expected to increase the validity of the 
results and decrease the chance of a “Hawthorne effect”. In our case, all 
shopkeepers had consented to being interviewed during the preceding shop survey 
and the central ethical aspects were addresses in that shop names or shop keepers’ 
names were never mentioned in connection with the results. Secondly, this approach 
is based on standard case scenarios. The situations are therefore more comparable 
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than observational data when customers present with a wide range of complaints. It 
is also likely that the mystery shoppers remember better the advice they were given 
compared to a randomly interviewed patient or caretaker. On the other hand, mystery 
shoppers need to be recruited from within the community in which the study is being 
conducted in order to avoid arising suspicion. This is especially important in rural 
settings where strangers are unlikely to purchase drugs in local shops. Without the 
assistance of village-based DSS field-interviewers, identifying capable candidates 
would have been difficult, while in urban settings, applying this approach would be 
much easier.  
 
12.2 Contributions to the understanding of access to malaria 
treatment 
Based on the set objectives, the following section reviews the contributions that the 
present thesis has made to the understanding of access to malaria treatment. Finally, 
it is discussed how this research contributed to the development of an access 
framework applicable to malaria and potentially other diseases. 
 
12.2.1 Investigation of treatment-seeking behaviour for malaria related 
illness episodes 
Our investigation of signs and symptoms as well as perceived causes of febrile 
illness episodes revealed a local understanding of malaria coming far closer to the 
biomedical model than described in earlier studies in Tanzania (Winch et al. 1996; 
Hausmann Muela et al. 2002). Nevertheless, traditional terminology was still used to 
describe certain illness patterns. A strong preference for biomedical treatment was 
noted, with 76% of children being brought to a health facility and 89% of children and 
83% of adults being treated with an antimalarial. This pattern was also reflected at 
national level in the 2004-05 DHS (National Bureau of Statistics 2005) and both 
sources are demonstrating a significant improvement compared to 37% antimalarial 
use in 2001 (Njau et al. 2006).  
 
These improvements over time are encouraging. They demonstrate that carefully 
developed social marketing and health education campaigns (such as the KINET 
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social marketing campaign) can be effective in sensitizing the community for a 
specific health issue. If carried out persistently over a period of time, this approach 
can result in notable behaviour change.  
 
However, while general usage rates of antimalarials are high, there is still a long way 
to go to achieve community effectiveness of malaria treatment. Despite the simple 
dosage scheme of the first-line drug SP, the level of timely antimalarial use in the 
correct dosage had not improved since 2001. Whether it was a result of poor provider 
compliance or patient adherence is unclear. Taking into account that (1) health facility 
use did not result in more accurate dosage, (2) exemption systems were not 
functional and (3) much of the drugs for children and even more for adults were 
bought from private retailers, the provider side appeared to contribute significantly to 
the low community effectiveness of antimalarial treatment. The consequences of the 
current situation were higher than necessary expenditures and less appropriate 
treatments, which are likely to be most detrimental for already poor and more 
vulnerable households (Worrall et al. 2005). 
 
12.2.2 Disease burden, access to health services, and responses to 
malaria related illness episodes of farming families during the 
cultivation period 
Compared to the population average, people who moved temporarily to a distant field 
site (shamba) were not at increased risk of experiencing a fever episode. Fever 
incidence in the fields was even lower than in the villages, similar to what had been 
reported from other areas (Mutero et al. 2004). However, these results do not 
necessarily override the initial hypothesis that farming families may be more 
vulnerable to malaria than those remaining in the villages. Protection against malaria 
transmission was extremely good (98% net usage), but coping with a disease 
episode remained a bigger challenge in the shamba than in the village. While within 
the shamba survey, we did not find a difference in treatment-seeking between 
episodes recognised in the field and at home, the overall health facility usage rate 
(54%) was considerably lower than in the 2004 community survey on treatment-
seeking (68%). Considering the characteristics of the two study samples, this could 
mean that families with a farming house located away from their residence would less 
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frequently attend a health facility than the population average. In the end, however, 
antimalarial use was equally high among all households, although home-stocking of 
drugs was not frequently reported. Mayumana and colleagues found in an in-depth 
exploratory study in the same area, that in the shamba more time is needed for the 
process of mobilising resources required to seek treatment (Mayumana 2007; 
Mayumana et al. 2007). This resulted in delayed treatment-seeking and consequently, 
children were already severely ill by the time they reached a health facility. They 
found that financial resources, passable roads, transport and social networks were 
most important for successful care-seeking. Considering that the poorest are more 
likely to live solely on farming activities (Njau et al. 2006), illness episodes occurring 
in the shamba may disproportionately affect the poor. In this situation, securing and 
improving the livelihoods of farming families alongside an investment in the quality of 
health service delivery might contribute to improved treatment effectiveness. 
 
12.2.3 Availability of antimalarials in the private retail sector following 
the change of first-line treatment from chloroquine to SP 
Treatment-seeking needs to be seen against the background of the availability of 
treatment sources. The study on availability of antimalarials described clearly how 
certain areas (villages) completely lacked any antimalarial provider and how there 
were 50% less antimalarial retailers in 2004 compared to 2001. More or less 
simultaneously, antimalarial stock-outs were recorded in 4/14 health facilities in the 
study area (Dillip et al. 2007). Interestingly, treatment-seeking rates with antimalarial 
drugs had not decreased between 2001 and 2004 (S.P. Kachur, cited in Hetzel et al. 
2006). Partly, this was attributed to the low importance of general shops in which 
most of the decline in availability had happened (Goodman 2004).  
 
Subsequent shop surveys in 2005 and 2006 showed that the retail sector was highly 
dynamic and that the number and locations of shops changed frequently. As shown 
in Figure 12.1, much of the 2001-2004 decline had been balanced by 2005 and 2006 
in the Ulanga DSS villages, while in the Kilombero DSS a general declining trend 
could be observed.  
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Figure 12.1: Number of retailers (drug stores and general shops) selling 
antimalarials in the DSS. 
 
Most importantly the results show how a combination of changed drug policy and 
strengthened regulatory mechanisms had influenced availability of life-saving 
medicines at a peripheral level. The impact of such a change may not be reflected 
directly in treatment rates or morbidity and mortality. Yet, as transport costs may 
account for a considerable proportion of treatment expenditures (up to 21% reported 
by Njau et al. 2006), the loss of nearby treatment providers may impact on household 
economies. Implications on household livelihoods should therefore be taken into 
consideration and be further explored. 
 
A reduction in the number of low-level treatment providers goes against the 
recommendations for an implementation of the community-component of IMCI (WHO 
1998) or the WHO/RBM-promoted home management of malaria strategy (WHO 
2005a). On the other hand, in the light of the recent switch to ACT there has been a 
controversy about the use of these drugs in the home management of malaria 
(Pagnoni et al. 2005; D'Alessandro et al. 2005). In Tanzania, neither of the two 
strategies has so far been implemented. But considering the results from our surveys, 
the availability of efficacious antimalarials (i.e. ACT) beyond health facilities seems 
absolutely essential. However, in order to avoid irrational use of ACTs, any provider – 
be it a community health worker, shopkeeper or health facility staff – needs to be 
appropriately trained and supervised.  
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12.2.4 Knowledge and behaviour of private drug retailers in terms of 
case-management of febrile illness episodes 
The approach using mystery shoppers allowed validating the results obtained in the 
shop survey. It confirmed the low availability of antimalarial drugs in general shops. A 
justification for the ban of prescription-drugs from general shops can be seen in the 
ignorance of general shop keepers towards appropriate antimalarial treatment. While 
the quality of fever case management in drug stores was also not satisfactory, it is 
expected to improve with the roll-out of the ADDO project which includes shop 
keeper training as part of the upgrading procedure (Ndomondo-Sigonda et al. 2005). 
Similar approaches have led to considerable improvements in service delivery at 
shop-level in Kenya (Marsh et al. 1999).  
 
Efforts to improve the performance of the retail sector through shopkeepers training 
should be coupled with a supportive national policy. Inefficacious drugs should be 
banned from the market and the dispensing of artemisinin monotherapies should be 
discouraged (Kachur et al. 2006a), while the quality of the drugs on the market needs 
to be monitored regularly. Drug regulatory authorities should issue and enforce 
regulations regarding the list of approved drug formulations, suitable packaging, and 
understandable dosage instructions. It was worrying that none of the medicines 
obtained in the mystery shoppers study contained dosage instructions in Swahili, the 
national language of Tanzania. While obviously tablets wrapped in newspaper pieces 
did not carry any instructions, those on pre-packed medicines were usually in English. 
Suspensions of different brands for example often carried different dosage 
instructions for exactly the same compound (ACCESS Programme, unpublished 
data).  
 
Clear dosage instructions are essential to guide providers and patients, especially 
with more complicated dosage regimens, such as the three-day course of the new 
first-line drug arthemether-lumefantrine (trade name Coartem). Unfortunately, 
anecdotal evidence from the study area suggests that even the packaging of 
Coartem (Novartis, Switzerland), which was adapted for the African context, is not 
clearly understandable. With a literacy rate of 69% in 2002 (United Republic of 
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Tanzania 2005) it might be justified to complement the pictograms on the package 
with clear instructions printed in Swahili.  
 
With the implementation of the ADDO project, the upgraded drug stores seem to be a 
realistic option for ACT delivery beyond the level of health facilities. Experiences with 
chloroquine have clearly shown, that even with a complex dosage regimen, training 
of shopkeepers can results in improved service-provision (Marsh et al. 2004). 
Importantly, however, ACTs should not only be available in ADDOs, but they should 
be sold at a highly subsidized price in order to achieve equitable access to treatment. 
 
12.2.5 Contributions to a better understanding of access and to a 
generic access framework 
The present thesis could contribute in several ways to an improved understanding of 
access to malaria treatment. First, it could be shown that a traditional understanding 
of febrile illness was not anymore a major barrier to access and that modern 
treatment was clearly preferred by most people in the study area. It results that 
demand-side barriers are likely to be rather related to the household’s ability to 
mobilise resources needed for treatment-seeking (financial resources as well as 
social networks) (Chuma et al. 2007; Mayumana et al. 2007). The Health Access 
Livelihood Framework (chapter 10) allowed for this by embedding access into the 
context of livelihood insecurity.  
 
While treatment-seeking action was initiated by virtually all study participants, young 
children and pregnant women did not appear to benefit fully from the interventions 
targeted at them. Exemption mechanisms for under-fives were not functional and 
many women did not receive IPTp, often due to stock-outs (K. Gross, personal 
communication). On the other hand, the new drug policy with SP as prescription-only 
drug was well implemented and enforced by the respective government bodies and 
private sector availability had consequently dropped. Hence, the degree to which 
existing policies are implemented “on the ground” can significantly influence patient’s 
access to health care. In the access framework this aspect is represented by the 
“PIOP” (policies, institutions, organizations, and processes). 
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Several determinants of utilization of health care providers were made explicit in the 
presented research: for example drug stock outs in health facilities (Dillip et al. 2007), 
long distances from the fields to a health facility (median distance 8km), or fear of 
drug side-effects, such as the Stevens-Johnson syndrome as reaction to SP. In the 
access framework they are represented by the “five A” which determine the “fit” 
between health services and patients needs (Penchansky & Thomas 1981).  
 
The high treatment rates and frequent health facility usage coupled with low 
treatment effectiveness points to an unsatisfactory level of quality of care. Drug 
stock-outs in health facilities and resulting diversion of patients to the private sector 
have a direct negative impact on quality of care, patient satisfaction and trust in 
formal health providers (Mamdani & Bangser 2004), as well as on household 
economies. Quality of care is consequently an integral and important part of the 
Health Access Livelihood Framework on the pathway from utilization to impact.  
 
Complementary to the framework embedded in a poverty-vulnerability-livelihood 
context, a further model is currently being developed based on the insights gained 
through the research presented here. The access malaria framework presented in 
Figure 12.2 can be understood as a cut-out of the Health Access Livelihood 
Framework, focusing specifically on the treatment-seeking process for malaria 
episodes (C. Lengeler et al., unpublished). The focus is thereby on specific issues 
concerning the interaction of patients and treatment providers, the pathways chosen 
in the treatment-seeking process and specific aspects of quality of care.  
 
The final aim is to be able to quantify the different treatment barriers as well as 
treatment options chosen by patients (N, n1-n4) in order to obtain a measure of 
treatment effectiveness. From the treatment-seeking study presented in chapter 6, for 
example, it may be concluded that for children in that study, n1=43/80 (53.8%), 
n2=27/80 (33.8%), n3=10/80 (12.5%), and n4=0. Obviously, Figure 12.2 over-
simplifies treatment-seeking processes since several treatment options may be 
chosen consecutively, or simultaneously. This framework is currently being refined 
using more detailed information derived from the thesis presented here, as well as 
from additional studies carried out within the frame of the ACCESS Programme. 
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Eventually, this should lead to a framework that can be applied more generally for the 
investigation of access to malaria treatment.  
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Figure 12.2: Access malaria framework 
Lengeler et al., unpublished 
 
12.2.6 Recommendations for malaria control interventions 
First and foremost, the results of this thesis demonstrate clearly the importance of 
health system factors in the effective delivery of health interventions. Specifically with 
regard to malaria control, it should be considered that strategies to reach those in 
need are unlikely to be effective if interventions are channelled exclusively through 
the public sector. Consequently, malaria treatment, and specifically the highly 
efficacious ACTs, should also be available at a subsidized price from trained retailers 
in the private sector. ADDOs are likely to be the most appropriate existing retail 
providers for ACTs in Tanzania. In order to guarantee effective delivery of care at 
health facilities, the drug supply systems needs to be strengthened and effective 
supportive supervision should enable facility staff to provide good quality of care. The 
INDENT system for medicine delivery to facilities needs to be revised and made to 
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function more effectively. Communities should be empowered to demand for the 
services to which they are entitled, particularly free treatment for under-fives and 
pregnant women, ITN vouchers, and IPTp. District authorities should regularly 
monitor and facilitate the effective implementation of exemption policies. In order to 
facilitate patient adherence, ACTs and other medicines should be dispensed in 
appropriate packaging and with easily understandable printed dosage instructions. 
These need to be standardised and printed in Kiswahili. Social marketing approaches, 
which can effectively deliver health messages to the community, should be integrated 
into the council health plans. In order to successfully plan and develop malaria 
control strategies, all involved government bodies, namely the National Malaria 
Control Programme and the Tanzania Food and Drugs Authority, need to work 
closely together. Finally, any implemented intervention should be monitored regularly 
with respect to community-effectiveness and be adjusted if deemed necessary.  
 
12.2.7 Recommendations for further research 
In order to target future interventions better, the following areas of research may be 
of importance. Firstly, it should be investigated how households can be strengthened 
so that they can more easily and more quickly initiate a treatment-seeking process 
and gain access to health services. It would be of particular interest to understand 
what resources are needed at household level to seek treatment, and how access to 
these resources may be facilitated. At the interface of patients and providers, the best 
ways to eliminate financial barriers should be explored (e.g. community health funds, 
conditional cash transfer, global subsidies). From a provider-perspective, new 
avenues have to be explored to improve services in health facilities. These 
interventions should be implemented and thoroughly evaluated. At the same time, 
complementary approaches to deliver treatment need to be tested, such as upgraded 
drug-stores (ADDO) or community-health workers. Deployment of ACT through these 
channels should be pilot-tested and their effectiveness evaluated. The impact of all 
these measures should be thoroughly evaluated with regard to cost-effectiveness 
and, most importantly, to equity.  
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In conclusion, the findings of this thesis underline the importance of a comprehensive 
approach to analyze and improve access to malaria treatment. In order to achieve a 
decline in malaria morbidity and mortality in Africa, a concerted effort of all 
stakeholders is needed to translate efficacious tools into effective, equitable and 
sustainable health interventions. It is the hope of the authors that the evidence 
gathered in the previous chapters can contribute to an improved understanding of the 
issues that need to be tackled in order to achieve a high community-effectiveness of 
malaria treatment.  
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APPENDIX 1: EXPLANATORY MODEL INTERVIEW 
CATALOGUE 
 
 EMIC CATALOGUE 2004 
for children 
DSS & Ifakara 
   
  
 
 
 
 
 
Malaria-Related Illness in Children Under Five Years 
 
Semi-Structured Interview for Caretakers  
 
 
 
 
 
EMIC for Children 
With or without degedege 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2004
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MALARIA-RELATED ILLNESS – INTERVIEW 
 
1. Respondent Study No:              Date: 
Day 
  
Month Year 
                      
2. Village Name:   
                                                                                                              
3. Respondent 
Name: 
 
First 
  
 
Last 
 
 
Age: 
 
 
 
         
    
Sex: 
 
M    W 
 
 
4. Name of 
child (patient): 
 
First 
  
 
Last 
 
 
Child’s permanent 
ID: 
  
 
5. “What is the age and sex of the child/patient?”   
 
Age: 
Months 
 
 
     
    Sex:   
 
M 
 
 
 
F 
 
 
6. ‘What is your relationship to this child?’ 
 
(Narrative) 
 
 
Tick √ accordingly 
  Mother 
1 
Father
2 
Grandmother
3 
Other specify 
4  
 
 
RESPONDENT’S SOCIAL AND DEMOGRAPHIC INFORMATION 
 
7. House Number: 
 
     As used in DSS HRS Books 
 
 
Tick one only 
 
8. Religion: 
 
 
Traditional Religion 
1 
 
Muslim 
2 
 
Christian 
3 
Other (specify) 
 6__________________ 
 
 Tick one only 
 
9. Marital Status: 
 
 
Never married 
1 
 
Married 
2 
 
Sep / Div 
3 
 
Remarried 
4#_____ 
 
Widowed 
5 
 
 
10. Relationship with 
Household Head 
 
Self 
 
1 
Spouse 
 
2 
Parent 
 
3 
Child 
 
4 
Other (specify) 
  
5 
 
Sex: 
 
M 
  
 
F 
 
 
 
11. Children & Elders 
(of the HH head): 
 
<5 Yrs 
 
≥5 Yrs 
 
 
 
<5 Yrs 
 
≥5 Yrs 
  
≥18yrs 
 
Sons 
N Alive Dead   Alive Dead  
Daugh 
ters 
Alive Dead Alive Dead Elder
s  
Aliv Dead 
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11.1. Apart from your children, how many other dependents live in your household at the 
moment (today)? Put total in the boxes 
 
Under 5 Yrs  
 
Elders (5 Yrs and 
older) 
 
 
 
12. Education: 
 
Years  
 
If no school: Functional Literacy? 
 
No 
0 
Yes 
1 
 
Occupation 
13. “What is your main source of income and livelihood?” 
 If married, “What about your husband/wife, what is her/his occupation?” 
 
1 Nil 
2 Student 
3 Housewife 
4 Unskilled labour 
5 Skilled labour 
6 Trade / Business 
7 Service 
8 Farmer 
9 Fisherman 
10 Farmer-Fisherman (both) 
11 Retired 
12 Teacher 
13 Deceased 
14 Other (specify)____________ 
 
Specify codes: 
 
Personal Occupation:
  
Spouse’s Occupation:  
 
14. “Is your household income usually regular and dependable?”  
 
 
 
 Tick one only 
Yes 
3 
Possibly 
2 
Uncertain 
1 
No 
0 
 
(Narrative) 
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PATTERNS OF DISTRESS 
Inclusion criteria: Caretaker noticed child was ill at most 14 days before interview, and child has been free of 
all symptoms for at least 24 hours at time of interview. 
SPONTANEOUS ACCOUNT OF PROBLEM: 
‘I appreciate your agreeing to talk to me about this child’s problem. It is a problem that also 
affects many other people in this district. I want to understand how you think about this 
problem. Keep in mind that it is your ideas that I am interested in, so please do not feel 
there is a right or wrong answer to the questions.”  
 
15. “What was the problem that the child was suffering from? Please tell me all that you 
know about it.”  Record account of problem, as described in respondent’s own words: 
(Narrative)  
 
 
 
 
16. “Where were you when you first noticed the child was not well?”   
Home 
1 
Shamba 
2 
 
17. “How did you first know that something was wrong with the child?” 
 
(Narrative) 
 
 
 
 
Tick spontaneously reported symptoms under the columns for “spontaneously” and “early”. Ask  about the 
others: Have they been noticed? If yes tick “probe”. Have they been noticed early on? If yes, tick also the 
block under the column “early”. 
 
Patterns of Distress 
Sp
on
  
Pr
ob
e 
 
  Patterns of Distress 
Sp
on
  
Pr
ob
e 
1. No interest to play (hataki kucheza) 14. Diarrhoea (kuharisha)  
2. Not happy (hana raha)  15. Vomiting (kutapika)  
3. Sleeps (analala)  16. Shivering (anatetemeka)  
4. Loss of appetite (hapendi kula)  17. Twitching (anastuka)  
5. Crying all the time (analialia)  18. Body becomes stiff (mwili 
unakauka; anakakama)  
6. No strength (hana nguvu)  19. Delirium (anaweweseka)  
7. Hot body (mwili wa moto, joto kali sana)  20. Eyes turn white (macho yanakuwa 
meupe)  
8. Hot head (kichwa cha moto)  21. Kicking of leg and arm (anarusha 
mkono na mguu)  
9. Hot abdomen (tumbo la moto)  22. Froth in the mouth (anatoa mate 
mdomoni)  
10. Periodic fevers (homa za vipindi) 23. Mouth twisted sideways (mdomo 
ulienda pembeni)  
11. Cough (anakohoa)  24. Falling down (anaanguka)  
12. Difficult breathing (anahema kwa shida)  25. Easily startled/frightened 
(anashtuka kwa urahisi/woga) 
13. Yellow eyes (macho ya njano)  26. Other physical symptoms:  
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18.  “Among all these symptoms, which one do you think is the single most dangerous?” 
Code single most dangerous symptom from the above numbered list of patterns of distress 
 
 
 
 
18.1. What is it about this symptom that makes it the most dangerous? 
 
(Narrative) 
 
 
 
 
 
19. “How do you call this illness in your language?”  Specify name, summary term, or short 
description in the patient’s words. 
(Narrative)  
 
 
 
 
 
Specify exact term used: _______________  Identified as homa?   
Yes 
1 
No 
0 
 
Identified as malaria?  
Yes 
1 
No 
0 
 
Identified as degedege?  
Yes 
1 
No 
0 
 
 
20. Did some particular features make you think it is the illness you identified (refer to the term 
mentioned above)? 
 
(Narrative) 
 
 
 
 
21. Did you know that yourself or did someone tell you? If so, who told you? 
 
Resource Persons Spon Probe 
1. I knew it myself      
2. Female elder    
3. Male elder    
4. Aunt (of the child)    
5. Father/ uncle (of child)    
6. Neighbour    
7. Government health facility staff    
8. Private health facility staff    
9. Shopkeeper (general store)    
10. Shopkeeper (Pharmacy)    
11. Shopkeeper (drug store )    
12. Community health worker   
13. Local healer     
 
Tick all that apply 
 
 
14. Other (mention):   
 
  
 
 EMIC CATALOGUE 2004 
for children 
DSS & Ifakara 
 
- 6 - 
21.1. What made you ask this person (the first person consulted)? 
 
(Narrative) 
 
 
 Spon Probe 
1. I knew it myself       
2. It is someone I can talk to     
3. He/she is experienced/ knowledgeable     
4. He/she is a medical professional     
5. I am expected to consult him/her (customs)     
 
Tick all that apply 
6. Other (mention):    
 
  
 
22. “Do you think that the illness that the child had was serious? In your opinion, how 
serious was the child’s condition? Might it be fatal?”’     
       Tick only one   
Usually fatal 
4 
Sometimes fatal 
3 
Serious but not fatal 
2 
Not serious 
1 
Cannot say 
0 
 
22.1. What makes this condition serious? 
 
(Narrative) 
 
 
 
PERCEIVED CAUSES  
  
23. “I would like to know what you think may have caused this child’s problem?” 
Summarize respondent’s ideas about causes in the respondent’s own words (first-person account). 
 
(Narrative) 
 
 
 
Tick the block for each of the reported causes under the column for “spontaneously”. Ask about the others, 
and for those affirmed tick the block under the column “probe”. 
 
 
Perceived Cause 
Sp
on
 
Pr
ob
e 
  
Perceived Cause 
Sp
on
 
Pr
ob
e 
Ingestion  Environmental 
1. Impure water        15. Sanitation/ Dirty environment       
2. Eating leftover food      16. Personal hygiene/not keeping clean    
3. Unbalanced diet      17. Plant     
4. Starchy food      18. Contamination - contact     
5. Breast feeding      19. Wind     
Insects / Worms  20. Heat (sun or fire)     
6. Mosquito bite      21. Cold weather     
7. Other insect bite      22. Other     
8. Houseflies      Supernatural 
9. Worms      23. Spirits (upepo, majini, shetani)     
10. Other      24. Evil eyes or sorcery (uchawi)     
Fatigue/Work/Constitution/blood strength  25. God     
11. Physical hard work (parent)      26 Failure to abstain from sex (parent)    
12. Stage of child growth      27. Bird/ insect called degedege     
13. Constitution/ blood weakness     28. Other mention:     
 
  
14. Hereditary      29. Don’t know       
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MOST IMPORTANT PERCEIVED CAUSE  
24. “Which of the causes that you have mentioned (or perhaps something else) do you 
consider the single most important cause of the problem in the child? 
 
(Narrative)  
 
 
 
 
Code single most important cause from the above list
   
 
 
 
 
25.  Did you know that yourself or did someone tell you? If so, who told you? 
Resource Persons Spon Probe
1. I knew it myself       
2. Female elder     
3. Male elder     
4. Aunt (of the child)     
5. Father/ uncle (of child)     
6. Neighbour     
7. Government health facility staff     
8. Private health facility staff     
9. Shopkeeper (general store)     
10. Shopkeeper (pharmacy)     
11. Shopkeeper (drug store)     
12. Community health worker     
13. Local healer     
 
Tick all that apply 
 
14. Other (mention):       
 
 
25.1. What made you consult this person (the first person consulted)? 
 
(Narrative) 
 
 
 
 
 
 
 
 Spon Probe 
1. I knew it myself       
2. It is someone I can talk to     
3. He/she is experienced/ knowledgeable     
4. He/she is a medical professional     
5. I am expected to consult him/her (customs)     
Tick all that apply 
 
6. Other (mention):   
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HELP SEEKING 
 
26. What did you do for your child immediately after recognizing he/she was ill? 
 
(Narrative) 
 
 
 
 
 
(FOR THE WHEN PART: Use 1= same day, 2= next day, 3= more than 2 days or 0 for none) 
 Spon Probe When 
1. Give antipyretics (e.g. Panadol)         
2. Give an antibiotic      
3. Give an antimalarial      
4. Give herbal medicine (home care)      
5. Sponging      
6. Ask for advice      
7. Divination      
8. Took child to a health facility      
9. Urinated on the child      
10. Give herbal medicine (from healer)      
Tick all that apply 
 
11. Other (mention):      
 
27. Why did you take that action first (specified above)? 
 
(Narrative) 
 
 
 
 
 
28. Where did you go for advice (who did you see for advice)?  
 
(Narrative) 
 
 
 
 
For each of the following sources of help, mark whether respondent reported use either spontaneously in 
response to the open-ended query, or in response to probe. Note whether person lives in same household.  
Household  
Help seeking 
Resource Persons 
 
Spon. 
 
Probe 
Same Other 
1. I knew it myself          
2. Male elder      
3. Female elder      
4. Father/ uncle (of child)      
5. Aunt (of the child)      
6. Health facility staff (public or private)      
7. Neighbour       
8. Shopkeeper (general store)      
9. Shopkeeper (drug store)      
10. Community health worker      
11. Local healer      
12. Other (mention):      
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29. Who of the people who gave advice you think gave you “most useful” and who gave 
“least useful” advice?  
Most useful advice   
Least useful advice   
 
Anti-malarial drugs 
30. Did you give any anti-malarial drug?  If yes, which ones?    
 
Yes 
 
No 
 
31. If the child was not given any antimalarial drug, go to Question 38. 
 
Order of giving Drug type 
1 2 3 
SP (and brands: Orodar etc) 
 
  
 
go to Q 32    
Chloroquine   
 
  
go to Q 33    
Amodiaquine  
 
  
 
go to Q 34    
Quinine           
 
  
 
go to Q 35    
Others (specify)         
 
  
 
go to Q 36    
Others (specify) 
 
  
 
go to Q 37    
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32. SP    
 
32.1. How long after onset of symptoms did you give SP to your child?    
 
Same Day 
3 
Next Day 
2 
> 2 days 
1 
 
32.2. In what form was the drug that you gave the child?  
1= Tablets 
2= Syrup 
3= Injection 
4= Drip 
5= Other (mention):__________
 
32.3. How much SP did you give? (Insert code in appropriate box – if syrup, estimates in 
teaspoon full)  
 
(Narrative) 
 
 
 
 
Codes: 1= Robo, 2=Nusu, 3=Kimoja, 4=Kimoja na nusu, 5=Viwili, 6=Vitatu, 7=Others  
Morning 
  
Midday 
  
Evening 
  
 
32.4. Where did you get SP that you gave the child? For each of the following sources, mark 
whether respondent reported use spontaneously or in response to probe. Note why they went there.  
 Codes: 1= Distance/time, 2=Timing, 3=Convenience, 4=Cost, 5=Good quality service, 
6=Inconvenience, 7=other (mention)_____ 
Help Seeking Spon. Probe Why 
(note code) 
1. I had them at home         
2. Female elder      
3. Male elder      
4. Aunt (of the child)      
5. Father/ uncle (of child)      
6. Neighbour      
7. Government / private health facility staff      
8. Government / private health facility      
9. Shopkeeper (general store)      
10. Shopkeeper (drug store)      
11. I knew myself      
12. Community health worker      
13. Local healer      
14. Other (mention):        
 
32.5. How much did it cost? 
 
 1. Consultation 
 
Tsh.  
  
 2. Drugs 
 
Tsh.  
  
 
32.6. Did you know yourself what drug to give the child or did someone tell you? If so, 
who told you?   
 (Based on the chart in Question 28 above) 
 
32.7. And what did he/she say? 
 
Narrative   
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33. Chloroquine   
 
33.1. How long after onset of symptoms did you give Chloroquine to your child?   
Same Day 
3 
Next Day 
2 
> 2 days 
1 
 
33.2. In what form was the drug that you gave the child?  
1= Tablets 
2= Syrup 
3= Injection 
4= Drip 
5= Other (mention):__________
 
33.3. How many tablets of Chloroquine did you give? (Insert code in appropriate box) 
 
(Narrative) 
 
 
 
 
           Codes: 1= Robo, 2=Nusu, 3=Kimoja, 4=Kimoja na nusu, 5=Viwili, 6=Vitatu, 7=Others 
Morning 
  
Midday 
  
Evening 
  
 
33.4. Where did you get Chloroquine from? For each of the following sources of help, mark 
whether respondent reported use spontaneously or in response to probe. Note why they went there.  
 
 Codes: 1= Distance/time, 2=Timing, 3=Convenience, 4=Cost, 5=Good quality service, 
6=Inconvenience, 7=other (mention)_____ 
Help Seeking 
 
Spon. Probe Why 
(note code) 
1. I had them at home         
2. Female elder      
3. Male elder      
4. Aunt (of the child)      
5. Father/ uncle (of child)      
6. Neighbour      
7. Government / private health facility staff      
8. Government / private health facility      
9. Shopkeeper (general store)      
10. Shopkeeper (drug store)      
11. I knew myself      
12. Community health worker      
13. Local healer      
14. Other (mention):        
 
33.5. How much did it cost? 
 
 1. Consultation Tsh. 
  
 2. Drugs Tsh. 
  
 
33.6. Did you know yourself what drug to give the child or did someone tell you? If so, 
who told you?    
 (Based on the chart in Question 28 above) 
 
 
33.7. And what did he/she say? 
 
Narrative   
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34. Amodiaquine    
 
34.1. How long after onset of symptoms did you give Amodiaquine to your child?  
   
Same Day 
3 
Next Day 
2 
> 2 days 
1 
 
34.2. In what form was the drug that you gave the child?  
1= Tablets 
2= Syrup 
3= Injection 
4= Drip 
5= Other (mention):__________
 
34.3. How many tablets of Amodiaquine did you give? (Insert code in appropriate box) 
 
(Narrative) 
 
 
 
 
           Codes: 1= Robo, 2=Nusu, 3=Kimoja, 4=Kimoja na nusu, 5=Viwili, 6=Vitatu, 7=Others 
Morning 
  
Midday 
  
Evening 
  
 
34.4. Where did you get Amodiaquine from? For each of the following sources of help, mark 
whether respondent reported use spontaneously or in response to probe. Note why they went there.  
 
 Codes: 1= Distance/time, 2=Timing, 3=Convenience, 4=Cost, 5=Good quality service, 
6=Inconvenience, 7=other (mention)_____ 
Help Seeking 
 
Spon. Probe Why 
(note code) 
1. I had them at home         
2. Female elder      
3. Male elder      
4. Aunt (of the child)      
5. Father/ uncle (of child)      
6. Neighbour      
7. Government / private health facility staff      
8. Government / private health facility      
9. Shopkeeper (general store)      
10. Shopkeeper (drug store)      
11. I knew myself      
12. Community health worker      
13. Local healer      
14. Other (mention):        
 
34.5. How much did it cost? 
 1. Consultation Tsh. 
  
 2. Drugs Tsh. 
  
 
34.6. Did you know yourself what drug to give the child or did someone tell you? If so, 
who told you?    
 (Based on the chart in Question 28 above) 
 
 
34.7. And what did he/she say? 
 
Narrative   
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35. Quinine     
 
35.1. How long after onset of symptoms did you give Quinine to your child? 
   
Same Day 
3 
Next Day 
2 
> 2 days 
1 
 
35.2. In what form was the drug that you gave the child?  
1= Tablets 
2= Syrup 
3= Injection 
4= Drip 
5= Other (mention):__________
 
35.3. How many tablets of Quinine did you give? (Insert code in appropriate box) 
 
(Narrative) 
 
 
 
 
        Codes: 1= Robo, 2=Nusu, 3=Kimoja, 4=Kimoja na nusu, 5=Viwili, 6=Vitatu, 7=Others 
Morning 
  
Midday 
  
Evening 
  
 
35.4. Where did you get Quinine from? For each of the following sources of help, mark whether 
respondent reported use spontaneously or in response to probe. Note why they went there.  
 
 Codes: 1= Distance/time, 2=Timing, 3=Convenience, 4=Cost, 5=Good quality service, 
6=Inconvenience, 7=other (mention)_____ 
Help Seeking 
 
Spon. Probe Why 
(note code) 
1. I had them at home         
2. Female elder      
3. Male elder      
4. Aunt (of the child)      
5. Father/ uncle (of child)      
6. Neighbour      
7. Government / private health facility staff      
8. Government / private health facility      
9. Shopkeeper (general store)      
10. Shopkeeper (drug store)      
11. I knew myself      
12. Community health worker      
13. Local healer      
14. Other (mention):        
 
35.5. How much did it cost? 
 
 1. Consultation Tsh. 
  
 2. Drugs Tsh. 
  
 
35.6. Did you know yourself what drug to give the child or did someone tell you? If so, 
who told you?     
 (Based on the chart in Question 28 above) 
 
 
35.7. And what did he/she say? 
 
Narrative   
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36. Others (specify) _______________________   
 
36.1. How long after onset of symptoms did you give the drug to your child?   
 
Same Day 
3 
Next Day 
2 
> 2 days 
1 
 
36.2. In what form was the drug that you gave the child?  
1= Tablets 
2= Syrup 
3= Injection 
4= Drip 
5= Other (mention):__________
 
36.3. How many tablets of the drug did you give? (Insert code in appropriate box) 
 
(Narrative) 
 
 
 
 
           Codes: 1= Robo, 2=Nusu, 3=Kimoja, 4=Kimoja na nusu, 5=Viwili, 6=Vitatu, 7=Others 
Morning 
  
Midday 
  
Evening 
  
 
36.4. Where did you get the drug from? For each of the following sources of help, mark whether 
respondent reported use spontaneously or in response to probe. Note why they went there.  
 
 Codes: 1= Distance/time, 2=Timing, 3=Convenience, 4=Cost, 5=Good quality service, 
6=Inconvenience, 7=other (mention)_____ 
Help Seeking 
 
Spon. Probe Why 
(note code) 
1. I had them at home         
2. Female elder      
3. Male elder      
4. Aunt (of the child)      
5. Father/ uncle (of child)      
6. Neighbour      
7. Government / private health facility staff      
8. Government / private health facility      
9. Shopkeeper (general store)      
10. Shopkeeper (drug store)      
11. I knew myself      
12. Community health worker      
13. Local healer      
14. Other (mention):        
 
36.5. How much did it cost? 
 
 1. Consultation Tsh. 
  
 2. Drugs Tsh. 
  
 
36.6. Did you know yourself what drug to give the child or did someone tell you? If so, 
who told you?     
 (Based on the chart in Question 28 above) 
 
 
36.7. And what did he/she say? 
 
Narrative   
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37. Others (specify) _______________________  
 
37.1. How long after onset of symptoms did you give the drug to your child?   
 
Same Day 
3 
Next Day 
2 
> 2 days 
1 
 
37.2. In what form was the drug that you gave the child?  
1= Tablets 
2= Syrup 
3= Injection 
4= Drip 
5= Other (mention):__________
 
37.3. How many tablets of the drug did you give? (Insert code in appropriate box) 
 
(Narrative) 
 
 
 
 
           Codes: 1= Robo, 2=Nusu, 3=Kimoja, 4=Kimoja na nusu, 5=Viwili, 6=Vitatu, 7=Others 
Morning 
  
Midday 
  
Evening 
  
 
37.4. Where did you get the drug from? For each of the following sources of help, mark whether 
respondent reported use spontaneously or in response to probe. Note why they went there.  
 
 Codes: 1= Distance/time, 2=Timing, 3=Convenience, 4=Cost, 5=Good quality service, 
6=Inconvenience, 7=other (mention)_____ 
Help Seeking 
 
Spon. Probe Why 
(note code) 
1. I had them at home         
2. Female elder      
3. Male elder      
4. Aunt (of the child)      
5. Father/ uncle (of child)      
6. Neighbour      
7. Government / private health facility staff      
8. Government / private health facility      
9. Shopkeeper (general store)      
10. Shopkeeper (drug store)      
11. I knew myself      
12. Community health worker      
13. Local healer      
14. Other (mention):        
 
37.5. How much did it cost? 
 
 1. Consultation Tsh. 
  
 2. Drugs Tsh. 
  
 
37.6. Did you know yourself what drug to give the child or did someone tell you? If so, 
who told you?     
 (Based on the chart in Question 28 above) 
 
 
37.7. And what did he/she say? 
 
Narrative   
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38. Skip this question if SP has been used, otherwise ask: Why didn’t you give the child SP (or other 
first line drug) tablets? 
 
 
(Narrative) 
 
 
 
 
 
 
 
 
 Spon Probe 
1. Fear of side effects       
2. Too strong for the child     
3. Family members said not to     
4. Friend said not to     
5. Told by health facility staff     
6. Told by shopkeeper     
7. Does not know     
 
Tick all that apply 
 
8. Other (mention):   
  
  
 
 
 
39. In addition to (or apart from) giving anti-malarials, did you do anything else to treat the 
child?  
     Tick all that apply 
 Spon Prob 
1. Give antipyretics (e.g. Panadol)       
2. Give an antibiotic     
3. Give herbal medicine (home care)     
4. Sponging     
5. Ask for advice     
6. Divination     
7. Urinated on the child     
8. Give herbal medicine (from healer)     
9. I brought him to a health facility     
10. Give SP     
11. Give Amodiaquine     
12. Give Quinine     
13. Give other antimalarials (1) specify     
14. Give other antimalarials (2) specify     
15. Do something else     
 
 
40. “Which of the treatment options mentioned (or something else) do you consider the 
most effective way of treating this problem?” (Regardless of whether it has been used or not in 
this particular disease episode) 
 
(Narrative) 
 
 
 
 
(Based on the chart in Question 39)  
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PREVENTION AND CONTROL 
 
41. “Could this child’s problem or condition have been prevented? Anything in particular 
that you think could have prevented it?’    
 
 
Tick one only
Yes 
3 
Possibly 
2 
Uncertain 
1 
No 
0 
 
(Narrative) 
 
 
 
 
 
Tick accordingly for mentioned preventive measures, both for that particular child  
 
Particular child Prevention and control 
 Spon. Probe 
1. Use of mosquito net (untreated)       
2. Use of a treated mosquito net     
3. Taking medicines regularly (herbal or biomedical)    
4. Parent to abstain from sex     
5. Reduction in strenuous/hard work     
6. Fumigation/ fogging     
7. De-worming regularly     
8. Avoid certain insect bites     
9. Clean the environment     
10. Keep personal hygiene     
11. Drinking clean water     
12. Attend to ancestral spirits and family gods     
13. Avoid offending evil spirits, especially the witches     
14. Mothers with malaria should not breast feed     
15. Don’t know/cannot tell     
16. Cannot be prevented     
17. Other (mention):      
  
  
 
 
General Question on DEGEDEGE  
 
42.  ‘‘When was the last time you saw a child with convulsion or who was just recovering 
from convulsion?’’ 
 
 
(Narrative) 
 
 
 
 
 
 ‘Record number of days, weeks, months and years in appropriate box’ 
 
Days 
  
Weeks 
  
Months 
  
Years 
  
 
Tick for ‘never seen a child with degedege’ 
Never seen a child 
with degedege 
  
  
43. What is that child’s relationship to you 
 
Own child 
1 
Neighbour’s 
child  
2 
Extended 
family relation 
3 
Other 
specify  
4 
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CONCLUDING ADVICE FROM RESPONDENT 
 
44. “Is there anything else you can tell me about this condition from your experience? Any 
further comments, advice or suggestions will be appreciated?’’  
 
 
(Narrative) 
 
 
 
 
 
 
 
 
 
Interviewer: 
 
  
 Supervisor:  
 
 
Interviewer Signature: __________________________ Supervisors Signature: _____________________ 
 
 
Interview Date: 
 
 
 
 
 
  
 
Day/Month/Year 
 
ADDITIONAL COMMENTS 
Notes concerning subject’s interest and the quality of the interview, and any other noteworthy features and 
details of this interview 
 
 
 
 
 
 
 
 
 
 
Supervisor:  
 
 
 
  
 
Date of supervision: 
 
 
 
 
 
  
 
Day/Month/Year 
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APPENDIX 2: ADDITIONAL FILES TO CHAPTER 7 
Patterns of distress (PD)
Children under five years of age
N=109
Homa Malaria Degedege Total P*
Homa-
malaria
Homa-
degedege
Malaria-
degedege
n 24 68 8 109
No interest to play 0.81 0.75 0.88 0.76 0.888
Not happy 0.85 0.87 0.88 0.84 0.995
Sleeps 0.78 0.77 0.75 0.79 1.000
Loss of appetite 0.78 1.10 1.00 0.96 0.178
Crying all the time 0.74 0.74 0.38 0.71 0.422
No strength 0.52 0.93 1.00 0.79 0.068 0.023 0.202 0.835
Body strength 1.30 1.49 1.50 1.42 0.355 0.156 0.432 0.973
Hot body 1.48 1.71 1.63 1.62 0.456
Hot head 1.22 0.93 0.88 0.96 0.151
Hot abdomen 0.96 0.94 0.88 0.92 0.953
Periodic fevers 0.70 0.86 0.63 0.80 0.498
Fever 1.74 1.87 1.75 1.81 0.589 0.370 0.937 0.515
Cough 0.63 0.55 0.50 0.59 0.839
Difficult breathing 0.33 0.46 0.50 0.44 0.537
Respiration 0.78 0.71 0.63 0.74 0.879 0.744 0.637 0.739
Diarrhoea 0.33 0.49 0.25 0.46 0.541 0.406 0.953
Vomiting 0.56 1.03 1.00 0.96 0.105 0.033 0.346 0.947
Diarrhoea/vomiting 0.74 1.14 1.00 1.08 0.173 0.058 0.582 0.739
Twitching 0.52 0.61 1.25 0.61 0.063 0.634 0.022 0.029
Stiff body 0.15 0.16 0.25 0.15 0.873
Delirium 0.22 0.38 0.88 0.36 0.137 0.359 0.052 0.109
Eyes turn white 0.22 0.16 0.25 0.19 0.795
Kicking of leg/arm 0.15 0.14 0.25 0.14 0.836
Froth in the mouth 0.00 0.09 0.13 0.08 0.770
Mouth twisted sideways 0.00 0.01 0.13 0.02 0.861
Falling down 0.00 0.01 0.00 0.01 0.993
Easily startled/frightened 0.30 0.28 0.63 0.29 0.258 0.813 0.163 0.102
Convulsions 0.59 0.77 1.25 0.75 0.099 0.299 0.036 0.092
Shivering 0.41 0.52 0.13 0.44 0.313
Yellow eyes 0.11 0.38 0.13 0.27 0.257
Other physical 0.30 0.29 0.25 0.28 0.977
Other 0.63 0.90 0.38 0.76 0.103 0.144 0.377 0.078
*Kruskal-Wallis test
P*Mean prominence
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Patterns of distress (PD)
Adults 12 years of age and older
N=88
P*
Homa Malaria Degedege Total P*
Homa-
malaria
n 29 54 2 88
Loss of appetite 0.62 0.76 1.00 0.71 0.634 0.369
No strength 1.04 0.93 0.00 0.93 0.220 0.576
Headache 1.38 1.39 0.00 1.35 0.140 0.963
Dizziness 0.42 0.57 0.00 0.53 0.450 0.432
Pain 0.15 0.41 0.00 0.31 0.610 0.361
Body strength, pain 1.62 1.63 1.00 1.62 0.743 0.861
Fever 1.46 1.00 1.00 1.15 0.019 0.006
Hot body 1.08 1.07 2.00 1.08 0.242 0.967
Hot head 0.85 0.91 1.00 0.88 0.889 0.689
Hot abdomen 0.38 0.50 0.50 0.45 0.870 0.615
Periodic fevers 0.73 0.65 0.50 0.68 0.861 0.655
Fever 1.62 1.52 2.00 1.55 0.402 0.400
Cough 0.38 0.24 1.00 0.32 0.545 0.485
Difficult breathing 0.23 0.22 1.50 0.25 0.105 0.869
Respiration 0.54 0.39 2.00 0.48 0.051 0.388
Diarrhoea 0.23 0.17 0.00 0.20 0.961 0.939
Vomiting 0.42 0.56 1.00 0.51 0.685 0.518
Nausea 0.50 0.52 1.00 0.51 0.826 0.841
Diarrhoea/vomiting 0.92 0.85 1.00 0.87 0.946 0.766
Yellow eyes 0.04 0.13 0.50 0.11 0.539 0.597
Shivering 0.38 0.48 1.00 0.46 0.683 0.565
Other physical symptoms 0.19 0.31 2.00 0.31 0.101 0.689
Bad dreams 0.27 0.24 0.00 0.25 0.817 0.837
Other 0.73 0.81 2.00 0.80 0.146 0.704
*Kruskal-Wallis test
** kwallis with categories "homa" and "malaria" only; "degedege" cases dropped
Mean prominence
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Perceived causes (PC)
Children under five years of age
N=109
Homa Malaria Degedege Total P*
Homa-
malaria
Homa-
degedege
Malaria-
degedege
n 24 68 8 109
Impure water 0.37 0.39 0.63 0.38 0.486 0.903 0.255 0.249
Eating leftover food 0.19 0.23 0.38 0.22 0.718 0.723 0.421 0.510
Unbalanced diet 0.22 0.16 0.50 0.19 0.284 0.634 0.239 0.117
Starchy food 0.07 0.07 0.25 0.08 0.709 0.991 0.455 0.413
Breast feeding / mother’s milk 0.11 0.09 0.25 0.12 0.716 0.779 0.556 0.423
Ingestion 0.59 0.52 0.75 0.55 0.493 0.560 0.480 0.263
Mosquito bite 1.22 1.55 1.13 1.37 0.083 0.083 0.680 0.089
Other insect bite 0.41 0.19 0.38 0.26 0.211 0.096 0.891 0.390
Houseflies 0.22 0.14 0.63 0.20 0.084 0.557 0.088 0.027
Worms 0.44 0.26 0.63 0.32 0.130 0.164 0.444 0.093
Bird/insect called degedege 0.41 0.29 0.25 0.35 0.173 0.338 0.255 0.084
Insects / worms 1.41 1.62 1.38 1.51 0.176 0.110 0.844 0.223
Physical hard work (parent) 0.11 0.06 0.13 0.08 0.895 0.687 0.953 0.757
Stage of child growth 0.78 0.46 0.63 0.56 0.093 0.033 0.596 0.428
Constitution/ blood weakness 0.41 0.20 0.13 0.25 0.245 0.121 0.231 0.720
Hereditary 0.15 0.10 0.00 0.10 0.813 0.723 0.530 0.640
Work / constitution 0.85 0.52 0.63 0.62 0.074 0.023 0.398 0.599
Sanitation/ Dirty environment 0.63 0.54 0.63 0.55 0.730 0.483 0.969 0.628
Personal hygiene/not keeping clean
0.41 0.25 0.63 0.30 0.140 0.222 0.356 0.081
Plant 0.19 0.19 0.38 0.19 0.660 0.948 0.421 0.367
Contamination - contact 0.44 0.23 0.63 0.30 0.062 0.083 0.444 0.063
Contamination 0.70 0.62 0.88 0.64 0.421 0.483 0.455 0.226
Wind 0.33 0.23 0.38 0.26 0.644 0.441 0.860 0.510
Heat (sun or fire) 0.44 0.43 0.75 0.44 0.292 0.705 0.195 0.125
Cold weather 0.85 0.46 0.75 0.60 0.044 0.023 0.814 0.161
Weather / climate 1.04 0.75 0.88 0.84 0.216 0.063 0.569 0.520
Spirits (upepo, majini, shetani) 0.30 0.14 0.50 0.19 0.177 0.251 0.388 0.102
Evil eyes or sorcery (uchawi) 0.22 0.22 0.38 0.21 0.742 0.903 0.517 0.443
God 0.63 0.65 0.50 0.64 0.896 0.955 0.637 0.664
Failure to abstain from sex (parent) 0.15 0.09 0.38 0.12 0.401 0.642 0.336 0.184
Supernatural 0.74 0.80 0.63 0.77 0.839 0.820 0.666 0.570
Cannot tell  0.19 0.28 0.25 0.27 0.893 0.642 0.937 0.854
*Kruskal-Wallis test
Mean prominence P*
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Perceived causes (PC)
Adults 12 years of age and older
N=88
P*
Homa Malaria All Mean P*
Homa-
malaria
n 29 54 88
Impure water 0.35 0.41 0.40 0.110 0.350
Eating leftover food 0.19 0.15 0.15 0.855 0.670
Unbalanced diet 0.15 0.19 0.18 0.885 0.735
Starchy food 0.08 0.07 0.07 0.984 0.983
Breast feeding 0.00 0.13 0.08 0.632 0.350
Ingestion 0.54 0.57 0.58 0.220 0.545
Mosquito bite 1.12 1.50 1.34 0.173 0.062
Other insect bite 0.15 0.20 0.19 0.707 0.719
Houseflies 0.23 0.20 0.24 0.163 0.845
Worms 0.31 0.28 0.29 0.857 0.829
Bird/insect called degedege 0.23 0.20 0.22 0.163 0.845
Insects / worms 1.15 1.52 1.36 0.185 0.068
Physical hard work 0.96 0.57 0.66 0.086 0.057
Stage of life 0.23 0.43 0.35 0.350 0.229
Constitution/ blood weakness 0.27 0.24 0.26 0.817 0.837
Hereditary 0.04 0.04 0.04 0.996 0.991
Work / constitution 0.96 0.81 0.84 0.658 0.482
Sanitation/ Dirty environment 0.23 0.57 0.46 0.041 0.030
Personal hygiene/not keeping clean
0.19 0.30 0.27 0.641 0.453
Plant 0.12 0.30 0.22 0.427 0.235
Contamination - contact 0.15 0.13 0.14 0.933 0.861
Contamination 0.35 0.67 0.56 0.070 0.040
Wind 0.27 0.17 0.21 0.669 0.611
Heat (sun or fire) 0.54 0.37 0.42 0.496 0.246
Cold weather 0.58 0.31 0.39 0.259 0.152
Weather / climate 0.81 0.48 0.59 0.097 0.057
Spirits (upepo, majini, shetani) 0.27 0.17 0.21 0.669 0.611
Evil eyes or sorcery (uchawi) 0.15 0.11 0.13 0.635 0.758
God 0.62 0.41 0.51 0.241 0.267
Failure to abstain from sex (parent) 0.04 0.11 0.09 0.853 0.600
Supernatural 0.69 0.61 0.66 0.600 0.611
Cannot tell  0.12 0.33 0.27 0.529 0.295
*Kruskal-Wallis test
** degedege category omitted
Mean prominence**
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